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ABSTRACT 
Proteins destined for the secretory pathway and endoplasmic reticulum (ER) resident 
proteins are targeted to the ER through an N-terminal signal sequence. Proteins then follow 
a post-translational maturation process to fold into functional proteins. For most of these 
proteins the formation of disulfide bonds (S-S) at the correct position is essential for 
structure and function. In eukaryotes, protein oxidation in the ER is catalysed by 
Endoplasmic reticulum oxidoreductases (EROs) which donate disulfide bonds to (and 
accept electrons from) Protein Disulfide Isomerase (PDI). In yeast, Erolp is essential for 
viability and protein secretion. Two ER resident homologues have been identified in the 
human genome, Erola and Erolj), which complement the yeast erol-1 temperature 
sensitive mutation. The main focus of this project was Erolj). 
Under steady state conditions in transfected cells, Ero 113 was captured in higher molecular 
weight complexes in the presence and in the absence of an alkylating agent. Ero-PDI 
covalent interactions are alkylation dependent, but alkylation independent Eroll3 
complexes were found in transfected cells and endogenous tissue. In Erola the CXXCXXC 
C-tenninal motif is important for protein folding, structural integrity and complex 
formation with the PDI. In Erolj), the AXXCXXC (C390A) mutation disrupts covalent PDI 
interactions but does not interfere with homodimer formation. The CXXCXXA (C396A) 
mutation caused disruption of Eroll3 homodimer formation. Modelling the dimer onto the 
Ero l p crystal structure suggested that this 396 cysteine is indirectly disrupting dimer 
formation by most likely displacing the cofactor FAD. Two FAD binding domain mutants, 
initially discovered in yeast, were constructed in Eroll3 and were found to cause instability 
of Eroll3 through misoxidation during temperature and reducing stress conditions. Eroll3 
expression patterns were studied using immunohistochemistry on human stomach and 
pancreas tissues. The data indicated that Eroll3 is constitutively strongly expressed in 
enzyme producing chief cells and hormone producing pancreatic islet cells. 
An interesting result from immunohistochemistry stammgs of healthy, Barrett's and 
oesophageal tumour tissue showed that the ER chaperone protein ERp57 is up-regulated 
only in dysplastic and oesophageal tumour tissue. These initial findings suggest ERp57 has 
potential as a marker in oesophageal tumour diagnosis. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Chapter 1: General introduction 
The native state of a protein generally corresponds to the most thermodynamically 
stable state under physiological conditions. Folding of a protein to this native 
conformation is currently modelled using energy landscapes. The unfolded polypeptide 
is at the sUJface of the landscape with the highest energy, and searches down a funnel-
like energy profile making intramolecular contacts towards the native state (reviewed in 
(Wolynes, 2005)). Pat1ially folded conformations on this landscape are more prone to 
aggregation, leading to intermolecular contacts ultimately resulting in protein 
misfolding diseases (reviewed in (Jahn & Radford, 2005)). Protein misfolding and 
aggregation are the basis of a number of pathological conditions including Alzhemier's 
and Parkinson's disease (reviewed in (Scheibel & Buchner, 2006)), Huntington's 
disease (Qin & Gu, 2004), cystic fibrosis (Kopito, 1999; Sharma et al., 2004), at-
antitrypsin deficiency (Lawless et al., 2004), the rheumatic disease ankylosing 
spondylitis (Ramos & Lopez de Castro, 2002) and Creuzfeld-Jakob disease (Aguzzi et 
al., 2004). All of these diseases are at least partly caused by amino acid changes that 
result in protein misfolding and/or degradation through the endoplasmic reticulum (ER) 
quality control system. 
Misfolded proteins trigger a system called the unfolded protein response (UPR) in 
which the synthesis of ER membranes and chaperones is induced to cope with the 
demands of high levels of protein production. This is achieved through ER to nucleus 
signalling pathways mediated by three ER resident transmembrane proteins; activating 
transcription factor (ATF6), the inositol requiting kinase 1 (IREl) and double stranded 
RNA-activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) 
(reviewed in (Kaufman et al., 2002; Schroder & Kaufman, 2005)). Accumulation of 
unfolded proteins in the ER results in cleavage of ATF6, to release a cytosolic fragment 
2 
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(bZIP domain) and of IRE1 to induce splicing of a specific mRNA that encodes XBP-1 
(X-box-binding protein-1) m mammalian cells. Processed XBP-1 initiates 
transcriptional activation of ER stress response genes (or unfolded protein response, 
UPR, genes) (Yoshida et at., 2001). PERK is also activated to phosphorylate and 
inactivate the translation initiation factor eiF2a (Kaufman et al., 2002). XBP-1 and ER 
stress were recently implicated in bipolar disorder (Kakiuchi et al., 2003), obesity and 
type 2 diabetes (Ozcan et al., 2004), suggesting that the UPR may have an important 
role in complex disease not previously linked to ER protein misfolding. 
With protein misfolding playing a crucial role in many diseases, understanding the 
fundamentals of protein folding is essential. This chapter focuses on protein folding in 
the endoplasmic reticulum and the associated quality control mechanisms. 
1.1 Protein entry into the ER 
Proteins expressed at the cell surface, that reside within the secretory pathway or that 
get secreted, are targeted to the ER by their signal sequence (Halic & Beckmann, 
2005), initially recognised by the signal recognition patticle (SRP, (Nagai et at., 2003; 
Egea et al., 2005)) which forms a ribosome nascent chain (RNC)-SRP complex. This 
complex then docks onto the membrane bound SRP-receptor (SR) in a GTP dependent 
manner (Wild et al., 2004). The polypeptide chain is translocated from the ribosome 
into the ER through the translocon, at the core of which lies an aqueous pore (reviewed 
in (Johnson & van Waes, 1999)). The translocon, called the Sec61 complex in 
eukaryotes and SecY complex in eubacteria and archaea, is a heterotrimeric integral 
membrane protein complex (Brundage et al., 1990; Gorlich & Rapoport, 1993) 
composed of the a-subunit (SecY in eubacteria and archaea; Sec61a in mammals), the 
3 
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P-subunit (SecG in eubacteria; Seep in archaea; Sec61P in mammals) and they-subunit 
(SecE in eubacteria and archaea; Sec61y in mammals). Electrophysiological studies 
demonstrated that the Sec61 translocon forms an aqueous, ion-conducting channel 
(Wirth et al., 2003) which is structurally dynamic, with an estimated maximum 
dimension of -15 A (Breyton et al., 2002). Due to the large diameter of the aqueous 
pore, a gating mechanism is needed to maintain the permeability barrier and maintain 
critical ion gradients (e.g. Ca2+ stores) across the ER membrane during translocation. 
These pore structures have been elucidated experimentally by incorporating fluorescent 
dyes into short nascent chains and determining the accessibility of the probes to the ER 
lumen using externally added quenching agents (Hamman et al., 1998). The ER 
permeability banier is maintained from the cytosolic side of the membrane by the ion-
tight binding of the ribosome to the translocon during translocation (Crowley et al., 
1994). The lumenal side of the translocation pore is sealed either directly or indirectly 
by BiP (Hamman et al., 1998) and this seal needs to be in place before the cytosolic 
side of the pore opens, to maintain a permeability banier. BiP (Grp78) is a Ca2+ and 
ATP dependent Hsp70 family member which was initially identified as an 
immunoglobulin heavy-chain binding protein (Haas & Wabl, 1983). BiP is an ER 
lumen chaperone which has a KDEL ER retention signal (Munro & Pelham, 1987). 
The local environment a nascent protein encounters as it is synthesised depends on 
whether it is destined to be a soluble protein, a membrane spannmg protein or a 
glycosylphosphatidyl inositol (GPI) linked protein, for example. Initial studies 
indicated that the ribosome, not the translocon, first recognised transmembrane 
sequences which initiated structural changes at the translocon (Liao et al., 1997). More 
recently, studies using Fluorescence Resonance Energy Transfer (FRET) have shown 
that both secretory and membrane proteins already differ in their folding within the 
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ribosome itself, even before entering the translocon (Johnson, 2004). Hydrophobic 
transmembrane sequences fold into tight helixes that retain their folded conformation as 
they move into the translocon, whereas secretory protein sequences take up a more 
extended conformation inside the tunnel (Woolhead et al., 2004; Sadlish et al., 2005). 
The Sec61/SecY complex forms a passive pore which allows a polypeptide chain to 
slide back and forth but needs to associate with partner proteins which can provide the 
driving force during translocation. Depending on the partner, the channel can operate in 
three different translocation modes (reviewed in (Osborne et al., 2005)). In co-
translational translocation (Figure 1.1A) found in all organisms, a ribosome nascent 
chain (RNC)-SRP complex is targeted to the membrane via its recognition by SRP, 
which allows binding of the ribosome to the channel. The ribosome then feeds the 
polypeptide chain directly into the channel. GTP hydrolysis during translation provides 
the energy for protein translocation (Halic & Beckmann, 2005). Post-translational 
translocation, found only in eukaryotes (Figure 1.18), has been described in 
Saccharomyces cerevisiae (Matlack et al., 1999) but is thought to be a conserved 
mechanism among higher eukaryotes as well. Here the partner proteins are the Sec61 
complex, Sec62/63 complex and the ER chaperone BiP, which provides the driving 
force for a ratcheting mechanism (Matlack et al., 1999). Polypeptides with a less 
hydrophobic signal sequence that escape binding to SRP are thought to undergo this 
mode of translocation (Ng et al., 1996) and thus require cytosolic chaperone proteins to 
keep the polypeptide in an unfolded form. The lumenal J domain of Sec63p interacts 
with A TP-bound BiP which has an open-peptide binding pocket. This interaction 
stimulates hydrolysis of ATP and the peptide binding pocket closes around the 
translocating protein. When the polypeptide has moved a sufficient distance into the ER 
lumen another BiP molecule binds, and this process is repeated until the entire 
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polypeptide is translocated. The third mode of translocation, seen only in eubacteria, 
also occurs post-translationally (Figure l.lC), where the channel pm1ner is a cytosolic 
ATPase called SecA. SecA pushes the polypeptides through the channel in a stepwise 
manner (Mori & Ito, 2001; Luirink & Sinning, 2004). 
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FIGURE 1.1: Components of the three different modes of translocation 
A. Cotranslational translocation in all organisms. The signal recognition particle (SRP) 
binds to the signal sequence of an emerging nascent polypeptide chain and to the 
ribosome to form a ribosome nascent chain (RNC) - SRP complex. This complex is 
targeted to the ER membrane by interaction with the SRP receptor, which releases SRP 
and targets ribosome bound polypeptide to the Sec61 complex. The polypeptide 
initially inserts into the channel as a loop with the N and C termini in the cytosol, and 
the remainder of the polypeptide moves through the channel into the ER. B. Post 
translational translocation in yeast and higher eukaryotes. Polypeptides synthesised in 
the cytosol are kept unfolded by binding cytosolic chaperones. This complex is targeted 
to the Sec61, Sec62/63 translocon through the signal sequence of the polypeptide after 
which the chaperone proteins are released. ADP bound BiP binds to the polypeptide 
chain as it emerges in to the ER lumen and when the polypeptide has moved a 
sufficient distance into the lumen another BiP molecule binds. This process is repeated 
until the entire polypeptide is translocated. C. SecA mediated posttranslational 
translocation in eubacteria. Polypeptides with a signal sequence are targeted to the 
Sec Y channel after binding to SecA and are inserted as a loop into the channel. The 
SecA polypeptide-binding groove is involved in pushing the polypeptide chain into the 
periplasm in a stepwise manner. Adapted and modified from (Osborne et al., 2005). 
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1.2 ER protein sorting 
Proteins that enter the ER need to reach vanous ultimate destinations to function 
properly. A protein may reside in the ER, assemble into complexes, remam as a 
monomer or get directed to the nuclear membrane, for example. How does the ER sort 
these proteins according to their destination? For ER resident lumenal proteins, the 
carboxy-terminal tetrapeptide, KDEL, has been shown to be necessary and sufficient to 
ensure their ER localisation (Munro & Pelham, 1987; Pelham, 1989), whereas the 
KKXX or di-lysine motif ensures ER localisation of membrane proteins (Nilsson et al., 
1989; Townsley & Pelham, 1994). ER localisation of soluble resident proteins largely 
depends on KDEL receptor-mediated retrieval from the intermediate compartment or 
Golgi apparatus (Pelham & Munro, 1993), whereas retrieval and retention mechanisms 
seem to cooperate in determining the ER localisation of cettain proteins like 
calreticulin (Sonnichsen et al., 1994). The existence of a true ER retention mechanism 
was evident from experiments using chimeric human cathepsin D molecules (lsidoro et 
al., 1996). These cathepsin D molecules were made by either attaching a KDEL motif 
or by attaching a C-terminal sequence from lgM fJ. chain (fJ.tp) with a cysteine residue. 
These results indicated that fJ.tp does not require recycling between Golgi and the ER 
and that thiol-mediated ER residency is due to true retention in this organelle. So while 
the evidence for a retrieving function with the KDEL receptor is overwhelming, it 
seems clear that additional mechanisms do contribute in determining the localisation of 
ER resident proteins (lsidoro et al., 1996). 
Another less-well characterised smting motif is the arginine-based ER-Iocalisation 
signal, first discovered in the context of MHC class II and invariant chain transp011 
(Bakke & Dobberstein, 1990). Arginine-based signals can localise a broad range of 
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proteins to the ER, and this exposed signal can localise unassembled subunits or 
incompletely assembled complexes to the ER (e.g. G protein-coupled y-aminobuyric; 
GABA8 , receptor: (Margeta-Mitrovic et al., 2000)). After functional complex assembly, 
the signal motif gets masked and this allows the transpott of the complex to the cell 
surface (Zerangue et al., 1999). From information generated so far, a consensus motif 
<DN'/R-R-X-R has been put together for the arginine-based signal, where <D/'1' denotes 
an aromatic or bulky hydrophobic residue and X represents any amino acid. These 
signals do not require exposure at the distal terminus of a membrane protein and only 
require being approximately 16-46 A away from the lipid bilayer in order to be 
functional ((Shikano & Li, 2003) and reviewed in (Michelsen et al., 2005)). A 
surprising finding has been that an arginine based signal is able to mediate access to 
viral type I membrane proteins from the ER to the inner nuclear membrane (INM) 
(Meyer & Radsak, 2000; Meyer et al., 2002), where the virus undergoes a characteristic 
maturation phase. Using immunofluorescence and cell fractionation studies on 
glycoprotein B from human cytomegalovirus (HCMV), Meyer and Radsak 
demonstrated that the DRLRHR sequence at the C-terminus was sufficient to target the 
membrane protein to the INM (Meyer & Radsak, 2000). This C-terminal sequence did 
not show any detectable nuclear localisation signal activity for soluble ~-Galactosidase 
and could not be substituted by the nuclear localisation signal of SV40 T antigen 
(Meyer & Radsak, 2000). These more recent findings suggest potential alternative 
functions for this arginine-based signal motif. 
Sorting and quality control of inner nuclear membrane proteins has had comparatively 
less attention than the quality control of secreted proteins. This situation is now 
beginning to change (Mattaj, 2004). The INM is contiguous with the ER membrane and 
it was generally presumed that, after leaving the translocon, membrane proteins 
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destined for INM diffuse through the ER membrane to reach the INM where the 
proteins are retained by binding to nuclear proteins or DNA (Worman & Courvalin, 
2000). This 'passive' diffusion-retention model has been challenged by more recent 
studies. An INM sorting motif (INM-SM) consisting of 18 hydrophobic amino acids 
was first discovered by Hong and colleagues using the viral envelope protein E66 
(Hong et al., 1997). Arthur Johnson's group used a photo cross-linking approach to 
study both cellular and viral proteins with an INM-SM-Iike sequence to show that an 
initial sorting decision is likely to occur early, within the translocon itself. This was 
based on preferential interaction of INM-SM with the TRAM (translocating chain-
associated membrane protein, a component of the translocon) protein and Sec61a 
(Saksena et al., 2004). The data also revealed that viral and host INM proteins 
interacted similarly with translocon proteins and that the translocon could discriminate 
between INM proteins and other membrane proteins (Saksena et al., 2004). More 
recently, the ER membrane associated importin-alpha-16 protein was found adjacent to 
Sec61a, and was shown to cross-link to INM-SM suggesting a possible involvement of 
this protein in the trafficking of integral membrane proteins to the INM (Saksena et al., 
2006). These results challenge the previous diffusion-retention model and suggest that 
sorting of INM proteins is an active signal driven process and also point to TRAM and 
importin-alpha-16 as important proteins in nuclear membrane sorting. 
A protein can also move apically or baso-laterally along the secretory pathway of 
polarised cells. Cellular polarity is essential for the proper function of many epithelial 
and endothelial cells (Nelson & Yeaman, 2001). In epithelial cells, baso-lateral sorting 
is directed by signal motifs found in cytoplasmic domains. Usually these motifs contain 
a conserved tyrosine residue (Y) and are of the form NPXY or YXX<D (where X can be 
any amino acid and <D is a hydrophobic residue), although some motifs are di-
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hydrophobic (e.g. the LDL receptor and Fe receptor) (Matter et al., 1994). Apical 
sot1ing signals are less well defined, and are generally present in the ER lumen side 
rather than the cytoplasm. Targeting may also be achieved by a GPI-anchor, as for 
decay-accelerating factor (DAF) (Lisanti et al., 1989). N-glycans are also found to act 
as an apical targeting signal for secretory proteins. Growth hormone (GH), which is 
normally non-glycosylated is secreted from both apical and basolateral sides from 
MDCK (Madin-Darby canine kidney) cells. However it is secreted from the apical side 
when glycosylated (Scheiffele et al., 1995). During biosynthetic transport, endolyn, a 
type I transmembrane protein, is targeted from the trans-Golgi network (TGN) to the 
apical cell surface of MDCK cells via a targeting signal found in the lumenal domain of 
the protein. This targeting signal is thought to override/compete with the basolateral 
and lysosomal sot1ing information found in the cytoplasmic tail (Ihrke et al., 2001). 
Site directed mutagenesis studies have pointed to a subset of the eight N-glycosylation 
sites as being necessary and sufficient for apical sorting of endolyn (Potter et al., 2004; 
Potter et al., 2006). In general, the decision between apical and baso-lateral sot1ing 
occurs mainly in the trans-Golgi network. However, the relationship between 
translocation, "early" sorting events and ER protein folding is sure to develop in the 
commg years. 
1.3 Signal peptide cleavage 
All proteins that get inserted co-translationally into the ER through the translocon have 
anN-terminal signal sequence that is recognised by a multi-protein complex termed the 
signal recognition particle (SRP) (Egea et al., 2005). The signal sequence is almost 
always cleaved from the mature polypeptide by signal peptidases (Gilmore, 1991). The 
signal peptidase complex (SPC) of the ER was biochemically and genetically 
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characterized in the 1990's, in both yeast and in mammalian systems (Shelness et al., 
1993). In mammalian cells the SPC is a hetero-oligomeric membrane complex 
comprised of 12, 18, 21, 22/23 and 25 kDa subunits (Evans et al., 1986). In 
Saccharomyces cerevisiae, the Secllp is necessary for signal peptide processing and 
cell viability, and is homologous to the 18 kDa and 21 kDa mammalian subunits (Bohni 
et al., 1988). 
Details are beginning to emerge as to how signal peptides can influence glycoprotein 
folding and how the timing of signal peptide cleavage can influence glycoprotein 
maturation. This area is particularly interesting for virologists, because many viral 
proteins start out as unprocessed polyproteins. Compact viral genomes use their limited 
complement of nucleotides by encoding proteins that must be processed from immature 
precursors. Processing by signal peptidase and related proteases can influence whether 
an immature polyprotein goes on to fold productively. In Semliki Forest Virus (SFV) 
for example, the p62-El coding unit encodes the precursor protein that is cleaved into 
the spike subunits p62 and El by host signal peptidases. This step is required for p62 
and El to form heterodimers from the same precursor protein (cis-heterodimerisation), 
and is co-ordinated with the ER chaperones calnexin and calreticulin, prior to transport 
to the plasma membrane (Andersson & Garoff, 2003). Another example is the Hepatitis 
C virus (HCV), which encodes two envelope glycoproteins, El and E2, which are 
released from HCV polyprotein by signal peptidase cleavage. This step is required for 
maturation (Voisset & Dubuisson, 2004). Thus efficient signal peptide cleavage can be 
seen as a component of the ER quality control for many viral glycoproteins. 
In addition to the signal peptidase complex, a signal peptide peptidase (SPP) has been 
identified and characterized (Weihofen et al., 2002). SPP is an unusual polytopic 
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aspartic acid type intra-membrane protease with homology to presenilin (Xia & Wolfe, 
2003). Presenilins (PS) 1 and PS 2 are required for the intra-membrane cleavage of the 
type I membrane protein amyloid precursor protein (APP) to form the amyloid ~ 
protein (A~), which is believed to be the initiator of pathogenesis in Alzheimer disease 
(Weihofen & Martoglio, 2003). The APP class of proteins is now attracting the interest 
of biologists interested in protein processing and misfolding. Ironically, viruses 
themselves exploit SPP. The capsid of Hepatitis C virus is composed of the p21 core 
protein which is formed by cleavage of the transmembrane domain of the precursor 
form (p23) by SPP. Although this SPP-catalysed cleavage is now thought to be non-
essential for HCV budding, it is still important for the stability of the viral capsid 
(Vauloup-Fellous et al., 2006). 
Signal peptides have uses after being cleaved from the mature polypeptide. One 
interesting example is in the antigen presentation function of Major Histocompatibility 
Complex (MHC) class I molecules. MHC class I molecules usually present peptide 
fragments derived from pathogens to CDS+ T cells of the immune system. Classical 
MHC class I molecules bind to viral peptides as they are synthesized in the ER. 
However, the non-classical MHC class I molecule HLA-E, doesn't bind to viral 
peptides but instead binds to peptides derived from the highly conserved signal 
sequences of other classical MHC class I molecules. This reassures cells of the immune 
system, particularly natural killer (NK) cells, that the cell is not virus-infected and 
inhibits NK-cell mediated cell lysis (Braud et al., 1998). Certain virus-infected cells fail 
to express classical MHC class I molecules at the cell surface, preventing recognition 
QyT-cells. However, due to the additional level of control provided by HLA-E peptide-
complexes, these infected cells will get eliminated by NK cells (Ljunggren & Kane, 
1990; Lanier, 1998). The signal peptide was found to be cleaved at the transmembrane 
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region (Weihofen et al., 2000) by signal peptide peptidase (Lemberg eta!., 2001). This 
releases a peptide fragment into the cytosol which gets transp01ted back into the ER 
lumen through the TAP transporter in order to bind HLA-E (Lemberg et al., 2001; Lee 
et al., 1998). 
Another recent function assigned to SPP is in dislocation of MHC class I heavy chains 
(HC) from the ER (Loureiro et al., 2006). In human cytomegalovirus (HCMV) infected 
cells, several viral proteins are synthesised to prevent surface expression of MHC class 
I molecules and thus allow HCMV to evade the host immune response. US2 and US 11 
are two of these immunoevasins that induce the dislocation of HC molecules from the 
ER and target them for proteosomal degradation in the cytosol (Jones & Sun, 1997; 
Wiertz et al., 1996). Using short hairpin RNAs (shPNAs) to reduce the expression of 
SPP in U373-MG cells expressing US2, Ploegh and colleagues have shown that 
interaction between US2 and SPP is essential for US2 (and not US11) mediated ER 
dislocation of HCs (Loureiro et al., 2006). Thus it is now emerging that SPP might not 
only be involved in signal peptide processing but also in other processors such as ER 
dislocation. 
1.4 Chaperone selection during glycoprotein folding in the ER 
Newly synthesised polypeptide chains targeted to the ER fold as they move through the 
translocon complex, and continue to fold co-translationally with the help of a variety of 
molecular chaperones and folding enzymes present in the ER lumen. Although most 
proteins that fold in the ER are glycoproteins, not all ER proteins are glycosylated 
(Apweiler et al., 1999). About 90% of glycoproteins are likely to caiTy N-linked 
glycans (Apweiler et al., 1999). N-linked glycosylation begins on the cytoplasmic side 
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of the ER with the assembly of the dolichol-linked oligosaccharide donor. This 
oligosaccharide gets 'flipped' to the ER luminal side and is transferred en bloc to an 
asparagine (Asn) residue in the Asn-X-Ser/Thr consensus sequence by the 
oligosaccharidetransferase (OST) (Figure 1.2; (Helenius & Aebi, 2004)). Although 
glycosylation is generally thought to be a post-translational modification, the majority 
of N-linked glycans are initially transfeJTed co-translationally (Nilsson & von Heijne, 
1993; Kowarik et al., 2002). 
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e Mannose 
* N-acetylglucosamine 
The initial composition of the carbohydrate (Glc3Man9GlcNAc2) transferred by the 
oligosaccharyl transferase (OST) onto potential N-glycosylation sites. Glycosidic 
linkages and site of action of various glycosidases are indicated. Gls and Mns indicates 
glucosidase and mannosidase cleavage sites respectively. Adapted and modified from 
(Hebert et al. , 2005). 
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The need for N-linked glycans for efficient secretion was first realised in the 1970's 
with the availability of an N-linked glycosylation inhibitor, tunicamycin (Olden et al., 
1982; Olden et al., 1978). Although glycosylation has been proven to be important for 
proper folding of many proteins, it should be noted that not all glycoproteins are 
equally dependent on their glycans for folding and secretion (reviewed in (Helenius, 
1994)). Some proteins only show partial misfolding in the absence of sugars. For 
example, nonglycosylated MHC class I antigens were still recognised by cytotoxic T 
cells, although their expression at the cell surface was greatly reduced. This defect in 
cell surface expression was not due to rapid degradation of the antigens but due to a 
defect in intracellular transport which effected expression at the plasma membrane 
(Helenius, 1994; Miyazaki et al., 1986). Secretion of different classes of 
immunoglobulins is inhibited to different extents when incubated with tunicamycin. 
For example in plasma cells, IgM secretion was inhibited 81% compared to just over 
background level inhibition of IgG secretion (Hickman & Kornfeld, 1978). 
The presence of glycans on nascent polypeptide chains attracts the attention of two 
Ca2+ binding lectin chaperones, calnexin and calreticulin. Calnexin is a type I ER 
membrane protein (Wada et al., 1991; David et al., 1993) whereas calreticulin is a 
soluble paralogue localised to the ER lumen by a KDEL retention sequence (Fliegel et 
al., 1989: Smith & Koch, 1989). The thiol-disulfide oxidoreductase ERp57 associates 
selectively with nascent glycoproteins in a complex with calnexin and calreticulin 
(Oliver et al., 1997). A protein that has been extensively studied as a model for 
glycoprotein folding is the influenza virus hemagglutinin (HA), a membrane fusion 
-protein produced by the 'flu' virus and synthesised in the ER. Structures of the HA 
fusion protein have been solved (Wi !son et at., 1981) and the HA folding pathway is 
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relatively well understood e.g. (Braakman et al., 1991). Mature influenza HA is a 
homo-trimer, with each monomer comprising an HAl and HA2 chain linked by an 
intermolecular disulfide bond. A recent study using truncated ribosome-bound HA 
nascent chains combined with ER-derived microsomes, followed the initial stages of 
HA maturation pathway (Daniels et al., 2003). HA chains were synthesised from 
truncated mRNA without a stop codon, which gave rise to translation intermediates of 
known lengths. Using 35S-labelled HA translocation intermediates, Daniels and 
colleagues suggested that multiple N-linked glycans are strategically positioned to bind 
the lectin chaperones and the oxidoreductase ERp57 as the nascent chain emerges from 
the translocon complex (Daniels et al., 2003). 
Although some proteins like influenza HA interact preferentially with calnexin and 
calreticulin but not with BiP (Daniels et al., 2003; Mulvey & Brown, 1995), other 
proteins like vesicular stomatitis virus (VSV) G protein have been found to first interact 
with BiP and then with calnexin (Hammond & Helenius, 1994b). However, some 
proteins like unassembled immunoglobulin chains interact sequentially with BiP and 
GRP94 (Melnick et al., 1994). Insight into chaperone selection during glycoprotein 
translocation came from monitoring the maturation of two Semliki forest virus (SFV) 
glycoproteins, p62 and El in infected CHO cells (Molinari & Helenius, 2000). Results 
from this study indicated that if proteins possess N-linked glycans close to the N-
terminus (within the first 50 residues) they are likely to enter the calnexin/calreticulin 
cycle without prior binding to BiP, as seen for p62. However, if glycoproteins have 
their glycans closer to the C-terminus (e.g. El and Vesicular Stomatitis virus; VSV), 
the proteins are more likely to interact with BiP and not seen by calnexin or calreticulin 
(Molinari & Helenius, 2000). The suggestion from these studies is that there is a choice 
between two chaperone systems for assistance with folding during nascent 
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glycoproteins maturation. One system comprises BiP and possibly PDI (Gonz lez et al., 
2002), and the other consists of calnexin, calreticulin and ERp57 (Molinari & Helenius, 
2000). However, it should be noted that this 'simple rule' might not be followed by 
every viral and normal cellular glycoprotein. It also remains unclear whether PDI and 
ERp57 will perform the same function (disulfide bond oxidation) within these two 
systems. Future work will undoubtedly shed more light on how chaperone selection is 
carried out by both viral and cellular proteins. 
1.4.1 Calnexin/Calreticulin cycle 
Glycoproteins that interact with calnexin and calreticulin are subjected to a rigorous 
quality control inspection (Figure 1.3). At first, a core oligosaccharide (Figure 1.2) is 
transferred from a dolichol-linked oligosaccharide donor to a nascent protein with an 
Asn-X-Ser/Thr motif by oligosaccharyl transferase (OST). This GJc3Man9GlcNAc2 
moiety has three terminal glucose residues that are trimmed by glucosidase I and II 
(Gls I and II) to give a monoglucosylated GlcMan9GlcNAc2 intermediate (Ellgaard & 
Helenius, 2003). Gls I is a type II membrane glycoprotein that acts rapidly and 
efficiently to trim the outermost glucose immediately after the addition of a glycan to 
the polypeptide chain (Deprez et al., 2005). On the other hand, the trimming of the 
middle glucose by Gls II (a soluble heterodimer) occurred efficiently only when a 
second glycan was present in the polypeptide chain (Deprez et al., 2005). It is now well 
established that monoglucosylated substrate proteins bind to both calnexin and 
calreticulin and are subsequently released following hydrolysis of the mono-glucose 
residue by glycosidase II (Gls II) (Hammond et al., 1994a). These substrates , may be 
re-glucosylated by UDP-glucose:glycoprotein glycosyltransferase (GT) allowing them 
to re-associate with calnexin (Caramelo et al., 2003). 
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By having a cycle that allows a nascent polypeptide chain to attach to and release from 
calnexin, the protein has sufficient time to find and fold into its most stable 
conformation. This system relies on the detection of localised, disordered 
conformations and exposed hydrophobic patches by GT (Ritter & Helenius, 2000). In 
this way GT determines whether a protein is misfolded or not and acts as the folding 
sensor. Thus a folded protein will not be reglucosylated, whereas a misfolded protein 
will be reglucosylated and sent back to the calnexin/calreticulin cycle. This 'lectin 
only' model (Figure 1.3) proposes that interaction between a folding glycoprotein and 
calnexin/calreticulin is controlled solely by the availability of a single terminal glucose 
residue. A question that arises from this model is how the lectins are able to suppress 
aggregation of the folding glycoproteins, as there doesn't seem to be any direct 
masking of hydrophobic sites by calnexin or calreticulin (Williams, 2006). One 
hypothesis is that the folding glycoprotein might become sequestered between the arm 
domain and globular lectin domain to reduce aggregation with other folding 
glycoproteins (Helenius & Aebi, 2004). There are several lines of evidence to suppot1 
this lectin only model (Wearsch et al., 2004), including the prevention of calnexin/ 
calreticulin interaction with glycoproteins after the addition of glucosidase inhibitors 
(Danilczyk & Williams, 2001). 
An alternative model is the 'dual-binding' model, where calnexin and calreticulin 
interact with folding glycoproteins through their lectin sites as well as their polypeptide 
binding site (Figure 1.3). This model would ensure the binding of hydrophobic 
segments on the folding glycoproteins by the lectins and thus suppress aggregation of 
these proteins (Williams, 2006). Over the past decade considerable evidence has come 
through to support this dual-binding model (lhara et al., 1999; Saito et al., 1999) 
including the use of calnexin point mutants within the lectin site that lacked lectin 
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function but retained the ability to bind ERp57. These mutants were still able to prevent 
aggregation of a nonglycosylated substrate but were compromised in their ability to 
prevent aggregation of a monoglucosylated substrate. Selected mutants, when co-
expressed with the heavy-chain subunits of MHC class I molecule in Drosophila cells, 
were still able to associate with heavy chains and prevent their rapid degradation 
showing that lectin-deficient calnexin still retains many of its chaperone functions in 
vitro and in vivo (Leach & Williams, 2004). Amidst all the evidence, this model does 
need further investigating, especially since an obvious hydrophobic binding site has not 
been precisely pin-pointed on the calnexin crystal structure (Schrag et al., 2001). If a 
protein still fails to fold properly, the slow acting ER al,2-mannosidase I will trim the 
terminal mannose from branch B (Figure 1.2) which will target the misfolded 
glycoprotein to EDEM (ER degradation enhancing 1,2-mannosidase like protein), 
another lectin-like ER resident protein (EIIgaard & Helenius, 2003; Molinari et al., 
2003; Oda et al., 2003). Disposal occurs through a process called ERAD (ER-
associated degradation), which will be discussed in section 1.6. 
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FIGURE 1.3: Two recently proposed models for calnexin/calreticulin mechanism 
of action 
Nascent polypeptides entering the ER lumen through the translocon complex may 
become N-glycosylated with the transfer of the preassembled Glc3Man9GlcNAc2 core 
oligosaccharide from dolicol phosphate to an Asn-X-Ser(Thr) motif by oligosaccharyl 
transferase (OST). The two terminal glucose residues are rapidly removed by 
glucosidase I and II (Gls I & II) to generate the GlcMan9GlcNAc2 oligosaccharide 
recognised by calnexin and calreticulin. In the lectin-only model (purple arrows), 
cycles of glycoprotein release and rebinding are controlled solely by the removal and 
re-addition of the terminal glucose residue by glucosidase II (Gls II) and UDP-
glucose:glycoprotein glycosyltransferase (GT), respectively. Chaperone binding serves 
to retain non-native glycoproteins within the ER and also recruit ERp57 to promote 
disulfide bond formation and isomerisation. In the dual-binding model (green arrows) 
calnexin and calreticulin recognise non-native glycoproteins through their lectin sites as 
well as through a polypeptide-binding site specific for non-native conformers. In both 
models, folded proteins are released from the chaperones, followed by further 
oligosaccharide trimming and export to the Golgi apparatus. Alternatively, for 
misfolded glycoproteins that remain for prolonged periods in the calnexin/calreticulin 
cycle, trimming by a-mannosidase I (Mns I) generates a Man8GlcNAc2 structure that 
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may be recognised by a putative lectin ER degradation enhancing 1,2-mannosidase like 
protein (EDEM). EDEM targets proteins for retrotranslocation and proteasomal 
degradation (ER-associated degradation: ERAD). Three terminal glucose residues are 
shown as red triangles with letter 'G' alongside. Adapted from (Williams, 2006). 
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Structural studies are beginning to help form a better understanding of how calnexin/ 
calreticulin and ERp57 all come together to form a complex that can recognise a wide 
range of glycans. A combination of NMR and a new membrane-based yeast two-hybrid 
system (MYTHS) have been used to show that direct interactions occur between the tip 
of calnexin P-domain (a stable, non-helical fold towards the C-terminus of the protein) 
and the basic carboxy-terminus of ERp57 (Pollock et al., 2004). The crystal structure of 
the noncatalytic domains (b and b') of ERp57 was published recently which revealed a 
conserved basic patch of residues in the b' domain as the site of calnexin interaction 
(Kozlov et al., 2006). The NMR structure of the calreticulin P-domain (from rat) has 
also been studied in detail. This P-domain has a hairpin fold that involves the entire 
polypeptide chain, with the two chain termini in close spatial proximity, to avoid 
folding back on itself (Ellgaard et al., 2001). Site-directed mutagenesis has been used to 
map amino acid residues that are critical for calreticulin function. This recent study has 
identified four amino acid residues (Glu239 , Asp241 , Glu243 , and Trp244) at the tip of the 
'extended arm' of the P domain which are crucial for the formation of a calreticulin-
ERp57 complex (Martin et al., 2006). The three dimensional structure of the ER 
lumenal portion of calnexin has been solved to 2.9 A which revealed an extended 140 
A ~-sandwich arm, including two proline-based motifs, topped with a globular lectin 
domain. The structure of calnexin is ideally positioned for substrate proteins to interact 
with ERp57 (Schrag et al., 2001). 
Calnexin and calreticulin are sometimes thought of as interchangeable proteins that 
perform essentially the same function, but calnexin may be able to perform additional 
tasks by virtue of its transmembrane domain. In pmticular, calnexin can interact with 
the tetraspanin glycoprotein CD82 in a transmembrane dependent manner (Cannon & 
Cresswell, 2001). CD82, a member of the tetraspanin superfamily (Maecker et al., 
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1997), is a lymphoid-specific partner of the immune accessory molecules CD4 and 
CDS. Truncated CD82 molecules lacking one or more transmembrane segments 
accumulate in the ER and are not transported to the cell surface. This occurs even when 
CD82 mutants have a properly folded ER lumenal domain, thus ER retention does not 
necessarily depend on misfolding of lumenal domains. Export of these proteins can be 
restored by co-expression of the CD82 first transmembrane segment, suggesting that 
these hydrophobic sequences are important for quality control of CD82. Glycosylated 
CD82 transiently associates with calnexin (but not with calreticulin), however, the 
truncated proteins associating with calnexin for an extended period of time imply that 
calnexin can sense misfolded conformations even within a bilayer (Cannon & 
Cresswell, 2001). 
1.4.2 Calnexin/Calreticulin involvement in non-glycosylated protein folding 
In contrast to glycosylated proteins, less is known about the quality control of non-
glycosylated proteins. Diseases associated with the ER retention of membrane and 
secretory proteins (not all of which are glycosylated, e.g. Perlizaeus-Merzbacher 
disease) highlight the importance of understanding the molecular mechanisms that 
underlie the quality control of glycosylated as well as non-glycosylated proteins 
(Brooks, 1997). Calnexin and calreticulin have been shown to bind and promote 
folding of non-glycosylated proteins, presumably through protein-protein interactions. 
Most of the evidence for these interactions comes from in vitro studies or using drug 
treatments to inhibit glycosylation artificially (Danilczyk & Williams, 2001; Ihara et al., 
1999; Saito et al., 1999). A recent in vivo study using proteolipid protein (PLP), a 
multi-membrane spanning, non-glycosylated ER protein suggests that calnexin 
contributes directly to ER quality control of PLP (Swanton et al., 2003). PLP is 
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expressed mainly by oligodendrocytes and Schwann cells, and is a major component of 
myelin. Naturally occurring mutations in the PLP sequence are associated with diseases 
including Perlizaeus-Merzbacher disease (PMD) and a milder form of this disorder 
known as spastic paraglegia type 2 (SPG2) (reviewed in (Inoue, 2005)), which cause 
the misfolded mutant protein to be retained in the ER, indicating it is recognised by the 
ER quality control system (Gow & Lazzarini, 1996; Koizume et al., 2006). Results 
from this in vivo study show that calnexin, but not calreticulin, is able to bind to newly 
synthesised PLP as well as to misfolded mutants of PLP through their transmembrane 
domain and that this interaction with calnexin inhibits the degradation of misfolded 
PLP (Swanton et al., 2003). Although the molecular details of how calnexin interacts 
with PLP (and CD82) need to be investigated further, it would be no surprise if 
calnexin is found to be impm1ant for the quality control of other multi-membrane 
spanning non-glycosylated proteins. 
1.4.3 Other quality control checkpoints 
The calnexin cycle is not the only quality control system in the ER. Other decisions 
must be made and check points passed for a protein to reach its final destination. The 
assembly of cargo at the correct ER exit point(s) has been intensively worked on in 
yeast and in mammalian cells (Watanabe & Riezman, 2004). For misfolded, membrane 
spanning proteins it appears that there are at least two check points that have to be 
passed. The first checkpoint examines the cytosolic domain, and if it is misfolded the 
protein is retained in the ER and degraded. Proteins passing this first test face a second 
checkpoint, which monitors the status of lumenal domains (Vashist & Ng, 2004). Once 
proteins (soluble and membrane) pass through these and possibly other ER checkpoints, 
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non-ER proteins are transp011ed to the Golgi where they face another checkpoint and 
eventually transported to their site of function once deemed fully folded. 
1.5 Role of Ca2+ and Zn2+ in the ER 
Another area that should not be overlooked is the role ions and small molecules play in 
the ER. Optimal calcium concentrations are necessary for protein folding (Ashby & 
Tepikin, 2001) and is also important for the function of calcium dependent proteins like 
calnexin and calreticulin. Ca2+ is released from the endoplasmic reticulum and the 
sarcoplasmic reticulum (SR, for a recent review (Rossi & Dirksen, 2006)) via three 
types of channels; inositol 1,4,5-trisphosphate receptors (IP3R), ryanodine receptors 
(RyR) and SCaMPER (sphingolipid Ca2+-release-mediating protein of endoplasmic 
reticulum) (reviewed in (Berridge et al., 1999)). Intracellular Ca2+ waves were initially 
seen in medaka eggs (Ridgway et al., 1977) and later in Xenopus laevis oocytes 
(Lechleiter et al., 1991), hepatocytes (Nathanson et al., 1994) and pig articular 
chondrocytes (D'Andrea & Vittur, 1995) among others. Ca2+ oscillations in Xenopus 
oocytes are triggered by opening of the inositol 1 ,4,5-trisphosphate receptor (IP3R) 
whereas re-uptake in to the ER lumen is mediated by sarco ER calcium ATPases 
(SERCAs) (Camacho & Lechleiter, 1993; Falcke et al., 2003). Calnexin and 
calreticulin are found to inhibit Ca2+ oscillations in a Xenopus oocyte system (Camacho 
& Lechleiter, 1993; Roderick et al., 2000). Calreticulin interacts with the C-te1minal 
sequence of SERCA 2b and is also involved in recruiting ERp57, which can interact 
with the two conserved cysteines found in the longest ER facing loop 4 (L4) of SERCA 
2b (Li & Camacho, 2004). The authors suggest that the classical calnexin-calreticulin 
cycle works in parallel with calnexin-calreticulin and SERCA to maintain optimum 
Ca2+ levels to promote proper glycoprotein folding (Li & Camacho, 2004). Another 
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important cation in the ER is zinc. Certain ER chaperones can depend on Zn2+ for their 
function, including the bacterial Hsp40 homologue, DnaJ and the ER-localised yeast 
homologue Scj1p (Szabo eta!., 1996; Linke eta!., 2003; Silberstein eta!., 1998). In the 
bacterial cytoplasm, DnaJ cooperates with the Hsp70 homologue DnaK and the 
nucleotide exchange factor GrpE in recognising polypeptides in their extended 
conformation, preventing protein misfolding prior to completion of translation (Houry, 
2001). It has also been shown that in yeast Msc2p, a member of the cation diffusion 
facilitator (CDF) family, is responsible for transporting of Zn2+ into the ER lumen 
(Ellis et a!., 2004). Depletion of Zn2+ induces an unfolded protein response (UPR) in S. 
cerevisiae and mammalian cells, which indicates the imp01tance of this metal ion in 
maintaining ER function (Ellis eta!., 2004). More recently, Msc2p was found to form a 
heteromeric zinc transport complex with another CDF family member, Zrg17, in the 
ER membrane (Ellis et a!., 2005). The mammalian homologues of Msc2p and Zrg17 
were also found to functionally interact, suggesting heteromeric complex f01mation to 
be an evolutionary important concept within this metal ion transporter family (Ellis et 
a!., 2005). 
1.6 ERAD 
Until recently it was thought that misfolded proteins get degraded within the ER 
(reviewed in (Fra & Sitia, 1993)), but this view has changed to the currently held 
concept that misfolded proteins are translocated back into the cytosol and degraded by 
the 26S proteasome through ER-associated degradation (ERAD) (for a recent review 
(Kostova & Wolf, 2003)). Interaction with EDEM (ER degradation enhancing 1,2-
mannosidase like protein) proteins is thought to release misfolded glycoproteins from 
the calnexin/calreticulin cycle (Molinari eta!., 2003; Oda eta!., 2003). InS. cerevisiae, 
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trimming of the terminal mannose residue gives rise to Man8GicNAc2 (M8, Figure 1.3) 
thought to be the glycan signal for binding to EDEM (Jakob et al., 1998). Recently 
however, Frenkel and colleagues have used the model ERAD substrates ASGRP 
(asialoglycoprotein receptor) H2a and unassembled CD3o, to show that mannose 
trimming can give rise to Man6GlcNAc2 (M6) and Man5GlcNAc2 (M5) structures in 
mammalian cells (Frenkel et al., 2003). These trimmed N-glycans do not have the 
terminal mannose residue recognised by UDP-glucose:glycoprotein glycosyltransferase 
(GT). This enables the proteins to escape re-entering the calnexin/calreticulin cycle 
thus providing a potential mechanism for targeting misfolded proteins for proteasomal 
degradation (Frenkel et al., 2003). Several other structures have also been shown to act 
as a glycan signal including Glc 1Man7GicNAc2, Glc 1Man8GicNAc and Mans-7GicNAc, 
(Kitzmuller et al., 2003; Hosokawa et al., 2003; Hirao et al., 2006). 
Three EDEM proteins have been characterised from mouse (Hirao et al., 2006; Olivari 
et al., 2005; Hosokawa et al., 2001) and humans (Mast et al., 2005), but so far only 
EDEM3 is found to stimulate mannose trimming showing a1,2-mannosidase activity in 
vivo (Hirao et al., 2006). However, all three EDEM proteins are able to accelerate 
ERAD of misfolded glycoproteins, indicating that the mechanisms that underlie their 
action are likely to be different. Although trimming of N-glycans is the main 
mechanism for targeting misfolded proteins for degradation, BiP (Plemper et al., 1997), 
PDI (Tsai et al., 2001) and Eps1p (Wang & Chang, 2003) have also been found to play 
a key roles in retrograde transpmt to the cytosol. Retro-translocation of ERAD 
substrates involves a number of components including a dislocation channel, ubiquitin 
ligases, AAA ATPase (Cdc48p in yeast and p97 in mammals), and for membrane 
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extracted substrates accessory factors such as Rad23p and Dsk2p (for a recent review 
(Meusser et al., 2005)). 
The protein conducting channel Sec61 p was initially suggested to be involved in the 
retro-translocation of misfolded proteins by Wiertz and colleagues (Wiertz et al., 1996). 
They showed that in HCMV (human cytomegalovirus) infected mammalian cells 
(US2+ cells), the viral ER resident protein US2 targets MHC class I heavy chains (HC) 
for proteasomal degradation via the Sec61 complex. In a subsequent study, genetic 
evidence to support the role of Sec61 p as a retro-translocation pore came with the 
isolation of two cold-sensitive mutants of sec61 (sec61-32 and sec61-41) (Pilon et al., 
1997). At 24°C pL1gpaf, the non-glycosylated and misfolded form of the mating 
phereomone precursor prepro-alpha-factor (ppaf) was found associated with Sec61 p in 
sec61 mutant membranes (Pilon et al., 1997). Another protein suggested to f01m the 
dislocation pore is the yeast protein Derl p (Knop et al., 1996) and its mammalian 
homologue Derlin-1 (Ye et al., 2004). Derlin-1 was found to interact with the HCMV 
viral protein US 11 and a novel membrane protein VIMP (VCP-interacting membrane 
protein) dUiing exp01t of MHC class I HC to the cytosol (Ye et al., 2004). Derlin-1 
interaction with VIMP is via the ATPase p97, which recognises poly-ubiquitinated 
proteins (Jarosch et al., 2002) and acts to extract misfolded glycoproteins from the ER 
membrane (for a recent review (Meusser et al., 2005)). The cytosolic C-terminus of 
Derlin-1 was recently found to interact with the N-terminus of the deglycosylating 
enzyme peptide:N-glycanase (PNGase) (Katiyar et al., 2005), showing that for a subset 
of glycoproteins interacting with Derlin-1, retro-translocation could be coupled to the 
subsequent steps leading to proteasomal degradation. In a recent study, Derlin-2 and 
Derlin-3 have been shown to provide the missing link between EDEM and p97 (Oda et 
al., 2006). Whereas Derlin-1 has not been found to associate with EDEM or the 
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degradation substrate (the null Hong Kong (NHK) mutant of a1-proteinase inhibitor 
(a1-Pl)), Derlin-2 and -3 do form this complex (Oda et al., 2006). All three Derlin 
proteins are targets of the IRE1-XBP1 pathway. 
1.7 Disulfide bond formation 
Disulfide bond formation is a vital part of the protein folding process in the ER (Tu & 
Weissman, 2004). A disulfide bond is a covalent modification that brings two cysteine 
residue sulfhydryls together to form a disulfide bridge. This bridge can be either 
intermolecular (between two cysteine residues in two different polypeptide chains) or 
intramolecular (between two cysteine residues in the same protein). Disulfide bridges 
are required for structural stability and enzymatic function, as well as for regulation of 
protein activity (Ellgaard et al., 1999), and can be formed co-translationally dming 
protein folding in the ER (Bergman & Kuehl, 1979a; Bergman & Kuehl, 1979b; Peters 
& Davidson, 1982; Bergman & Kuehl, 1979a). 
Disulfide bonds are found mostly in secreted and membrane proteins folded in the ER. 
But there are some impm1ant examples of cytosolic proteins like molecular chaperones 
(HSP33) and transcription factors (OxyR and YAPl) that are subjected to regulated 
disulfide bond switching (Linke & Jakob, 2003). Thiol-based regulatory switches play 
central roles in cellular responses to oxidative stress, nitrosative stress, and changes in 
the overall thiol-disulfide redox balance (Paget & Buttner, 2003). The yeast 
transcriptional regulator protein Yap 1 p, which resides in the cytoplasm, requires 
disulfide bond formation in its N-terminal cysteine 1ich domain and/or C-terminal 
cysteine rich domains to accumulate in the nucleus upon oxidative stress (Kuge et al., 
1997), in order to induce expression of genes that encode antioxidant proteins (Kuge et 
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al., 1997; Coleman et al., 1999). A mammalian neuronal cell line HT22 has been used 
to identify disulfide-bonded proteins (DSBP) after exposure to various oxidative insults. 
This revealed that disulfide bond formation within families of cytoplasmic proteins is 
dependent on the nature of the oxidative insult and might provide a common 
mechanism used to control multiple physiological processes (Cumming et al., 2004). 
1. 7.1 The role of glutathione in disulfide bond formation 
Glutathione is a tripeptide (L-y-glutamyl-L-cysteinyl-glycine) that is synthesised in the 
cytosol from the precursor amino acids glutamate, cysteine and glycine and is a 
ubiquitous molecule produced in all organs, especially the liver (Meister & Anderson, 
1983; Ziegler, 1985; Pastore et al., 2003). In the 1960s, Anfinsen and colleagues 
showed that disulfide bond formation in proteins occuned spontaneously in vitro 
(Anfinsen et al., 1961). These studies led to the long-held assumption that disulfide 
bond formation was spontaneous in vivo. However, in vivo disulfide-linked protein 
folding was a slow process and the discovery of PDI a few years later (from rat liver, 
(Goldberger et al., 1963)) hinted at this process being enzyme assisted. It was almost 
thirty years later with the discovery of dsbA mutant cells in Escherichia coli which 
secrete proteins (including beta-lactamase and alkaline phosphatase) lacking disulfide 
bonds, that it was confirmed that disulfide bond formation was in fact a catalysed 
process in vivo (Bardwell et al., 1991). 
In eukaryotes, before the discovery that Ero1 oxidises PDI, oxidised glutathione 
(GSSG) was commonly thought to provide oxidising equivalents for the formation of 
disulfide bonds. This assumption was based on a study by Hwang and colleagues who 
measured the ratio between oxidised (GSSG) and reduced (GSH) glutathione within the 
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secretory pathway using a thiol tetrapeptide (NYTC; N Acetyi-Asn-Try-Thr-Cys-NH2) 
(Hwang et al., 1992). The study showed that the ratios changed between 30-100 GSH: 
1 GSSG in the cytosol to 3 GSH: 1 GSSG in the secretory pathway (Hwang et al., 
1992). This initial work did not, however, measure absolute concentrations or 
determine glutathione ratios in the ER lumen. More recently, absolute glutathione 
concentrations have been measured using the thiol-specific probe monobromobimane 
(mBBr) in rat liver microsomes (Basset al., 2004), but glutathione can still leak during 
microsome isolation providing only an approximate ratio between GSH and GSSG 
(3: 1). Taken together the results do show that the ER is more oxidising than the cytosol 
and has ratios similar to that found in redox buffers optimum for in vitro oxidative 
protein folding. 
Ero1 can drive the oxidation of substrates in vitro and in vzvo through PDI in the 
absence of GSH or GSSG (Franc! & Kaiser, 1998; Franc! & Kaiser, 1999; Pollard et al., 
1998; Tu et al., 2000), or even in the presence of excess GSH (Tu et al., 2000), 
indicating that the process of disulfide bond formation can occur independently of 
GSSG. Recent work in mammalian cells, however, shows that glutathione still has an 
important role to play in the ER. Lowering intracellular GSH levels using specific 
inhibitors of GSH synthesis caused an acceleration in disulfide bond formation in 
model proteins such as tPA (tissue-type plasminogen activator) but the majority of 
these disulfide bonds were non-native and needed to undergo isomerisation to achieve 
the native state (Chakravarthi & Bulleid, 2004). In microsomes derived from HT1080 
cells, the oxidoreductase ERp57 is reduced by GSH in a cytosol-dependent manner and 
biotinylated glutathione is found in mixed disulfide with ERp57 (Jessop & Bulleid, 
2004). The importance of a reducing cytosol for the oxidative function of the ER was 
also shown by Molteni and colleagues using a semi permeabilised cell system (Molteni 
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et al., 2004). COJTect disulfide bond formation thus requires both Erol and GSH, with 
GSH controlling the reductive pathway of the endoplasmic reticulum, rather than the 
oxidative pathway (Chakravarthi & Bulleid, 2004). Under steady state conditions more 
than half of the glutathione in rat liver microsomes exists as mixed disulfides with ER 
resident proteins (Bass et al., 2004), but whether this pool is a major player in the 
bigger scheme of in vivo disulfide bond formation is yet to be determined. 
Another potential role for glutathione is during oxidative stress. Disulfide bond 
formation in the ER of both yeast and mammalian cells can lead to the formation of 
reactive oxygen species (ROS) (Harding et al., 2003; Haynes et al., 2004). In S. 
cerevisiae, HIP (Hrdlp-independent proteolysis)-deficient cells (en;29L1) are unable to 
remove misfolded proteins from the ER (Haynes et al., 2002) and thus show increased 
sensitivity to ER stress and accumulation of ROS (Haynes et al., 2004). Overexpression 
of CPY* (a mutant misfolded form of protein carboxypeptidase Y) in erv29L1 cells 
causes accumulation of ROS and inhibition of cell growth, but addition of GSH to the 
growth medium allows these cells to grow by lowering the levels of ROS (Haynes et al., 
2004). Studies from both yeast and mammalian cells have shown that the response to 
an increase in oxidative stress is a rise in the levels of glutathione, which can be used to 
eliminate ROS and aid in disulfide bond formation. The emerging picture from all these 
studies is that glutathione plays a key role in allowing native disulfide bonds to form as 
well as to protect cells during oxidative stress (for a recent review see (Chakravarthi et 
al., 2006)). 
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1.7.2 The role of PDI in disulfide bond formation 
POI has a domain architecture that is based on the prototypical cytoplasmic redox 
protein thioredoxin (Darby et al., 1996). Limited proteolysis (Darby et al., 1996; 
Freedman et al., 1998; Freedman et al., 1994) was used to identify the four structural 
domains of PDI, abb'a' (Figure 1.4). The a and a' domains each contain one 
catalytically active WCGHC motif, while the b and b' domains are redox inactive 
(Farquhar et al., 1991; Kemmink et al., 1997). The high redox potentials for the a and 
a' domains of PDI were initially measured in a glutathione redox buffer by measuring 
the free -SH groups in PDI after alkylation with iodoacetate (- -175 mV from calf liver 
POI) (Lundstrom & Holmgren, 1993). Similar redox potentials were reported recently 
with yeast PDI (- 188 mV for a domain, -152 mV for a' domain) (Tian et al., 2006). 
The PDI redox potentials were in-between the strongest oxidant, DsbA (- 120 m V 
(Zapun et al., 1993)) and the strongest reductant, thioredoxin (-270 mV (Aslund et al., 
1997)), which indicated the ability of PDI to catalyse both oxidation and reduction of 
disulfide bonds. The b and b' domains show significant sequence similarity to each 
other and although their amino acid sequences do not show significant similarity to 
other members of the thioredoxin family, NMR studies have shown the b domain to 
contain a thioredoxin fold (Kemmink et al., 1997). The b' domain provides the primary 
peptide-binding site, but does require the assistance of the other domains especially 
during binding of larger substrates like non-native proteins (Kiappa et al., 1998; Darby 
et al., 1998). The refolding activity of the b domain was investigated recently using 
truncated variants of yeast PDI, which showed that deletion of the b domain did not 
greatly influence the refolding of rRNase (reduced ribonuclease) but did decrease the 
r(!te of refolding of sRNa~e (scrambled ribonuclease) (Tian et al., 2006). The data so far 
suggests that the b domain may have a structural role in PDI rather than a catalytic role 
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(reviewed in (EIIgaard & Ruddock, 2005)), but may also contribute to the refolding rate 
in selected substrates (Tian et al., 2006). The C-terminal domain (c) is acidic and 
harbours the KDEL ER retention sequence. The existence of an inter-domain linker (x, 
Figure 1.4) region (19 amino acid residues) between b' and a' domains was 
experimentally confirmed by Pimeskoski and colleagues using b' and b'x constructs 
from human PDI (Pimeskoski et al., 2004). The physiological importance of having 
this x region is to be determined. 
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a b b' X a' c 
-CGHC- -CGHC- KDEL 
FIGURE 1.4: Domain structure of PDI 
PD I is composed of four thioredoxin like domains; a, a', b and b'. Of these a and a' 
domains contain the catalytically active thioredoxin motif Cys-Gly-His-Cys, whereas 
the b and b' are non-catalytic domains. The c region is made up of mainly acidic amino 
acids and contains the -KDEL ER retention motif whereas the x region is a linker 
between the b' and a' domains. Adapted and modified from (Freedman et al., 2002). 
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NMR spectroscopy had been used to determine the individual a and b domain 
structures of human PDI but it was only in early 2006 that the first full length PDI 
crystal structure (to 2.4 A resolution) was published (Tian et al., 2006). This yeast PDI 
(Pdi 1 p) crystal structure revealed that the four thioredoxin domains are aiTanged in the 
shape of a twisted 'U' with the active sites facing each other. The crystal structure 
supplements most of the earlier biochemical data, for example by showing the presence 
of a highly hydrophobic pocket in the b' domain for substrate binding and the detection 
of a disulfide bridge only between the two cysteines at the a and not the a' domain 
(Tian et al., 2006). 1272 of human PDI was recognised as an essential residue for 
substrate binding (using fl.-somatostatin, mastoparan and sRNase) by Pirneskoski and 
colleagues (Pimeskoski et al., 2004) and has been mapped to the bottom of the 
hydrophobic pocket in the b' domain in the yeast PDI crystal structure, confirming 
previous mutational data (Tian et al., 2006). A 17 residue connection with a mostly 
extended conformation corresponding to the x linker region between the b' and a' 
domains was confirmed in the crystal structure (Tian et al., 2006). Activity assays 
carried out with RNase demonstrated that the full length PDI, including the C-terminal 
tail, is required for full catalytic activity (Tian et al., 2006). 
In yeast, Pdilp is required for oxidation and isomerisation of disulfide bonds. The 
precise contribution Pdi1p makes to oxidation and isomerisation has been open to 
debate. Initially using active site mutants of Pdil p, it was claimed that isomerisation 
was the essential function of Pdi1p (Laboissiere et al., 1995). However, Pdi1p deficient 
yeast can be reconstituted with an inducible active site a domain construct essentially 
lacking isomerase activity (Solovyov et al., 2004). This module restores both viability 
and oxidative protein folding to the Pdi 1 p deficient yeast. These results suggest that 
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oxidation, rather than isomerisation, is the essential activity of Pdi 1 p, although both 
oxidation and isomerisation reactions are likely to be undertaken by Pdi 1 pin vivo. 
Work in mammalian cells suggest that PDI is at least partly oxidised, which supports its 
role as a primary protein oxidant (Mezghrani et al., 2001). A more recent study by 
Jonathan Weissman and colleagues shows an asymmetry in the rate of oxidation of the 
two active sites in full length PDI molecules (Kulp et al., 2006). Two active site 
mutants of PDI were constructed with either the pair of cysteines in the a domain active 
site (aAXxAa' cxxc) or the a' domain active site (acxxca' AXXA) mutated to alanines. The 
Erolp oxidative folding pathway was reconstituted using purified Erolp, FAD, 
RNAase (Tu et al., 2000) and the oxidase and isomerase activity of the two PDI 
mutants monitored by using the artificial substrate cCMP (Kulp et al., 2006). Data 
shows that the C-terminal active site is a disulfide oxidase compared to the disulfide 
isomerase activity at theN-terminus (Kulp et al., 2006). This asymmetry in active sites 
is only observed in the context of the full length PDI protein, indicating that the 
specific order of thioredoxin domains in PDI is important in allowing the a and a' 
domains to serve as an isomerase and an oxidase, respectively (Kulp et al., 2006). 
PDI is a multifunctional protein that, besides its oxidoreductase activity, can also act as 
a chaperone to facilitate the folding of proteins devoid of disulfide bonds (Wang & 
Tsou, 1993). It is able to recognise terminally misfolded proteins, targeting them to 
proteasomal degradation thus acting as a component of the quality control machinery in 
the ER (Gillece et al., 1999). PDI is also involved in forming a multi-protein complex 
in the assembly and retention of procollagen (Bottomley et al., 2001). PDI is required 
for the exp011 of cholera toxin (Tsai et al., 200 1) and Pseudomonas exotoxin A (PE) 
(McKee & FitzGerald, 1999) from the ER to the cytosol, and for the reduction of ricin 
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toxin pnor to export to the cystoplasm (Spooner et al., 2004). In addition, PDI 
constitutes the p subunit of prolyl-4-hydroxylase tetramer (P4H, a 2p2) (Koivu et al., 
1987; Wilson et al., 1998; Myllyharju, 2003) and is a component of the microsomal 
triglyceride transfer protein complex (Wetterau et al., 1990). Within the P4H tetramer 
PDI plays a role in retaining the insoluble a subunit in a soluble, active conformation 
as well as in localising the tetramer within the ER (Vuori et al., 1992a; Vuori et al., 
1992b ). A recent study has shown that cooperativity between three PDI domains, a, b' 
and a', is needed for efficient tetramer assembly, whereas mutations in b' domain 
residues important for peptide binding do not prevent tetramer assembly or reduce P4H 
enzyme activity (Koivunen et al., 2005). PDI is also found to prevent neurotoxicity 
associated with ER stress and protein misfolding, a protective role that is inhibited 
through S-nitrosylation (transferring of NO groups to a and a' cysteine thiols) in 
neurodegenerative diseases like Alzheimer's and Parkinson's disease (Uehara et al., 
2006). 
PDI is not the only protein disulfide isomerase in the ER. In yeast, Pdi1p homologues 
include Mpd1 p, Mpd2p, Eug1 p and Eps 1 p. To some extent the functions of these 
proteins are overlapping and redundant, although Mpd1p is the only homologue 
capable of performing all the essential functions of Pdilp (Norgaard et al., 2001). Eps1 
is unusual in that it is membrane associated, and has been implicated in the quality 
control and trafficking of the yeast H+-ATPase Pma1p. Eps1p is required for Pma1p 
cell surface expression (Wang & Chang, 1999). PDI-family members identified so far 
in humans include ERp57, ERp44 and ERp72; these and other family members are 
. descrjbed in a rec.ent review by Ellgaard an.d Ruddock (Ellgaard & Ruddock, 2005). 
ERp57 can catalyse oxidation, reduction and isomerisation reactions in vitro (Fricke! et 
al., 2004) and is an important component of the calnexin/calreticulin cycle as discussed 
40 
Chapter 1: General introductio11 
in section l.4.2. Both PDI and ERp57 were found to form transient complexes with two 
viral glycoproteins, E1 and p62, in Semiliki Forest virus infected CHO cells, but 
calnexin and calreticulin were only found in ternary complexes with ERp57 (Molinari 
& Helenius, 1999). ERp57 is also a component of the MHC class I loading complex 
(Cresswell et al., 1999) but whether it is involved in oxidation, isomerisation or 
reduction reactions within the complex was unclear (Dick et al., 2002) until a recent 
study by Zhang and colleagues (Zhang et al., 2006; Solda et al., 2006). They showed 
that depletion of ERp57 using siRNA in mouse L cells slowed down the formation of 
the second disulfide bond in MHC class I HC but did not greatly affect peptide loading 
of class I molecules, indicating the importance of ERp57 in in vivo disulfide bond 
formation (Zhang et al., 2006). In addition, ERp57 was recently shown to play a crucial 
role in post translational disulfide bond reshuffling during influenza virus 
hemagglutinin (HA) folding to attain its native confmmation (Solda et al., 2006). 
ERp44 lacks the C-terminal active site cysteines, but the N-terminal active site 
cysteines are involved in the ER retention of Ero1 and nascent secretory proteins 
(Anelli et al., 2002; Anelli et al., 2003). ERp44 was recently shown to be involved in 
Ca2+ signalling (Hi go et al., 2005). Inositol 1 ,4,5-trisphosphate receptors (IP3R) are 
Ca2+ releasing channels on the ER that play a major role in generating complex Ca2+ 
signalling patterns (reviewed in (Patterson et al., 2004)). ERp44 was shown to interact 
with the third lumenal loop of IP3R (IP3R1) and is thought to act as an ER Ca2+ sensor 
contributing to regulating intralumenal and cytosolic Ca2+ concentrations (Higo et al., 
2005). The function of the non-thioredoxin-like C-terminal two thirds of ERp44 is still 
unknown. Less is known about the function of ERp72, other than that it can be 
selectively found in ce1tain chaperone/substrate complexes, for example in the folding 
of thyroglobulin (Sargsyan et al., 2002), and in mediating ER retention of misfolded 
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transmembrane proteins like low density lipoprotein receptor (LDLR) (Sorensen et al., 
2006), misfolded secretory proteins like matrilin-3 (MATN3) (Cotterill et al., 2005) 
and a mutant form of thyroglobulin (cogTg) as well as toxins like cholera toxin (CT) 
(Forster et al., 2006). 
During the past few years several new PDI family members have been reported 
including, ERpl8 (Aianen et al., 2003), ERp46 (Knoblach et al., 2003), ERdj5 (Cunnea 
et al., 2003), thioredoxin-related transmembrane protein 2 (TMX2 (Meng et al., 2003)), 
TMX3 (Haugstetter et al., 2005) and PDILT (van Lith et al., 2005), all of which have a 
wide range of domain architectures and active site motifs (for a recent review (EIIgaard 
& Ruddock, 2005)). Of these new PDI members, ERpl8 possesses the ability to 
catalyse thiol-disulfide exchange reactions (Aianen et al., 2003). The newest member to 
join the PDI family is the two domain (b and b') ER resident protein ERp27, which 
lacks a CXXC active site making it a non-catalytic family member unable to catalyse 
thiol-disulfide reactions (Aianen et al., 2006). However, unlike other non-catalytic PDI 
family members (e.g. ERp29), ERp27 does not seem to follow the general pattem of 
having one thioredoxin fold domain and one a-helical domain. Instead it has two 
thioredoxin domains, which the authors suggest could form a novel sub-family within 
the PDI family (Aianen et al., 2006). ERp27 interacts with ERp57 using the same site 
on the ERp57 b' domain utilized by calnexin and calreticulin, suggesting that ERp57 is 
unlikely to bind both ERp27 and calnexin/calreticulin together. Identifying the specific 
substrates of ERp27 and ERp57 could shed more light on the mechanism of action for 
these proteins (Aianen et al., 2006). 
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1. 7.3 Prokaryotic disulfide bond formationlisomerisation 
In prokaryotes, there are two well established pathways, the oxidative pathway which is 
involved in the formation of disulfides, and the isomerisation pathway, which shuffles 
incorrectly formed disulfides (Figure 1.5, reviewed in (Collet & Bardwell, 2002; 
Kadokura et al., 2003)). Disulfide bonds are donated directly to unfolded polypeptides 
by DsbA; DsbA gets reoxidised by DsbB (Bardwell et al., 1993). Beckwith and 
colleagues used a DsbA mutant that altered the cis proline-151 residue, to capture 
mixed disulfide complexes between DsbA and its substrates in vivo to identify potential 
substrates of DsbA (Kadokura et al., 2004). DsbB generates disulfides from oxidised 
quinones, which get reoxidised by the electron transpm1 chain (Kobayashi & Ito, 1999). 
In the isomerisation pathway, the two isomerases DsbC (Zapun et al., 1995) and DsbG 
(Andersen et al., 1997; Bessette et al., 1999), are kept reduced and thus in their active 
form by the membrane protein DsbD. DsbD is kept reduced by cytosolic thioredoxin in 
an NADPH-dependent reaction (Rietsch et al., 1997). Although questions have been 
answered as to the importance of these pathways in bacteria, numerous questions still 
remain unanswered including how DsbB utilises quinones as mobile electron carriers 
and if DsbA and DsbC show specificity in the typ~s of substrates they use (Kadokura et 
al., 2003). 
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FIGURE 1.5: Disulfide bond formation, isomerisation and reduction pathways in 
prokaryotes 
A. Substrate proteins are oxidised in the bacterial periplasm through a thiol-disulfide 
exchange reaction with DsbA. DsbA is reoxidised by the cytoplasmic membrane 
protein DsbB, which in turn transfers electrons to quinones (Q) and via the electron 
transport chain (E.T.C) to the final acceptor, oxygen. B. Disulfide bond isomerisation 
in the periplasm is catalysed by the soluble oxidoreductase DsbC, which is kept in a 
reduced form by the cytoplasmic membrane protein DsbD. DsbD is kept in a reduced 
form by cytoplasmic thioredoxin, which obtains electrons from NADPH via 
thioredoxin reductase. Black arrows show the flow of electrons. Adapted from (Sevier 
& Kaiser, 2006a). 
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1.7.4 Disulfide bond/ormation by Erol in eukaryotes 
In yeast, the essential genes required for the catalysis of disulfide bonds in the ER are 
ER01 and PDI (Frand & Kaiser, 1998; Pollard et al., 1998). The gene product, Ero1p, 
is an ER-resident flavoprotein that uses 0 2 as its terminal electron acceptor and passes 
oxidative equivalents on to Pdilp (Figure 1.6), the yeast protein disulfide isomerase 
(Frand & Kaiser, 1999; Tu et al., 2000). A second membrane-associated flavoprotein, 
Erv2p, was identified recently which can operate in parallel with Ero1p in yeast 
(Gerber et al., 2001; Grosset al., 2002). Ero1p and Erv2p both directly oxidise PDI, but 
unlike Ero1p, Erv2p is not essential for cell viability (Sevier et al., 2001). Erv2p a small, 
largely a-helical dimer contain a tightly bound FAD cofactor adjacent to a CXXC motif 
and a second cysteine pair located on a flexible loop (Grosset al., 2002). 
45 
Chapter 1: General introduction 
SH 
Newly synthesised 
protein 
FIGURE 1.6: Oxidising equivalents flow from Erolp to Pdilp and target proteins 
In Saccharomyces cerevisiae (and other eukaryotes) Pdilp is oxidised through dithiol-
disulfide exchange with Ero 1 p. Proteins folding in the ER requiring disulfide bonds can 
then be oxidised through thiol-disulfide exchange with Pdi 1 p. Adapted and modified 
from (Fassio & Sitia, 2002). 
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Two clusters of conserved cysteine residues are important for Ero structure and 
function (Frand & Kaiser, 2000; Benham et al., 2000). Mutational and biochemical 
studies of the yeast ERO 1 gene have shown that the N-terminal active site cysteines are 
involved in a dithiol-disulfide reaction with PDI. Accepted electrons are then 
transferred on to the C-terminal active site cysteines that then pass on electrons to 
molecular oxygen via FAD (Frand & Kaiser, 2000; Tu & Weissman, 2002). The crystal 
structure of yeast Ero1 p was determined recently (Gross et al., 2004) which 
complimented previous biochemical data and revealed the spatial relationship between 
the functionally important cysteines and bound cofactor. The CXXCXXC motif is in 
contact with a non-covalently bound FAD molecule and in yeast Ero1p the FAD 
cofactor is held between helixes a2 and a3 in a bent conformation (Grosset al., 2004). 
Comparison of the two Ero1 p crystal forms revealed a flexible loop containing the 
Cl00/Cl05 disulfide bond which adopts an 'in' and 'out' conformation (Gross et al., 
2004). Electrons accepted from PDI by the Cl00/Cl05 disulfide bond in the 'out' 
conformation could shuttle the electrons onto the C352/C355 active site disulfide when 
in the 'in' conformation. 
There are two Ero1p counterparts in mammals, Erola and Ero1P (Cabibbo et al., 2000; 
Pagani et al., 2000). Both hEROs are capable of rescuing the S. cerevisiae ero1-1 
thermosensitive mutant and catalysing the oxidation of model substrates (Mezghrani et 
al., 2001; Cabibbo et al., 2000; Pagani et al., 2000), indicating that these proteins are 
involved in disulfide bond formation. Mutational studies at the CXXCXXC motif in 
Ero1a has shown that this active site is important for the folding, structural integrity, as 
well as the stability of the Ero1a-PDI complex (Benham et al., 2000). Although Ero1a 
and ErolP have many similar biochemical prope11ies there are some important 
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differences between them. At the transcription level, Ero1a and Ero1j3 mRNAs show 
some differences in their tissue specific distribution, with Ero1j3 being noticeably 
expressed more in secretory tissues such as pancreas, stomach and pituitary gland 
(Pagani et al., 2000). Ero1j3 transcript expression can be induced chemically by 
preventing N-glycosylation and disulfide bond formation, both of which trigger the 
unfolded protein response (UPR) (Pagani et al., 2000). Ero1a, on the other hand is 
induced by hypoxia (Gess et al., 2003). Recent evidence examining the disulfide bond 
rich secreted proangiogenesis factor VEGF (Vascular endothelial growth factor) 
showed that Ero1a is involved in a HIF-1 (hypoxia-inducible factor-1) mediated 
pathway used to induce protein secretion under hypoxic conditions (Forsythe et al., 
1996; May et al., 2005). May and colleagues found that reducing the level of Ero1a by 
siRNA significantly inhibited VEGF secretion, compromised proliferation and induced 
apoptotic death (May et al., 2005). Thus targeting Ero1a expression in tumour cells 
(where hypoxic conditions prevail) might be a potential therapeutic target for future 
cancer therapies. 
Similar to yeast and animals, higher plants also produce disulfide bonded secretory 
proteins in the ER. Two Erolp homologues (AER01 and AER02) have been detected 
in plants (Arabidopsis thaliana) (Dixon et al., 2003). The N-terminal CXXXXC region 
of the two AERO proteins were identical (CRLRDC) but were significantly different 
from yeast and human sequences. At the C-terminus active site, the AERO protein 
sequences were similar to Erolj3, having a strongly charged CXXCXXC motif, which 
was more common among the Ero proteins aligned in this study. Thus the authors 
·suggest the charged !3-like CXXCXXC motif to be the ancestral sequence. Of the two 
AERO genes, AERO l has several upstream UPR response elements, indicating that 
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like mammals plants might also have one inducible oxidoreductase (similar to Erolf3) 
and a housekeeping oxidoreductase (Dixon et al., 2003). When in vitro translated in 
HT 1080 cells, the plant signal sequences were able to target the two AERO proteins to 
the mammalian ER where they were glycosylated. Plants also encounter different stress 
conditions (for example anoxic conditions and free radical damage) similar to ER 
stresses in animals, thus Arabidopsis could be used as a potential model in 
understanding the biochemistry of disulfide bond formation and how a multi-cellular 
organism has evolved to deal with different oxidative processes under changing 
conditions (Dixon et al., 2003). 
1. 7.4.1 Localisation of EROs in the ER 
Ero 1 a and Ero 1 f3 both lack a known ER localisation motif, making it unclear how 
these hEROs are retained in the ER lumen. Yeast Ero1p has a C-terminal tail of 127 
amino acids that enable this protein to be localised in the ER (Pagani et al., 200 I). 
Mutant Ero1p6C (Erolp lacking the C-terminal tail) and Ero1a, when expressed in 
yeast cells with the endogenous ERO gene disrupted (6ER01), behave like soluble 
proteins and fail to complement 6ER01 cells (Pagani et al., 2001). This was somewhat 
surprising since biochemical analysis has shown that hEROs are closely associated with 
ER membranes in human cells (Pagani et al., 2000). In vitro translated hEROs in 
presence of semi permeabilised (SP) HT1080 cells, were used in extraction 
experiments at pH 11 and pH 13. Membrane associated proteins like calreticulin are 
partially extracted from the membranes at pH 11, but completely extracted at pH 13. 
Ero1a and Ero1f3 behaved similar to calreticulin and thus suggested that the hEROs are 
soluble proteins that form strong associations with some component of ER membranes. 
Taken together, the literature suggests that the mechanism which mediates retention of 
49 
Chapter 1: General introduction 
Ero proteins has diverged from yeast and mammalian cells. More recently Erola has 
been found in mixed disulfide complexes with ERp44. ERp44, a member of the 
thioredoxin family, is a UPR-induced ER resident protein with an RDEL ER 
localisation motif (Anelli et a!., 2002). ERp44 has been shown to form mixed disulfides 
with folding intermediates as well as with both hEROs (Anelli eta!., 2002; Anelli eta!., 
2003). Thus covalent interactions between ERp44 and hEROS are likely to contribute 
to their ER localisation. Another protein that could mediate ER retention of Ero 
proteins is PDI, as shown through over-expression experiments, probably by virtue of 
its KDEL motif (Otsu et a!., 2006). Further analysis of human EROs will be discussed 
in the relevant subsequent chapters. 
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1.8 Aims of this thesis 
In yeast, the oxidoreductase Erolp is involved in disulfide bond formation and the 
EROl gene is found to be essential for cell viability. Of the two human Erolp 
homologues, Erolp has been the main focus of this project. The main objectives of this 
project were: 
* To study the folding pattern, biosynthesis and possible dimerisation of Erol p. 
* To investigate the importance of the Erolp carboxy-teminal CXXCXXC active 
site in PDI interactions and dimer formation. 
* To investigate the role of two FAD domain mutants of Erolp, discovered 
initially in yeast. The importance of these two mutations was studied in context 
of their ability to dimerise and interact with PDI, as well as to withstand 
temperature and various stress conditions. 
* To establish the expression pattern of Erol p and a number of ER chaperone 
proteins in different secretory human tissues and in tumours of the digestive 
system. 
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2.1 Antibodies and tissues 
The polyclonal antiserum against Ero1~ was raised against the unique internal Erol~ 
peptide YTGNAEEDADTKTLL (Sigma Genosys). Thirteen of the fifteen residues 
were conserved between mouse and human Erolf3. Polyclonal rabbit anti-serum, 
against PDI was raised against purified rat PDI as described (Benham et al., 2000). 
aEro1a (D5) was raised in rabbit against reduced, non-reduced and denatured forms of 
an E. coli expressed and purified MBP fusion protein (Mezghrani et al., 2001). The 
polyclonal PDip antiserum was a gift from Michael Lan (Desilva et al., 1997), 
polyclonal anti-ERp57 and anti-ERp72 (used only in immunohistochemistry) were a 
gift from Prof. Neil Bullied, monoclonal ERp44a (36C9/39) and ERp44b (39E5/39) 
were a gift from Prof. Roberto Sitia. Polyclonal antisera against BiP and insulin (H-86) 
(both Santa Cruz), polyclonal antisera against ERp72 (Calbiochem, used in 
immunoblotting), the mouse monoclonal antibody HA-7 (Sigma, antigen 
YPYDVPDY A), the anti-Myc antibody clone 9B 11 and the anti-Myc polyclonal 
antibody (antigen EQKLISEEDL, both Cell Signalling) were commercially available. 
In immunoblotting, the secondary antibodies used were swine anti-rabbit HRP and goat 
anti-mouse HRP conjugates, both from DAKO. For immunoflouresence, swine anti-
rabbit TRITC, donkey anti-rabbit FITC and donkey anti-mouse FITC (all DAKO) were 
used as secondary antibodies. Normal goat serum was obtained from DAKO and 
normal rabbit serum (NRS) was obtained from a pre-immune rabbit used to generate 
the POI antibody. Murine tissue samples were obtained from male Balb/c or CD 1 mice. 
Anonymous healthy human stomach and pancreas tissue samples and healthy human 
oesophagus (3396-00 B1), Barrett's oesophagus (6199-02 A2), oesophageal tumour 
(1 039-03 B2), gastroesophageal (OG) junction tumour (6199-02 A4) and gastric 
tumour (6591-01 C4) tissue were obtained embedded in wax from Medical Solutions, 
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Nottingham, UK and James Cook University Hospital, Middlesbrough, UK 
respectively, with full ethical consent. 
2.2 Immunohistochemistry 
2.2.1 Protocol] 
Paraffin embedded tissues were sectioned at 4 f.lm thickness onto Apes coated slides 
and placed at 60°C for 1 hr. The slides were cleared through xylene and 100% - 70% 
alcohol before blocking endogenous peroxidase activity in 0.5% hydrogen peroxide 
(BDH) in methanol (Fisher Scientific) for 10 min. Slides were washed in ddH20 prior 
to performing four different antigen retrieval techniques. 
l. Trypsinisation: sections were pre-heated to 37°C in distilled water and 
transferred to a freshly prepared pre-heated (36-38°C) trypsin solution (0.2 g 
porcine pancreatic trypsin to 200 ml of 0.1% CaCh, pH 7.8) for 5 min. 
2. Pressure cooker: in 90 mM citrate buffer (BDH, pH 6.0) for 2 min. 
3. Microwave: in 10 mM citrate buffer (BDH, pH 6.0) for 20 min. 
4. Microwave: in 600 ml of 1x high pH target retrieval solution (DAKO) for 20 
mm. 
Slides were washed 5 min each, in ddH20 and TBS (130 mM NaCI, 5 mM Tris pH 7.4) 
and tissue sections blocked in 1% normal goat serum (DAKO) for 10 min prior to 
incubating with different primary antibodies at 4°C overnight. Sections were washed in 
TBS for 5 min, incubated with 0.01% biotinylated goat anti-mouse/rabbit antibodies 
_(DAKO) for 30 min and developed using StreptABComplex/ HRP Duet (DAKO) and 
diaminobenzidine (DAB, Sigma). Primary and secondary antibodies as well as the 
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blocking solution was made in TBS. Counterstaining was with haematoxylin. 
2.2.2 Protocol 2 
Paraffin embedded tissues were sectioned at 4 J..tm thickness onto polylysine coated 
slides and placed at 50°C overnight. The slides were cleared through histoclear and 
100% - 70% alcohol before blocking endogenous peroxidase activity in 3% hydrogen 
peroxide (BDH) in methanol (Fisher Scientific) for 10 min. Slides were washed in 
ddH20 for 5 min and sections digested in a 90°C water bath with 10 mM citrate buffer 
for 20 min. After the antigen retrieval technique, the slides were allowed to reach room 
temperature prior to washing in 0.2% BSA (Sigma) in PBS for 5 min. Tissue sections 
were blocked in 5% normal goat serum (DAKO) for 30 min and incubated with 
different primary antibodies for 1 hr. Slides were washed in 0.2% BSA in PBS for 5 
min, incubated with 0.01% biotinylated goat anti-mouse/rabbit antibodies (DAKO) for 
45 min and developed using StreptABComplex/ HRP Duet (DAKO) and 
diaminobenzidine (DAB, Sigma). Primary and secondary antibodies as well as the 
blocking solution were made in 0.2% BSA in PBS. All antibody incubations were at 
room temperature. Counterstaining was with haematoxylin. 
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2.3 Molecular Biology 
2.3.1 Construction of ErolPmutants 
The wild-type pcDNAErolj3-HA and pcDNAErolj3-Myc constructs were a kind gift 
from Roberto Sitia. Site directed mutagenesis (Quikchange, Stratagene) was used to 
create Myc and HA tagged Erolj3 mutants with the following forward ptimers: 
C390A: 
GAATATCTCCCGTATAATGGACGCTGTTGGATGTGACAAATGCAG 
C393A: 
GTATAATGGACTGTGTTGGAGCTGACAAATGCAGATTATGGGG 
C396A: 
GACTGTGTTGGATGTGACAAAGCCAGATTATGGGGAAAATTACAG 
G252S: 
GAGTCTTCTATAAGCTTATATCGTCACTTCATGCTAGCATCAATTTAC 
H254Y: 
CTATAAGCTTATATCGGGACTTTATGCTAGCATCAATTTACATCTATG 
Each construct was vetified by DNA sequencing. Erolj3G252S-HA and Erolj3H254Y-
HA mutants were constructed by cloning the appropriate mutation region from the Myc 
tagged counterpat1s into the wild-type pcDNAErolj3-HA vector. pcDNAErolj3-HA, 
Erolj3G252S-Myc and Erolj3H254Y-Myc (3 f.!g each) were digested with 1.5 111 Nhel 
(Promega) at 37°C for 2 hr. The 5' phosphate group from the vector was removed by 
incubating pcDNAErolj3-HA at 37°C with 2 ~tl of alkaline phosphatase (Promega) for 
30 min. This treatment will prevent self-ligation of the vector and enhance ligation with 
the insert DNA. The appropriate bands were cut out on a UV illuminator after 
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separating the vector and the two inse1ts on a 1% agarose gel (section 2.3.4). DNA was 
extracted from these bands according to manufacturer instructions using the QIAquick 
Gel Extraction kit (Qiagen). 1.5 ~Ll of vector was ligated with 12 ~Ll of insert (G252S of 
H254Y) at 37°C for 1 hr. DH5a competent bacterial cells were transformed using the 
ligation products as described in section 2.3.3. The Ero1a-Myc tagged constructs have 
been previously described (Benham et al., 2000). 
2.3.2 XLI-Blue transfonnation 
Following site directed mutagenesis, the non-mutated parental DNA template was 
digested with 1 111 of Dpnl restriction enzyme for 1 hr at 37 °C and the mutated plasmid 
DNA used to transform XL1-Biue supercompetent cells (Stratagene). 1 ~tl plasmid 
DNA was mixed with 50 ~ll bacteria cells and incubated on ice for 30 min. Bacteria 
were heat shocked at 42°C for 45 sec, incubated on ice for a further 2 min prior to 
mixing with 500 111 of pre-heated (42°C) NZY broth (10 g/1 NZ amine, 5 g/1 yeast 
extract, 5 g/1 NaCI, pH 7.5 supplemented with 12.5 mM MgCh, 12.5 mM MgS04, 20 
mM glucose) at 37°C for 1 hr with constant agitation. Bacteria cells were centrifuged at 
800 g (Eppendorf) for 2 min at room temperature and the resuspended bacterial pellets 
were spread on LB-agar plates (10 g/1 tryptone, 5 g/1 yeast extract, 10 g/1 NaCI, 15 g/1 
agar) supplemented with 0.1 mg/ml ampicillin and grown overnight at 37°C. Next day, 
a single colony was inoculated in 5 ml of LB supplemented with ampicillin (0.1 mg/ml), 
and grown overnight at 37°C with constant agitation. The overnight culture was used to 
extract plasmid DNA (using the Qiagen MiniPrep according to manufacturer protocol) 
and mutations were verified by DNA sequencing. 
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2.3.3 DHS a transformation 
DHSa competent cells were transformed with the mutant plasmid DNA and used in 
transfections (section 2.5). For each transformation, 50 111 of DHSa competent cells 
was mixed with purified plasmid DNA ( -1-2 ng) and incubated on ice for 10 min. 
Bacteria were heat shocked at 42°C for 1.5 min, returned to ice for a further 10 min 
after which 500 111 of LB was added. Cells were incubated at 37°C for 30 min and 
centrifuged at 800 g (Eppendorf) for 2 min at room temperature. Resuspended bacteria 
pellets were spread on LB-agar plates supplemented with 0.1 mg/ml ampicillin and 
grown overnight at 37°C. A single colony was picked the next day and innoculated 
overnight (at 37°C with constant agitation) into 100 ml of LB supplemented with 0.1 
mg/ml ampicillin. The overnight culture was used to extract plasmid DNA (using 
Qiagen MaxiPrep kit, according to manufacturer instructions). 
2.3.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate PCR and restriction digest products. 
The appropriate amount of agarose (Bioline) was melted in a suitable volume ofT AE 
(20 mM Tris, 0.002% glacial acetic acid, 0.5 mM EDTA, pH 8.0) buffer in a 
microwave. Ethidium bromide was added to a final concentration of 0.6 mg/ml prior to 
pouring into a tray to set. The percentage of the gel was decided according to the size 
of the DNA fragments to be separated. The gel was submerged in TAE buffer and 
samples were loaded into the wells after mixing 6:1 with 6x loading buffer (15% Ficoll; 
type 400, Pharmacia, 5 mM EDTA, pH 8.0, 0.25% bromophenol blue). Following 
electrophoresis, gels were visualised by UV illumination and photographed using a 
BioRad Gel Doc. 
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2.4 Cell culture 
Human cervical carcinoma HeLa cells were maintained in Minimum essential medium 
(MEM, Invitrogen) and human fibrosarcoma HT1080 cells were maintained in 
Dulbecco's modified Eagles's medium (DMEM, Invitrogen), both supplemented with 
8% fetal bovine serum (FBS, Sigma), 2 mM glutamax (Invitrogen), 100 units/ml 
penicillin and 100 Jlg/ml streptomycin (Invitrogen) at 5% C02. Both cell lines were 
serially passaged at 70-80% confluency using 0.05% trypsin (Trysin-EDTA, 
Invitrogen) to digest the monolayer. 
2.5 Transfection 
Transfections with Lipofectamine 2000 (Invitrogen) were performed according to 
manufacturer's instructions. Sub-confluent cells in 6 em dishes were washed twice with 
PBS (Invitrogen), and transfected with 1 or 2 Jlg DNA for 6 hr in the presence of 
Optimem serum free medium (Invitrogen). The medium was replaced after 6 hr with 
complete medium and the cells analysed 24 hrs post-transfection. 
2.6 SDS-PAGE and immunoprecipitation 
Cells were lysed in lysis buffer (20 mM MES, 30 mM Tris, 100 mM NaCI, pH 7.4) 
with 1% Triton X-100 (Sigma), supplemented with 10 p,g/ml each of chymostatin, 
leupeptin, antipain and pepstatin A, (CLAP) and 20 mM N-ethylmaleimide (NEM) 
where required. Nuclei were removed by centrifugation at 16,100 g (Eppendorf) for 10 
min at 4°C. Post-nuclear cell lysates, immunoprecipitates or comparable amounts of ·o· 
mouse tissue lysates were taken up in 2x sample buffer ((Laemmli, 1970), 1 M Tris, pH 
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6.8, 20% SOS, 5% glycerol, 0.01% bromophemol blue), heated at 95°C for 5 min and 
analysed by SOS-PAGE (resolving gel consists of 8% or 10% acrylamide, 0.375 M 
Tris (pH 8.8) and 0.1% SOS, 0.1% APS, 0.04% TEMEO; stacking gel consists of 5% 
acrylamide, 0.125 M Tris (pH 6.8), 0.1% SOS, 0.075% APS and 0.075% TEMEO; 
Hoefer system). For non-reducing analysis, OTT was left out of the sample buffer, 
whereas for reducing conditions, 50 mM OTT was added. Immunoprecipitations (IP) 
were carried out using 1 111 of monoclonal antibodies or 8 111 of polyclonal antibodies 
immobilised on 50 ~Ll of a 20% suspension of Protein A sepharose beads (Sigma) for 2 
hr at 4°C, followed by two washes with lysis buffer (without NEM or CLAP). The gel 
running buffer used was lx Tris-Glycine SDS running buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS, pH 8.6, Sigma). 
2. 7 Western blotting 
Following SDS-PAGE proteins were transferred to PVOF membranes (Millipore) in 
transfer buffer (190 mM glycine, 25 mM Tris in 20% Methanol) at 150 rnA for 2 hrs or 
30 V overnight using a Bio-rad powerpack 200. The membranes were blocked in 8% 
milk/PBST (PBST made up of 1x PBS with 0.001% Tween 20) for 1 hr or overnight. A 
list of primary antibodies, their host species together with the corresponding dilutions 
used in immunoblotting is shown in table 2.1. After washing six times with PBST, 
membranes were incubated with corresponding secondary antibodies (DAKO) at 
1:3000 for 1 hr, washed extensively, and visualised by ECL (Amersham) and exposure 
to film (Kodak). Protein markers were from Biorad. 
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Table 2:1: List of primary antibodies and dilutions used in immunoblotting 
Primary antibody Host Dilution 
aMyc Mouse 1:5000 
aMyc Rabbit 1:1000 
aHA Mouse 1:2000 
aEro1a (D5) Rabbit 1:1000 
aPDI Rabbit 1:1000 
aEro1~ Rabbit 1:50 
aCNX Rabbit 1:1000 
aBiP Rabbit 1:200 
aERp72 Rabbit 1:1000 
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2.8 Determination of protein concentration 
Protein concentrations were determined using the Bio-Rad DC protein assay, which is a 
colorimetric assay compatible with a wide range of detergents based on the Lowry 
protocol (Lowry et al., 1951). The assay is based on the reaction of protein with an 
alkaline copper tartrate solution and Folin reagent, which gives a characteristic blue 
color with a maximum absorption at 750 nm. BSA protein standards from 0.5 mg/ml to 
1.5 mg/ml were used to plot a standard curve. The components recommended in the 
manufactures protocol were scaled down 5 times, and thus 20 ~tl of standards or 
samples were mixed with the appropriate volume of reagents. Absorbance was read 
after 15 min at 750 nm. All samples measured in this assay were in lysis buffer (section 
2.6) and thus 20 ~tl of lysis buffer (without NEM or CLAP) was mixed with the 
protocol reagents and used as the blank. 
2.9 Metabolic labelling and pulse-chase analysis 
Subconfluent cells in 6 em dishes were starved with MEM or DMEM lacking cysteine 
and methionine (both ICN Biomedicals Inc.) for 40 min, pulse-labelled for the times 
stated with MEM or DMEM lacking cysteine and methionine supplemented with 10 
mM HEPES, pH 7.4 (Invitrogen) and 75 ~tCi of in vitro 35S-labeling mix (GE 
Healthcare/ Amersham) per dish and subsequentely chased when necessary with 
complete medium supplemented with 5 mM methionine (Sigma), 5 mM cysteine 
(Sigma), 5% FBS and 10 mM HEPES, pH 7.4. 
At gJVen time intervals the chase was stopped with ice-cold ·HBSS (Invitrogen) 
supplemented with 20 mM NEM to trap folding intermediates. Cells were lysed in 600 
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~-tl of lysis buffer (section 2.6) with 1% Triton X-100, supplemented with 10 J.Lg/ml 
each of chymostatin, leupeptin, antipain and pepstatin A. Proteins from the lysates were 
subjected to specific immunoprecipitation after removing the nuclei for 10 min at 4°C 
and 16,100 g. Unbound proteins were washed off using the wash buffer (30 mM NaCl, 
10 mM Tris-HCL, 0.05% Triton X-100, 0.05% SDS, pH 8.6) prior to being taken up in 
2x sample buffer. Samples were boiled, reduced with 50 mM DTT where required and 
analysed by 8% SDS-PAGE. 
Gels were fixed in 1x fixing solution (12% w/v trichloracetic acid, 3.5% 5-
sulfosalicylic acid; Sigma) for 30 min and washed in ddH20 before staining with a 
Brilliant Blue G Colloidal (mixed 4: 1 in methanol, Sigma) solution for 1-2 hrs. Gels 
were then destained with 10% acetic acid in 25% methanol for 60 sec, rinsed twice in 
25% methanol, washed for 5 min in PBS and incubated with 0.5 M Na Salicylate in 
PBS for 15 min to enhance the radioactive signal. Gels were dried down on a gel dryer 
(Jencons) before exposing to Kodak BioMax MR film at -80°C. 
2.10 Immunofluorescence 
HeLa cells were grown on 16 mm coverslips until 70-80% confluent and transfected 
with appropriate DNA constructs (section 2.5). Coverslips were washed twice in PBS 
fixed in ice cold MeOH for 10 min, washed twice in PBS and blocked in 0.2% BSA 
(Sigma) for 1 hr. Primary antibodies (aPDI, 1:500 and aMyc, 1: 1000) were applied in 
the presence of 0.2% BSA for 1 hr at room temperature, washed three times in PBS and 
incubated with fluorescein labelled donkey anti-mouse Ig (FITC) and rhodamine 
labelled swine anti-rabbit lg (TRITC) at 1:50 in 0.2% BSA for 1 hr in the dark. Three 
PBS washes were canied out before mounting the coverslips onto microscope slides 
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usmg vectashield (VECTOR) and analysis under a Zeiss Bio-Rad CSM confocal 
microscope system. 
2.11 DTT, Diamide, BSO, H20 2 and temperature treatments on living 
cells 
Transfected HeLa cells were washed with PBS (Invitrogen) and incubated with 
complete medium containing; 10 mM DTT (Sigma) for 15 min; 5 mM DTT for 30 min; 
5 mM Diamide (Sigma) for 5 min; 25 f.!M BSO (buthionine sulphoximine) for 18 hr; 
1.5 M H20 2 for 10 min or buffer only at 37°C. Transfected HT1080 cells were also 
incubated with complete medium containing 5 mM OTT for 30 min at 37°C after 
washing the cells with PBS. For temperature treatment, transfected HeLa cells were 
incubated at 24°C, 37°C and 42°C on water baths for 1 hr in complete medium buffered 
with 10 mM HEPES, pH 7.4 (Invitrogen). Cells were washed three times in PBS and 
lysed as in section 2.6. Post-nuclear supernatants were subjected to analysis by 8% 
SDS-PAGE (section 2.6). 
2.12 Trypsin sensitivity assay 
Post nuclear supernatants were incubated in 0, 0.25, 1.25, 2.5 flg/ml TPCK-treated 
Trypsin (Sigma) for 30 min at 4°C. Proteolytic digestion was terminated by the addition 
of 200 mg/ml SBTI, in addition to 10 JLg/ml each of chymostatin, leupeptin, antipain 
and pepstatin A. Samples were taken up in 2x sample buffer and analysed by 10% 
SDS-PAGE (section 2.6). 
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2.13 Gel Filtration 
Gel filtration was performed usmg a Superdex 200 Precision Column 3.2/30 
(Amersharn/GE Healthcare). Chicken egg albumin (45 kDa) and BSA (66 kDa, 132 
kDa) (both Sigma) were used as standards. Proteins and tissue lysates injected in a 
volume of 200 f.!l were eluted with 50 mM Tris-HCl, 150 mM NaCl, pH 7.0, at a flow 
rate of 0.5 ml min- 1, with samples collected every two minutes. Samples were 
trichloroactetic acid (TCA; Sigma) precipitated as described in section 2.14. 
2.14 TCA protein precipitation 
Gel filtration sample fractions were mixed 1: 1 with 20% trichloroacetic acid (TCA) and 
incubated for 30 min at 4°C. Samples were centrifuged at 16,100 g for 20 min after 
which the supernatants were removed leaving an intact protein pellet. The protein pellet 
was dried, neutralised with Tris and taken up in 2x sample buffer, heated at 95°C for 5 
min and analysed by 8% SDS-PAGE (section 2.6). 
2.15 Analysis of ER protein products with/without semi permeabilised 
cells 
2.15.1 RNA preparation 
DNA (5 f.!g) was linearised with a restriction enzyme that cut once downstream of the 
ORF of interest. The restriction enzyme Eagl (Promega) was used for Ero1a and Xhol 
(Promega) for Ero1p. Digestion was canied out at 37°C for 2 hr, after which 
linearisation was confirmed by 1% agarose gel electrophoresis (section 2.3.4). The 
volume of each digest was brought to 300 ~d with 1x TE before phenol/chloroform and 
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EtOH precipitating the linearised DNA (section 2.15.1.2). The pellet was dissolved in 
10 ~-tl of ddH20 and used for subsequent transcription. Sterile, RNAase free tips and 
eppendorfs were used during in vitro transcription reactions (section 2.15.1.1). 
2.15.1.1 In vitro transcription 
Transcription was carried out according to the manufacturer protocol (Promega 
Riboprobe in vitro Transcription System) in a total volume of 50 Ill (table 2.2) at 37°C 
for 1 hr using linearised DNA. The DNA template was removed by digesting with 1 
unit of RNase-free DNAse for each 1-lg of template DNA at 37°C for 15 min. 
Transcribed RNA was phenol/chloroform and EtOH precipitated (section 2.15.1.2) and 
the pellet resuspended in 50 ~-tl of RNase-free water. For long term storage 1 ~-tl of 100 
mM DTT and 1 ~tl of RNAsin was added to the RNA. DNA and RNA concentration 
was measured using the Bio photometer (Eppendorf) with a UVette (220-1600 nm 
range; Eppendorf). Absorbance was read at 260 nm and concentrations calculated for 
dsDNA 1 OD = 50 1-lg/ml and for RNA, 1 OD = 40 ~-tg/ml. 
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Table 2.2: In vitro transcription reaction components 
Components Volume (J.ll) 
Lineatised DNA (5 !lg) 10 
5x transcription buffer 10 
lOOmMDTT 5 
RNAsin Ribonuclease inhibitor (50 units) 1.2 
rNTP mix (with 2.5 mM each of rATP, rGTP, 
5 
rCTP and rUTP) 
40 mM m 1G(5') pppG Cap Analog (Ambion) 0.62 
T7 RNA polymerase (40 units) 2 
Nuclease free water 16.18 
Total volume 50 
-< 
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2.15.1. 2 Phenol/Chloroform extraction 
Phenol/Chloroform extraction was canied out to precipitate DNA/RNA from solution. 
Equal volumes of DNA/RNA were mixed with phenol:chlorofmm:isoamylalcohol 
(25:24:1, Fisher Scientific) vortexed and centrifuged for 1 min at 16,100 g. The 
aqueous phase was transfened to a new tube and mixed with equal volume of 
chloroform (Fisher Scientific), vortexed and centrifuged for 1 min at 16,100 g. The 
aqueous phase was transfened to a new tube, mixed with 1110 volume of 3 M sodium 
acetate pH 5.2 (Fisher Scientific) and 2 volumes of 100% ethanol. The tube was then 
placed on ice for 15 min and centrifuged for 15 min at 16,100 gat 4°C. The pellet was 
washed with 70% ethanol, centrifuged for 15 min at 16,100 gat 4°C and air dried until 
it became translucent. The pellet was resuspended in an appropriate volume of RNAase 
free water. 
2.15.2 Preparation of semi (SP) cells 
HeLa cells approx. 80% confluent (- 6.2 X 105 cells/ml) were rinsed in PBS, 
trypsinised and resuspended in KHM buffer (110 mM KOAc, 20 mM HEPES, 2 mM 
MgOAc, pH 7.2) with 0.1 mg/ml of SBTI. Cells centrifuged at 260 g for 3 min at 4°C 
were then resuspended in ice-cold KHM with 40 f.lg/ml of digitonin (Sigma), mixed 
immediately by inversion and incubated at 4°C for exactly 5 min. Digitonin was diluted 
out with ice-cold KHM and centrifuged at 260 g for 3 min at 4°C. Cells were then 
resuspended in ice-cold HEPES buffer (50 mM HEPES, 90 mM KOAc, pH 7 .2) and 
incubated at 4°C for 10 min before pelleting cells at 260 g for 3 min at 4°C. Cells were 
resuspended carefully in 1 ml of jce-coldKHM and left on ice. An aliquot of cells was 
mixed 1:1 with trypan blue (Sigma) and observed on a haemocytometer to check for 
permeabilisation. Cells were transferred to a microcentrifuge tube, spun at 9,300 g 
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(Eppendorf) for 30 sec at 4°C and resuspended in 100 111 of KHM with 1 ~tl of 
micrococcal nuclease (Sigma) and 1 mM CaCiz. at room temperature for 12 min. 
Micrococcal nuclease was used to digest DNA and RNA in SP cells to avoid translation 
from endogenous mRNA. 4 mM EGTA (Sigma) was then added to chelate the calcium 
and inactivate the nuclease. Cells were washed, centrifuged for 30 sec and resuspended 
in an appropriate volume of KHM and approx. 105 cells were used per 25 f.ll translation 
reaction. 
2.15.3 In vitro translation 
For each 25 111 reaction, components (table 2.3) were added from a Flexi Rabbit 
Reticulocyte Lysate system (Promega), gently mixed and incubated at 30°C for 1 hr. 
Table 2.3: Components for in vitro translation 
Components Volume (J-tl) 
Flexi Reticulocyte lysate 16.5 
Amino acids lacking Met 0.5 
1 MKCI 0.2 
mRNA template 1 
SP cells ( -10) cells) 5.25 
J)S-labeling mix 1 
RNase free water 0.55 
Total volume 25 
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Some of the translation reactions were performed in the absence of SP cells and 35S-
Iabeling mix. The samples were quenched by 20 mM NEM and cells centrifuged at 
16,100 g for 2 min. The supernatant was either directly analysed on SDS-PAGE after 
mixing 1: 1 with 2x sample buffer or when SP cells were used, the cell pellet was 
washed in KHM buffer, resuspended by tapping on the microcentrifuge tube and 
centrifuged at 16,100 g for 2 min. This cell pellet was resuspended in KHM buffer, 
mixed 1:1 with 2x sample buffer, boiled at 95°C for 5 min and analysed by 8% SDS-
PAGE (section 2.6). 
2.15.4 Endo H treatment 
In vitro translated proteins in the presence of semi permeabilised HeLa cells were lysed 
in the presence of 20 mM NEM, kept on ice for lO min and, centrifuged at 16,100 g for 
10 min at 4°C. Samples were denatured with 0.5% SDS, boiled, allowed to reach room 
temperature and were either mock treated or digested with 0.7 J.ll of endoglycosidase H 
(Endo H, NEB) at 37°C for 1.5 hr in a total volume of 15 J.ll. Samples were taken up 
into 2x sample buffer prior to analysis by 8% SDS-PAGE. 
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3.1 Introduction 
Disulfide bonds provide proteins with structural stability (Ortega et al., 1991), and are 
required for enzymatic function and regulation of protein activity (Ellgaard et al., 1999). 
Under strongly reducing conditions, like those prevailing in the cytosol, disulfide bond 
formation is kinetically and thermodynamically disfavoured (Seckler & Jaenicke, 1992). 
However, using the model glycoprotein influenza hemagglutinin, it was shown that 
excessively oxidising conditions lead to misfolding of proteins through incorrect inter-
and intra-molecular disulfide bond formation (Marquardt et al., 1993). Therefore, in 
order to allow efficient disulfide bond formation, the ER must closely regulate its redox 
potential. Understanding how cells establish oxidising conditions has been the focus of 
attention for many biochemists over the last two decades or more. The thiol-disulfide 
cycle (Figure 1.3) responsible for introducing disulfide bonds to proteins has two key 
players, protein disulfide isomerase (PDI) and endoplasmic reticulum oxidoreductases 
(Ero). The PDI protein family was discussed in detail in Chapter 1 (section 1.7.2). Two 
human equivalents (hEROs) to the yeast Ero1p, Ero1a (Cabibbo et al., 2000) and 
Ero1P (Pagani et al., 2000) were identified recently. Sequence alignment of the two 
hEROs with Erolp from S. cerevisiae, spEro1b p from S.pombe and ero-1 from 
C.elegans showed similarities between the Ero proteins as well as significant 
differences (Figure 3.1). Ero1P shows 50% and 74% similarity with and 40% and 65% 
identity to yeast Erolp and Ero1a respectively (Pagani et al., 2000). TheN-terminal 
CXXXC motif cysteines are conserved between the Ero proteins (Pagani et al., 2000)) 
as well as the C-terminal CXXCXXC motifs and TALK residues. Ero1p has a long C-
terminal tail (127 amino acid residues) not seen in either of the hERO proteins. Ero1a 
has 15 cysteine residues whereas Ero1p and Ero1j3 have 14 (Figure 3.1, shaded in blue). 
72 
J:roll> H.a 
J:roll>:H .a 
J:rola_H.a 
J:rol C.e 
J:roib_s .p 
J:rol_S . c: 
J:rolb H.a 
J:roll>:H.a 
J:rola_H .a 
J::rol C . e 
J:rolb s.p 
J:rol_s .c 
J:rolb_H . a 
J:ro1b_H.a 
J:rola_H.• 
J:ro1 c .e 
J:rolb_s .p 
J:rol_S . c 
l:rolb_H . • 
J:ro1b_M.a 
J:ro1a_H.a 
Brol C . e 
sroib_s .p 
J:ro1_S . c 
J:rolb_H . a 
£ro1b_H.a 
l:rola_H . • 
J:rol c .e 
J:rolb_S.p 
l::rol_S .c 
J:roll>_H . a 
J:roll>_H .• 
J:rola_H . a 
Erol c .e 
J:rolb_S .p 
Ero1_S . c 
Eroll>_H.a 
J:ro1b_H .a 
£ro1a_H .a 
J:ro1 c .e 
J:ro1b_S .p 
£ro1_S .c 
120 140 
220 240 
320 340 
420 440 
520 540 
Chapter 3: Initial characterisation of Erol fJ 
80 100 
xnKi§" · " -u ISAim-G 
xnK • • · • -u r~-G 
RLQK' s• · 1 -u ~~!-s 
HUYJ:KVQ • · ' ~-K'I ~D-R 
RVSPLLPDL'l'EKS• · YIILDDIV 
-J:IUDDLs+xs ll)c'tnLDo~~K~ S~AIIDG 
260 280 300 
360 310 400 
460 410 500 
560 580 600 
88 
88 
u 
86 
100 
98 
183 
183 
184 
185 
189 
184 
211 
211 
212 
268 
219 
245 
: 311 
: 311 
: 312 
: 365 
: 311 
: 330 
: 461 
: 461 
: 468 
: 461 
: 411 
: 426 
: HI----------------------------------TAADGPPRKSIKIDL------------------------------------------------- : 418 
AS----------------------------------FKUVLRRXKQLLrSVTrVALHPFLQKTSSILVDLYFDFKAERDIVMLGFRYVPASYLRFrRLF : 531 
SDaLSSITQIIII'I'IIILKJ:AGKS I:&Y'l'XDDIS'ft(J:GKKK'I'IIliSQSRVI'DDLKHPKUIYrRPSIG'l'VIKIIKKADTI:VIIVL&AI'RPrtaSYLDLP UI : 52 6 
620 
KrVLI'SQESPI'LIIII'l'SRRLQRYUKIIIIrPEVASV--- : 511 
: 11J:LSIMKVYKJ'IIIIXPIGVADYVSD:'nt£PISYKLDIQ : 563 
FIGURE 3.1: Sequence alignment ofEro proteins 
Sequence alignment ofHuman Erolj3 (Erolb_H.s, Q86YB8; H. sapiens), mouse Erolb 
(Erolb_M.m, Q8R2E9; M musculus), human Erola (Erola_H.s, Q96HE7; H. sapiens), 
ero-1 (Erol_C.e, NP_001021704.1; C. elegans), spErolb p (Erolb_S.p, Q9Y7Pl; 
S.pombe), Erolp (Erol_S.c, Q03103; S. cerevisiae). TheN-terminal and C-terminal 
active site cysteines are shaded red, all other cysteines are shaded blue, identical 
residues are in black and partially conserved amino acids are shaded in light grey. 
Alignment made with ClustralX and Genedoc programs. 
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A schematic diagram of the hEROs is shown in Figure 3.2. Both hEROs have an N-
terminal signal sequence that targets these proteins to the ER, where they are resident. 
Ero1a has a predicted signal sequence (using Signal IP) between positions 23-24 
whereas for Ero1P it is at 33-34. Due to the indistinguishable size difference seen 
between hERO proteins translated in the absence and in the presence of ER membranes 
(translocated and deglycosylated proteins), the signal sequence was initially thought not 
to undergo cleavage once in the ER (Cabibbo et al., 2000; Pagani et al., 2000). Work 
published by Pagani and colleagues did later show through mass spectrometry and N-
terminal sequence analysis that the leader sequence does get efficiently cleaved in 
Ero1a (Pagani et al., 2001). Ero1a and Ero1P both lack a known ER localisation motif 
and their possible retention mechanisms are discussed in chapter 1 (section 1.7.4.1). 
Another difference between the hEROs is that Ero1a has a EF calcium binding motif 
(159-171 amino acids) not found in Ero1 p (Cabibbo et al., 2000; Pagani et al., 2000). 
Both hEROs are capable of rescuing the S. cerevisiae ero1-1 thermosensitive mutant 
and catalysing the oxidation of model substrates (Cabibbo et al., 2000; Pagani et al., 
2000; Mezghrani et al., 2001), indicating that these proteins are involved in disulfide 
bond formation. 
Ero1a has two N-glycosylation sites (Figure 3.2, at positions 280 and 384), whereas 
Ero1P has four (Figure 3.2, at positions 122, 140, 145 and 383), but whether 
glycosylation could affect protein function is largely unexplored. Recent studies using 
non-glycosylated (NG) Ero1a mutants has shown that glycosylation is not essential for 
folding into an active conformation which can complement the yeast ero1-1 mutant 
(Bertoli et al., 2004). These glycosylation mutants were still able to bind PDI and form 
OX1 OX2 redox isoforms (Bertoli et al., 2004). But in an over expressed system, wild-
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type Ero1a gets secreted whereas the non-glycosylated Ero1a mutants form aggregates 
and are retained in the ER (Otsu et al., 2006). Studying these mutants in more detail 
could shed light on the involvement of glycans in hERO function. 
A 
B 
FIGURE 3.2: Schematic representation of hERO proteins 
A. Ero1a. B. Ero1~. The N-terminal CXXXC and C.-terminal CXXCXXC active site 
motifs are shown. Ball and sticks represents potential N-glycosylation sites. s.s, signal 
sequence. Adapted from (Dias-Gunasekara & Benham, 2005). 
Of the two hERO proteins, much of the attention has been focused on Ero 1 a, looking 
at its folding under steady state and pulse-chase conditions (Benham et al., 2000) and 
its interacting partners (Mezghrani et al., 2001). This chapter has focused on detecting 
Ero 1 ~ from endogenous and transfected cell lines, studying its interacting partners and 
its possible heterodimerisation with Ero 1 a. 
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3.2 Results 
3.2.1 Detection of Erol p protein 
Endogenous Ero l ~ protein levels are very low or almost non-detectable in all 
mammalian cell lines examined so far, making studying of Erol ~ protein behaviour in 
tissue culture very difficult. To overcome this problem, cells were transfected with 
Erol ~ constructs which provide an alternative model to investigate its interactions in 
vivo. Although transfected cells resemble an over-expressed system it should be noted 
that this system was used to study interactions of Erol~, and where possible novel 
interactions were tested using mouse tissue Iysates. Erol ~ constructs were either Myc 
tagged or HA tagged at the C-terminus to aid in detection of the transfected protein. To 
verify that the constructs could be transfected, HeLa cells were mock transfected (lane 
4) or transfected with Erol~-Myc (lane 1), Erol~-HA (lane 2), co-transfected with 
Erol~-Myc plus Erol~-HA (lane 3) and post-nuclear Iysates analysed on reducing 
SDS-PAGE. Blots probed with aMyc (Figure 3.3A) and aHA (Figure 3.38) verified 
that the tagged proteins (about 60 kDa) were recognised in the relevant lanes. 
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FIGURE 3.3: Expression of transfected Ero1J3 tagged proteins 
HeLa cells mock transfected (lane 4) or transfected with wild-type (wt) Ero 1 J3-Myc 
(lane 1), wtEro1J3-HA (lane 2) or wtEro1J3-Myc and wtEro1J3-HA (lane 3) were lysed 
in the presence ofNEM, analysed under reducing (R) SDS-PAGE, and western blotted 
(WB) membranes probed with either aMyc (A) or aHA (B) primary antibody. The 
tagged Ero 1 p protein is recognised by both aMyc and aHA antibodies. 
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Studies at the mRNA level have indicated that Erol ~ transcripts are up-regulated in 
specific tissues like stomach and pancreas (Pagani et al., 2000). In order to detect 
endogenous Ero1~ in tissue samples, a polyclonal antibody was raised against a peptide 
unique to Ero1~ protein (YTGNAEEDADTKTLL). This antibody should not cross 
react with the second mammalian oxidoreductase Ero1a. An alignment of Ero1~ and 
Ero1a from this region showed that only 7 of the 15 amino acids are conserved 
between the two hEROs (Figure 3.4A). The polyclonal anti-Ero1~ serum was then 
tested to verify that the serum does recognise Ero1~ protein. HeLa cells were mock 
transfected (lane 3) or transfected with Ero 1 a-M yc (lane 1) or Ero 1 ~-M yc (lane 2), 
and post-nuclear lysates analysed on reducing SDS-PAGE. Blots were probed with a 
dilution series of Ero1~ serum, starting from 1:500 (no signal observed, data not 
shown), 1: 100 (Figure 3.48) and 1:50 (Figure 3.4C). Ero1~ serum used at the highest 
concentration (Figure 3.4C) recognised a protein around 60 kDa not present in Ero l a 
(lane 1) or mock transfectants (lane 3). Using the Ero 1 ~ serum at this concentration did 
however give rise to a number of non-specific background bands around 75 kDa. 
In order to increase the specificity of the Ero1 ~ serum, 0.1% SDS was added during the 
antibody incubation and subsequent washing steps. These conditions were then tested 
on similar reduced lysates as Figure 3.3A and B with the additional use of Ero1a-Myc 
transfected lysate (Figure 3.4D). Ero1j3 serum recognised both tagged versions of 
Erolj3 but not Ero1a (Figure 3.4D, lane 1) indicating its specificity. The use of0.1% 
SDS was sufficient to allow the detection of the transfected Ero 1 ~ protein without the 
appearance of background bands. Ero1j3-HA migrated faster than Ero1j3-Myc due to its 
size/charge difference at the C-terminal tag (a triple Myc tag apposed to a single HA 
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tag). As a positive control for Erola, the membrane from Figure 3.4D was reprobed 
with D5, a polyclonal serum raised against Erola (Benham et al., 2001), which 
recognised the Erola-Myc tagged protein (Figure 3.4£, lane 1). 
To investigate whether the ErolP serum could be used to detect disulfide bonded 
interactions of Erolp protein, HeLa cells were transfected with Erolp-Myc (Figure 
3.4F, lane 1) or ErolP-HA (Figure 3.4F, lane 2) and post-nuclear lysates analysed by 
non-reducing SDS-PAGE. Transferred proteins were detected with the Erolp serum, 
which was used at the tested concentration (1 :50) in the presence of 0.1% SDS. Erol p 
serum weakly recognised the differentially tagged monomer states, however, the 
detection of higher molecular weight complexes was poor (Figure 3.4F, lane 1) with 
some non-specific bands (*). Thus the Erol p serum was not used in subsequent 
experiments under non-reducing conditions. 
One approach for investigating protein-protein interactions is to immunoprecipitate the 
protein of interest, analyse on SDS-PAGE and western blot with antibodies against 
potential interacting partner proteins. Lysates from Erolp-Myc (Figure 3.4G, lane 1) 
and mock (Figure 3.4G, lane 2) were analysed by reducing SDS-PAGE or first 
subjected to immunoprecipitation with the Erolp serum. Western blotted membranes 
probed with the Erolp serum confirmed the expression of the protein (Figure 3.4G, 
lane 1) and also established that this antibody was unable to immunoprecipitate (Figure 
3.4G, lane 3). 
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FIGURE 3.4: Optimising conditions for EroJ3 serum in immunoblotting 
A. Alignment of human Ero1J3 (accession no: Q86YB8), human Ero1a (accession no: 
Q96HE7) containing the 15 amino acid residues (shaded in grey) against which the 
aEroJ3 serum was raised against. Conserved residues are indicated below the alignment. 
Different dilutions of aErop serum (B, 1:100 and C, 1 :50) were tested in 
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immunoblotting on wtErola-Myc (lane 1), wtErolf3-Myc (lane 2) or mock transfected 
(lane 3) HeLa cell lysates analysed under reducing (R) SDS-PAGE. A protein 
corresponding to Erolf3 -60 kDa was weakly identified in C, lane 2. D. HeLa cell 
lysates from wtErola-Myc (lane I), wtErolf3-Myc (lane 2), wtErolf3-HA (lane 3) and 
wtEro1f3-Myc and wtErolf3-HA (lane 4) transfected or mock transfected (lane 5) were 
analysed by reducing SDS-PAGE prior to probing the membrane with aErof3 serum at 
1:50 dilution in the presence of 0.1% SDS. aErof3 serum recognises Myc and HA 
tagged Erolf3 (lanes 2-4) proteins but not Erola (lane 1) E. the membrane from D was 
reprobed with aEroa serum D5 without stripping the membrane. D5 recognises Ero1a 
(lane 1). F. wtErolf3-Myc (lane 1), wtEro1f3-HA (lane 2) or mock (lane 3) transfected 
HeLa cell lysates were analysed under non-reducing (NR) SDS-PAGE, and transferred 
proteins probed with aErof3 at 1:50 dilution in the presence of 0.1% SDS. Erolf3 
monomer and higher molecular weight complexes are indicated with arrows; * = non-
specific binding. G. Immunoprecipitation using aErof3 serum. wtEro 1(3-Myc (lane 1 
and 3) and mock transfected (lane 2 and 4) HeLa cell lysates were analysed directly 
(lanes 1-2) or immunoprecipitated with aErof3 serum (lanes 3-4) prior to reducing 
SDS-PAGE. The membrane probed with aErof3 recognised the Erolf3 protein from cell 
lysate (lane 1) but not after immunoprecipitation (lane 3). ab =antibody. 
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To investigate whether the Erol ~ serum recognised endogenous protein, samples of 
mouse tissue from gut, stomach, liver, kidney and pancreas were lysed in the presence 
of NEM, clarified by centrifugation, and equal amounts of protein were analysed by 
reducing SDS-PAGE prior to blotting with aEro!~ serum (Figure 3.5A). HeLa cells 
transfected with wild-type Erol ~-Myc were used as a positive control (Figure 3.5A and 
B, lane 1). Although Erol~ serum recognised a -60 kDa protein corresponding to the 
endogenous Erol~ in stomach and pancreas (Figure 3.5A, lanes 3 and 6), some 
background bands could be seen in gut, liver and kidney Iysates (Figure 3.5A, lanes 2, 4 
and 5). Mouse tissue lysates were subjected to concanavalin A (con A) affinity 
chromatography prior to reducing SDS-PAGE in an attempt to reduce this non-specific 
signal (Figure 3.5B). Con A is used to isolate glycoproteins with terminal a-D-
mannosyl and a-D-glucosyl residues (Figure 3.5B). This technique confirmed the 
detection of N-glycosylated, ER resident Erol ~ protein in stomach and pancreas tissues 
(Figure 3.5B, lanes 3 and 6). The results indicated that transfected Erol ~ protein could 
be detected using either of the C-terminal tags or the Erol~ serum (Figure 3.3-3.4) and, 
the endogenous Erol~ protein could be detected by the Ero~ serum (Figure 3.5). 
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FIGURE 3.5: Detection of endogenous Eroll3 protein 
A. Equal amounts of murine tissue lysates, lysed in the presence of NEM, were 
subjected to western blotting after reducing (R) SDS-P AGE. The membrane was 
probed with aEro!} serum at 1 :50 in the presence of 0.1% SDS. B. Same lysates as in A 
were first subjected to concanavalin A (ConA) affinity chromatography and 
immunoblotted with aErol3 serum. Ero 113 is specifically detected in stomach (lane 3) 
and pancreas (lane 6) tissue. wtEro 113-Myc transfected cell lysates were used as the 
positive controls (A and B, lane 1). 
83 
Chapter 3: Initial characterisation ofErolfJ 
3.2.2 Erol f3 engages in disulfide dependent and alkylation independent 
interactions in the ER 
In vitro translation with semi-permeabilised HT 1080 cells and pulse-chase analysis 
with HeLa cells revealed that Ero1a monomer had three distinct redox states. This 
included two oxidised forms, OX1, OX2 and a reduced form (Benham et al., 2000). 
Ero1B monomer oxidation state was investigated by transfecting wild-type ErolP-Myc 
into HeLa and HT 1080 cells. The transfected cells were lysed in the presence or 
absence of the alkylating agent NEM. Addition of an alkylating agent blocks the 
transfer of intermolecular and intramolecular disulfides by binding to free thiols, thus 
preventing disulfide bond isomerization and rearrangement. In yeast, acid precipitation 
and alkylation is required to trap Ero1p-PDI mixed disulfide complexes (Frand & 
Kaiser, 1999) whereas in mammalian cells alkylation alone is sufficient to capture these 
disulfide interactions (Mezghrani et al., 2001; Benham et al., 2000). Post nuclear 
supernatants were examined by western blotting after non-reducing and reducing 8% 
SDS-PAGE. Running the gels under non-reducing conditions preserved disulfide bonds 
and allowed disulfide dependent interactions to be observed. The transferred proteins 
were probed with the 9E11 aMyc monoclonal antibody which detected the Myc tagged 
Ero1p. 
In HeLa cells at steady state in the presence of NEM and under non-reducing (NR) 
conditions, monomeric wild-type Ero1B exists as -60 kDa pmtly oxidised partly 
reduced molecules (OX and R) whereas in the absence of NEM Ero1B monomer was 
Jess compact (Figure 3.6A, lanes 1 and 2), confirming that NEM is required to. trap the 
oxidised monomer. In HT 1080 cells, monomeric Erol B was mainly oxidised and more 
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compact (OX) in the presence of NEM but remained more reduced in the absence of 
NEM (Figure 3.6B, lanes 1 and 2). The exact ratio of oxidised to reduced Ero1~ (OX: 
R) vmied to some extent between transfections and was dependent on the cell type. The 
oxidised molecules migrated faster on SDS-PAGE due to the presence of disulfide 
bonds which form a more compact molecule. Reduction of the samples with DIT 
resulted in the appearance of a single reduced band (Figure 3.6A and B, lanes 6, 7) 
demonstrating that the shifts seen in the non-reducing gels are a result of disulfide bond 
formations and not degradation. These results are similar but not identical to those 
found with Ero1a (Benham et al., 2000), the most notable difference is that Ero1~ does 
not form discrete oxidation states like Ero1a when analysed by 8% non-reducing SDS-
p AGE (Mezghrani et al., 2001; Benham et al., 2000). 
The redox states of Ero1 ~ were also analysed using radio-labelling of transfected cells. 
HeLa cells were either mock transfected (Figure 3.6C, lanes 5 and 9) or transfected 
with Ero1a-Myc (Figure 3.6C, lanes 1 and 2) and Ero1~-Myc (Figure 3.6C, lanes 3-4 
and 7-8) and starved for 40 min in medium lacking methionine and cysteine. Following 
starvation, cells were 35S labelled for 15 min, chased for 45 min and lysed in the 
presence of the alkylating agent NEM. Lysates were immunoprecipitated with aMyc 
and examined by non-reducing (Figure 3.6C, lanes 1, 3-5) and reducing (Figure 3.6C, 
lanes 2, 7-9) SDS-PAGE. The addition of an alkylating agent upon cell lysis combined 
with the analysis of lysates on non-reducing SDS-PAGE, allowed the visualisation of 
any folding intermediates, oxidation states and disulfide-dependent interactions 
(Braakman et al., 1992). 
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For Erola, the redox states OX1, OX2 and R were consistent with Benham et al., 2000 
(Figure 3.6C, lane /), resolving into a single band when reduced with DTT (R; Figure 
3.6C, lane 2). Ero1p on the other hand resolved as a smear of bands under non-
reducing conditions (OX, Figure 3.6C, lanes 3-4) which compact into a single band 
upon reduction (R, Figure 3.6C, lanes 7-8). During a 10 min pulse and a 15-60 min 
chase, Ero1P continued to remain as a smear of oxidised forms (Figure 3.6D, lanes 1-4) 
which even during a 6 hr chase remained unchanged (data not shown). Disulfide-
dependent Ero1P higher molecular weight complexes were seen during the 15-60 min 
chase which were not present in the reduced Iysates (*, Figure 3.6D, lanes 6-9) and 
were also absent from the mock transfected (Figure 3.6D, lane 10). To determine the 
half life of Ero1p, transfected HeLa cells radio labelled for 10 min were chased for 3-
22 hr, immunoprecipitated with aMyc and analysed on reducing SDS-PAGE (Figure 
3.6£). Quantitation of the immunoprecipitates from Figure 3.6£ showed that Ero1P is a 
relatively stable protein with a half life of 24-25 hrs. 
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FIGURE 3.6: Ero1[3 monomer is partly oxidised partly reduced 
A. non-reducing (NR, lanes 1-4) and reducing (R, lanes 6-9) SDS-PAGE of Myc 
transfected wtEro1[3 (lanes 1-2 and 6- 7) and mock transfected (lanes 3-4 and 8-9) 
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HeLa cells lysed in the presence (lanes 1, 3, 6 and 8) or absence (lanes 2, 4, 7 and 9) of 
NEM and probed with aMyc. B. Same as A using HT1080 cell lysates. In both A and 
B lane 5 is loaded with sample buffer only. Erol~ monomer oxidation states are 
labelled as oxidised (OX) and reduced (R). C. wtErola-Myc (lanes 1-2), wtErol~-Myc 
(lanes 3-4 and 7-8) and mock (lanes 5 and 9) transfected HeLa cells were pulsed-
labelled for 15 min, chased for times indicated and immunoprecipitated with aMyc 
(lanes 1-9) prior to non-reducing (lanes 1, 3-5) and reducing (lanes 2, 7-9) SDS-PAGE. 
Erola oxidation states, OXl and OX2 are observed under NR conditions, compared to 
a smear of oxidation states (OX) in Erol~. Lane 6 is loaded with only sample buffer. D. 
Same as C using wtErol~-Myc (lanes 1-9) and mock (lane 10) transfected HeLa cells 
pulse-labelled for 10 min, analysed by non-reducing (lanes 1-4) and reducing (lanes 6-
10) SDS-PAGE. Lane 5 is loaded with sample buffer only. * indicates disulfide-linked 
higher molecular weight complexes. E. Same as D, with reducing SDS-PAGE of 
wtErol ~-Myc (lanes 1-4) and mock (lane 5-6) transfected He La cells with chase points 
from 3-22 hrs (lanes 2-4 and 6) to determine the half-life of Erol~. 
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To investigate the ability of Erol ~ protein to form higher molecular weight complexes, 
HeLa and HT1080 cells were transfected with Erol~-Myc (Figure 3.7A and B, lanes 1-
2, 6-7) or mock (Figure 3.7A and B, lanes 3-4, 8-9) and analysed under non-reducing 
(Figure 3.7A and B, lanes 1-4) and reducing (Figure 3.7A and B, lanes 6-9) SDS-PAGE. 
In both HeLa and HT1080, wild-type Erol ~ formed a ladder of higher molecular 
weight complexes in the presence and in the absence of NEM (Figure 3.7A and B, lanes 
1, 2). The smear of bands seen in the absence of NEM was less prominent in HT1080 
cells (Figure 3.7A, lane 2 in comparison to B, lane 2). Addition of the reducing agent 
DTT to the samples prior to gel electrophoresis disrupted the ladder of higher 
molecular weight complexes, showing they were disulfide-dependent interactions 
(Figure 3.7A and B, compare lanes 1-2 with 6-7). The 9Ell aMyc antibody gave a 
non-specific background band around -130 kDa seen more prominently in HeLa cell 
lysates (Figure 3.7A). The non-specific nature of the band and the reproducibility of the 
results were confirmed by using a polyclonal aMyc antiserum which specifically 
recognised the Myc tagged Erol ~protein complexes (Figure 3.7C). 
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A and B. Same lysates as FIGURE 3.6A and B, but looking at ErolP complex 
formation at steady state. In both HeLa and HT1080 ErolP is able to form disulfide 
linked complexes in the presence (lane 1) and in the absence (lane 2) of NEM under 
non-reducing (NR) SDS-PAGE. Lane 5 is loaded with sample buffer. Note the 
presence of a non-specific background band around 130 kDa in A. C. non-reducing 
SDS-PAGE analysis of wtErolp-Myc (lane 1) and mock (lane 2) transfected HeLa 
cells lysed in the presence ofNEM and probed with a polyclonal a.Myc antiserum. 
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In Figure 3.7A and 8, one of the higher molecular weight bands should correspond to 
Erol~-PDI complex (Mezghrani et al., 2001). Mock transfected HT1080 cells lysed in 
the presence or absence of NEM, analysed by non-reducing and reducing SDS-PAGE 
and probed with an anti-serum raised against PDI, emphasised the dependency of 
disulfide-linked PDI complexes on alkylating agents (Figure 3.8A, compare lanes 1 and 
2). Erol~-Myc and mock transfected HeLa cell lysates were subjected to 
immunoprecipitation with a aPDI antibody (Figure 3.88). The Erol~-PDI dimer was 
NEM dependent as expected (Figure 3.88, lane 1). 
To further study the nature of Erol~ complexes, endogenous PDI was depleted from 
Erol~ transfected cell lysates by consecutive rounds of immunoprecipitation. All 
detectable PDI was removed by this procedure, whereas calnexin levels remained 
unaffected (Figure 3.8C, compare lane 1 with lanes 3 and 4). Analysis of the PDI-
depleted lysates by non-reducing SDS-PAGE and immunoblotting with aMyc showed 
that the Erol~-PDI complex was selectively removed, whereas the lower complex 
remained(*) along with the Erol~ monomers (Figure 3.8D, lanes 1, 3 to 4). The nature 
of Ero L ~ disulfide complexes was also investigated during in vivo metabolic labelling 
experiments. HeLa cells transfected with Erol~ (Figure 3.8£, lanes 1-2) and mock 
(Figure 3.8£, lane 3) were pulse-labelled for 10 min and used in an 
immunoprecipitation with aMyc and aPDI antibodies p1ior to analysis by non-
reducing SDS PAGE (Figure 3.8£). Analysis of the higher molecular weight complexes 
from these immunoprecipitates revealed that one of the bands (**) Is 
immunoprecipitating with both aMyc and aPDI only from the Erol~ transfected cell 
lysates (Figure 3.8£, lanes 1 and 2 respectively), indicating the presence of Erol~-PDI 
complexes. These data complemented the steady state results from Figure 3.8D. 
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FIGURE 3.8: Erolf3 forms non-PDI but disulfide linked complexes 
A. non-reducing (NR, lanes 1-2) and reducing (R, lanes 3-4) SDS-P AGE analysis of 
mock transfected HeLa cells, lysed in the presence (lanes 1 and 3) or in the absence 
(lanes 2 and 4) of NEM, and immunoprecipitated with aPDI. PDI monomer is 
indicated. Disulfide dependent PDI interactions are preserved only in the presence of an 
alkylating agent(**). B. non-reducing (lanes 1-4) SDS-PAGE analysis of Myc tagged 
wtEro1f3 (lanes 1-2) and mock (lane 3-4) transfectants subjected to 
immunoprecipitation with aPDI and immunoblotted with aMyc. Ero-PDI complex is 
captured in the presence ofNEM. Antibody complexes (ab) migrate just above the Ero-
PDI dimer C. reducing SDS-P AGE of wtEro 1 ~-Myc transfected HeLa cell lysates 
subjected to sequential immunodepletion of PDI prior to detection of calnexin (CNX) 
and PDI. All detectable PDI is specifically removed from the lysates (lanes 3 and 4) 
when compared with the immunodepletion using a rabbit pre-immune serum (PS, lanes 
5-6). D. non-reducing SDS-PAGE analysis of the same lysates used in C, but probed 
with the aMyc antibody. 1st = first immunodepletion, 2"d = second immunodepletion, 
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tel = total cell lysate prior to immunodepletion. The Ero-PDI complex is depleted 
(anow), whereas the major Ero complex remains (*). E. non-reducing SDS-PAGE 
analysis of wtEroli3-Myc (lanes 1-2) and mock (lanes 3) transfected HeLa cells pulse-
labelled for 10 min, lysed and immunoprecipitated (IP) with aMyc (lanes 1) and aPDI 
(lanes 2 and 3). A smear of oxidation states (OX) was observed for Eroll3, and ** 
indicates the possible Ero-PDI complex. PDI monomer is indicated. 
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3.2.3 Erolpforms disulfide-dependent homodimers 
A number of thioredoxin family proteins and redox enzymes are known to f01m dimers 
(Zhao et al., 2003). Immunodepletion experiments (Figure 3.8C and D) as well as 
analysis of Erol~ transfected celllysates on non-reducing SDS-PAGE (Figure 3.7A-B) 
proved that there were complexes other than Erol~-PDI present in cells. The ability of 
Erol~ to form dimers was investigated using two differentially migrating Erol~-Myc 
and Erol~-HA proteins. 
HeLa cells were either mock transfected (Figure 3.9A, lane 4) or transfected with 
Erol~-Myc (Figure 3.9A, lane 1), Erol~-HA (Figure 3.9A, lane 2) and Erol~-Myc plus 
Erol~-HA (Figure 3.9A, lane 3). The cells were lysed in the presence of NEM, 
analysed by non-reducing SDS-PAGE and after westem blotting, the membrane was 
probed first with aMyc (Figure 3.9A, lanes 1-4) and the same membrane re-probed 
with aHA (Figure 3.9A, lanes 5-8) without stripping the blot. Any mixed disulfide-
dependent Erol~-Myc - Erol~-HA dimers should appear as an intermediate band 
present only in the double transfected lysates. An intermediate band of -125 kDa 
representing this Erol ~-Myc - Erol~-HA dimer was present in Figure 3.9A, lanes 3 
and 7 (M+H). In the single transfectants the Erol~-Myc - Erol~-Myc dimer (Figure 
3.9A, M+M) and the Erol~-HA - Erol~-HA dimer (Figure 3.9A, H+H) was also 
prominent. Note the presence of an extra non-specific band of -130 kDa in both the 
Myc and HA blots (Figure 3.9A, lanes 2, 4 and 8). The same cell lysates as in Figure 
3.8A were subjected to immunoprecipitation with aHA-7, and the membrane probed 
with aMyc after reducing SDS-PAGE (Figure 3.98). The formation of an Erol~-Myc-
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Erol~-HA dimer was confirmed by the presence of a Myc signal in the 
immunoprecipitates from the double transfectant (Figure 3.98, lane 3). 
To investigate whether Erol~ was able to form homodimers in the absence of an 
alkylating agent, the same experimental setup as in Figure 3.9A and B was performed 
where HeLa cell transfectants were lysed in the absence of NEM (Figure 3.9C and D). 
Cell Iysates were either directly analysed on reducing SDS-PAGE to confirm the 
expression of the transfected proteins (Figure 3.9C) or were subjected to 
immunoprecipitation with a.HA-7 prior to analysis under reducing SDS-PAGE (Figure 
3.9D). Cell lysates analysed under non-reducing SDS-PAGE before 
immunoprecipitation (similar to in Figure 3.9A), gave a smear of bands around 150 kDa 
in the Erol~-Myc - Erol~-HA double transfected lysates (data not shown), which 
although not as discrete as in the presence of NEM (Figure 3.9A, lanes 3, 7), did imply 
the formation of disulfide-bonded homodimers. Analysis of immunoprecipitates 
confirmed that the Erol ~-Myc tagged protein could interact with the Erol ~-HA protein 
(Figure 3.9D, lane 3). These experiments indicate that Erol ~ formed disulfide 
dependent but alkylation independent homodimers at steady state in the endoplasmic 
reticulum. 
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A. HeLa cells transfected with wtErol~-Myc (lanes 1 and 5), wtErol~-HA (lanes 2 
and 6), wtErol~-Myc and wtEro l ~-HA (lanes 3 and 7), and mock transfectants (lanes 
4 and 8) were lysed in the presence of NEM and subjected to immunoblotting after 
non-reducing (NR) SDS-PAGE. The membrane was probed with aMyc (lanes 1-4) and 
repro bed without stripping the membrane with aHA (lanes 5-8). A mixed wtEro 1 ~­
Myc- wtErol~-HA (M+H) dimer is clearly visible (lanes 3 and 7). M+M= wtErol~­
Myc dimer, H+H= wtErol~-HA dimer. B. The same lysates as in A, first subjected to 
immunoprecipitation with aHA prior to reducing (R) SDS-PAGE, and the membrane 
probed with aMyc. wtErol~-Myc co-immunoprecipitated with the wtErol~-HA (lane 
3) thus forming a specific complex. C and D. HeLa cells transfected with the same 
eDNA constructs as in A, but lysed in the absence ofNEM, and either analysed directly 
on reducing SDS-PAGE and immunoblotted with aEro~ (C) or first subjected to 
immunoprecipitation with aHA and after western blotting probed with aMyc (D). Myc 
and HA tagged wtErol~ coOimmunoprecipitated (D, lane 3). ab= antibody. 
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3.2.4 Erol P complexes differ in abundance in stomach and pancreas 
Ero1~ is able to homodimerise (section 3.2.3). Mouse stomach and mouse pancreas 
tissue Iysates were used to study the ability of Ero1~ to form complexes including 
dimers in vivo. Both tissues were lysed in the absence of NEM, which prevents 
formation of Ero1~-PDI covalent interactions (Figure 3.88). Ero1~ complexes could 
not be directly detected due to the inability of the aEro1~ serum to work under non-
reducing conditions (Figure 3.4F). As an alternative method, gel filtration was 
performed where mouse tissue lysates were run on a superdex 200 precision column to 
separate proteins according to their molecular weight. The elution profile of Ero1 ~ was 
compared with bovine serum albumin (monomer of 66 kDa and dirner 132 kDa, Figure 
3.10A) and chicken egg albumin (monomer of 45 kDa, Figure 3.108). Fractions from 
the gel filtration were trichloroacetic acid-precipitated and analysed by reducing SDS-
PAGE prior to immunoblotting with the Erol~ serum. Ero1~ from the stomach was 
recovered infractions 10-13, with a peak infraction 12 conesponding to the likely size 
of the glycosylated monomer (Figure 3.10C). Fractions 10 and 11 probably conespond 
to Ero1~ complexes (Figure 3.10C). In contrast, in the pancreas, Ero1~ was recovered 
mainly from fractions 9 and 10, which relates to the expected size of the Ero1~ dimer, 
and was also detected in fractions 13 and 14 (Figure 3.10D). These results suggest that 
Ero1~ can be found in complexes (other than Ero-PDI complexes) in vivo but their 
relative abundance in different tissues can vary. 
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FIGURE 3.10: Gel :filtration of Eroll3 in stomach and pancreas 
A. UV absorption spectra of the bovine serum albumin (66 kDa monomer; 132 kDa 
dimer) and B. albumin standards ( 45 kDa). C. trichloroacetic acid precipitated fractions 
from mouse stomach and D. mouse pancreas were analysed by reducing SDS PAGE 
and irnmunoblotted using aErol3. 
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3.2.5 Erol a and Erolfiform mixed disulfide dependent complexes 
To investigate whether at steady state the two oxidoreductases, Erola and Erolp, are 
able to interact, HeLa cells were transfected with Erola-Myc, ErolP-HA or Erola-
Myc together with ErolP-HA (Figure 3.11A and B). Cell lysates were analysed under 
reducing SDS-PAGE, the western blotted membrane probed with aMyc (Figure 3.11A, 
lanes 1-4) and reprobed with aHA (Figure 3.11A, lanes 5-8) without stripping the 
membrane. These two figures confitmed the expression of the transfected Era proteins. 
The lysates were subjected to immunoprecipitation with aHA-7 followed by probing 
the western blotted reducing gel with aMyc (Figure 3.11B). The co-
immunoprecipitated Erola-Myc protein was detected as a Myc signal only in the 
double transfectant (Figure 3.11B, lanes 3) which showed Erola interacting with 
Erolp. This expe1iment demonstrated the ability of the two oxidoreductases to 
associate in the endoplasmic reticulum. 
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FIGURE 3.11: Complex formation between Erola. and ErolJ3 
A and B. HeLa cell lysates expressing wtEro1a.-Myc (lanes 1 and 5), wtEro1J3-HA 
(lanes 2 and 6), wtEro1a.-Myc and wtEro1J3-HA (lanes 3 and 7), or mock transfected 
(lanes 4 and 8) were analysed directly by reducing SDS-P AGE (A) or first subjected to 
immunoprecipitation with a.HA (B). Immunoblotting was with a.Myc (A and B, lanes 
1-4) and repro bing was with a.HA (B, lanes 5-8). Wild-type Ero 1 a. and Ero 1 J3 form a 
specific complex (B, lane 3). Ab = antibody. 
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3.2.6 Under in vivo reducing conditions Erol pis only partially reduced 
Treatment of eukaryotic cells with the membrane permeable reducing agent 
dithiothreitol (DTT) inhibits disulfide bond formation in the endoplasmic reticulum. To 
study the effects of the reducing agent DTT on Erolp proteins, HeLa cells (Figure 
3.12A) and HT1080 cells (Figure 3.12B) were either mock transfected (lanes 3, 4, 7 and 
8) or transfected with Erolp-Myc (lanes 1, 2, 5 and 6) and were treated in vivo with 5 
mM DTT for 30 mins prior to analysis on non-reducing (lanes 1-4) and reducing (lanes 
5-8) SDS-PAGE (Figure 3.12A and B). Treatment of living cells with DTT caused the 
Erolp monomer to become partially reduced when compared to the reduction of 
samples with DTT in vitro, where both the OX forms collapsed to form a single 
reduced band (Figure 3.12A, compare lanes 2 and 6). The shift seen with DTT 
treatment also confirms that the monomer banding pattern seen in non-reducing gels 
(for example Figure 3.6A and B) is the result of compaction by disulfide bonds and not 
degradation. 
The effect of a reducing environment on Erolp complex formation was investigated by 
transfecting HeLa cells with Erolp-Myc or co-transfecting with Erolp-Myc and 
ErolP-HA. Transfected cells were incubated with DTT before analysing the Iysates by 
non-reducing (Figure 3.12C, lanes /-6) and reducing (Figure 3.12C, lanes 7-12) SDS-
PAGE. At steady state, 10 mM DTT in the medium was sufficient to eliminate the 
majotity of disulfide dependent (Ero-PDI and Ero-Ero) complexes (Figure 3.12C, lanes 
1 and 3). The Erolp monomer form shows the same partial reduction pattern observed 
in Figure 3.12A. The slight variation in shifts seen in the monomer form with DTT 
treatment between Figure 3.12A, lanes 1-2 and Figure 3.12C, lanes 1-4, was due to the 
use of two alkylating agents (NEM and IAA respectively). Samples analysed by 
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reducing SDS-PAGE recovered a single reduced band for each protein (Figure 3.12C, 
lanes 7-10), which also confirmed the expression of the transfected proteins. The small 
shift in mobility of Ero 1 p after exposing the cells to DTT was a consequence of 
increasing availability of -SH groups to the alkylating agent (Figure 3.12C, compare 
lanes 7 and 8, and lanes 9 and 10). 
To confirm that ErolP complex formation was abolished by in vivo DTT treatment, 
DTT-treated and untreated cell lysates were subjected to immunoprecipitation with 
aMyc and probed with aErolp serum after immunoblotting. As expected, the ErolP-
Myc protein from single transfectants was detected regardless of DTT treatment 
(Figure 3.12D, lanes 1 and 2). However, ErolP-HA was co-immunoprecipitated with 
Ero1P-Myc only in the absence of DTT treatment (Figure 3.12D, lane 4). The 
conclusion from these experiments was that a strong reducing environment was able to 
disrupt the majority of Ero 1 P-mediated covalent and non-covalent interactions at 
steady state. 
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HeLa (A) and HT1080 (B) cells transfected with wtEro1p-Myc (lanes 1-2 and 5-6) and 
mock (lanes 3-4 and 7-8) were treated with (lanes 2, 4, 6 and 8) or without (lanes 1, 3, 
5 and 7) 5 mM DTT for 30 min, and lysed in the presence of NEM and analysed by 
non-reducing (NR, lanes 1-4) or reducing (R, lanes 5-8) SDS-PAGE. Immunoblotting 
was with aMyc. C and D. HeLa cells transfected with wtEro1p-Myc (lanes 1-2, 7-8), 
wtEro1p-Myc and wtEro1J3-HA (lanes 3-4, 9-10) and mock (lanes 5-6, 11-12) were 
treated with 10 mM DTT for 15 min. Cells were lysed in the presence of NEM and 
analysed by immunoblotting with aMyc after non-reducing SDS-PAGE (lanes 1-6) and 
with aEroJ3 after reducing SDS-PAGE (lanes 7-12) or after D immunoprecipitation 
with aMyc. *=disulfide-dependent Ero-PDI and Ero-Ero complexes. Oxidation states 
of Ero 1 p monomer are indicated as OX ( oxidised) and R (reduced). 
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3.3 Discussion 
In this chapter the Erolj) protein, one of the two human ER oxidoreductases discovered 
to date, was characterised by the use of C-terminally tagged DNA constructs 
transfected into two different cell lines. Tagged Ero 113 proteins can restore viability to 
yeast Erolp temperature sensitive mutants (Pagani et al., 2000) and support oxidative 
protein folding of model substrates (Mezghrani et al., 2001), demonstrating that tagging 
does not effect Erolj) function. A new polyclonal antibody raised against a unique 
peptide of Erolj) was optimised for use in western blotting to detect tagged transfected 
Erolj) protein (Figure 3.4) as well as to detect endogenous Erolj) from murine tissue 
lysates (Figure 3.5). 
At steady state (Figure 3.6A and B) and dUJing biosynthesis (Figure 3.6C), Erolj) was 
present as a smear of oxidised f01ms, collapsing into a single reduced form upon in 
vitro reduction. On the other hand Erola, formed more distinct OX1/0X2 states of 
which the more compact OX2 was regarded the most stable state in vivo (Figure 3.6C; 
(Benham et al., 2000)). The variation in Erolj) redox states observed between cell lines 
in this study could be partly due to the influence of other chaperone proteins and/or the 
redox potential of the protein in the different cell lines. Both Erolj) and Erola have 
long half-lives (from this study and (Benham et al., 2000) respectively) compatible 
with a role for the proteins in ER homeostasis. Erolj) is expressed at low levels in 
cultured cell lines and thus the general assumption is that low expression of an 
oxidoreductase is sufficient to drive the oxidation of many substrate proteins through 
the use of many PDI molecules. At the same time, electron acceptors like Ero proteins 
could cause damage through production of free radicals if expressed at high levels in 
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vivo. To overcome this situation, Era proteins might be expressed in low abundance but 
will then need to catalyse a large number of thiol-disulfide reactions through PDI. 
However, Figure 3.5 shows that Ero1~ is expressed at surprising high levels in stomach 
and pancreas, suggesting that it may do more than just act as a catalyst for PDI. 
The ability of Ero1~ to form mixed disulfides with PDI was first demonstrated by 
Mezghrani et al using a pulse-chase approach (Mezghrani et al., 2001). Ero1~-PDI 
complexes are alkylation dependent (Figure 3.8A and B) as previously observed for 
Ero1a and Ero1p (Mezghrani et al., 2001; Benham et al., 2000; Frand & Kaiser, 1999). 
However, Ero1~ was able to form disulfide-dependent complexes in the presence and 
in the absence of an alkylating agent (Figure 3.7A and B). In PDI immunodepletion 
experiments (Figure 3.8C and D), the existence of non-PDI disulfide linked complexes 
was strong! y evident. 
Although protein oxidation is inhibited by DTT, it is reversible and protein translation, 
translocation, N-glycosylation and signal sequence cleavage are not affected 
(Braakman et al., 1992). For example, addition of OTT to S. cerevisiae cells blocked 
the folding and transport of carboxypeptidase Y (CPY), but it did not however interfere 
with secretion of invertase, a protein that lacked disulfide bonds (Simons et al., 1995). 
Data from this chapter shows that subjecting Ero 1 ~ transfected cells to a reducing 
(DTT) environment disrupts the majority of Ero1 ~-mediated covalent and non-covalent 
complexes, but that an oxidised monomer pool of Ero1~ still remained. 
Looking at the electrophoretic pattern of Erola and Ero1~ in diagonal, non-
reducing/reducing gels, Mezghrani and colleagues initially suggested formation of a 
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covalent homodimer in hEROs (Mezghrani et al., 2001). The ability of Ero1p to form 
these covalent homodimers was shown in this chapter using Myc and HA tagged Ero1 P 
proteins (Figure 3.9). These homodimers were recovered inespective of whether an 
alkylating agent was present at the point of lysis. Dimerisation has been a feature of a 
number of thioredoxin proteins (Liepinsh et al., 2001; Zapun et al., 1995). DsbC, the 
prokaryotic counterpart of PDI, exhibits both disulfide isomerase and chaperone 
activity and it is shown to be a V-shaped homodimer (Chen et al., 1999; McCarthy et 
al., 2000). DsbC mutant proteins present as a monomer were able to complement a 
DsbA null mutation in the presence of DsbB, which suggested that mutant DsbC was 
converted from an isomerase into an oxidase. These results suggest that keeping DsbC 
protein in a dimer prevents its oxidation by DsbB, preventing cross-talk between the 
oxidative and reductive pathways and allowing them to co-exist in vivo in the bacterial 
periplasm (Bader et al., 2001). Hybridising DsbA domains with no isomerase or 
chaperone activity to DsbC monomers created dimers with increased chaperone and 
isomerase activity (Zhao et al., 2003). These results suggest that dimerisation could be 
a possible means of bestowing novel activity to monomeric proteins, which would be 
an interesting feature for hERO proteins. The recovery of Erola-Ero1P heterodimers 
adds to the complexity of interactions found between oxidoreductases in the ER. 
Although complexes other than Ero1P-PDI were recovered at different abundance from 
murine tissue Iysates, some of which COITespond to possible dimers, the in vivo picture 
still remains incomplete. The molecular requirements for Erolp dimer formation will 
be studied and discussed in more detail in Chapter 4. 
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4.1 Introduction 
The interactions and behaviour of wild-type Erol~ were discussed in Chapter 3. Erola 
and Ero1~ both have two conserved redox active motifs, a CXXXXC motif towards the 
N-terminus and a CXXCXXC motif near the C-terminus (Figure 3.2, A and B, (Cabibbo 
et al., 2000; Pagani et al., 2000)). The importance of these two motifs in dithiol-
disulfide exchange was initially identified in yeast Ero1p (Frand & Kaiser, 2000). The 
authors showed that mutants with cysteine to alanine substitutions at CIOO, C105, C352 
and C355 were not able to restore growth to ero1-1 temperature sensitive cells at the 
restrictive temperature, or rescue the inviability associated with a chromosomal 
deletion of ERO 1. These mutants when expressed in ero1-1 cells retained the vacuolar 
protease CPY in a reduced form within the ER, indicating that these four cysteines are 
required for efficient disulfide-bond formation. A CGHS-CGHS active site mutant of 
Pdilp and a CQHA mutant of Mpd2p were used to identify CIOO as the cysteine 
preferentially attacked in Ero1p. TCA precipitation and AMS modification was used to 
examine the oxidation states of these mutants in vivo which showed that the majority of 
C352 and C355 mutants were in the reduced form. Taken together, data from this paper 
suggested that the Cl00/C105 pair was important for thiol~disulfide exchange with 
Pdi 1 p and Mpd2p, whereas the C352/C355 pair was required to maintain the fully 
oxidized state ofErolp (Frand & Kaiser, 2000). 
These mutational and biochemical studies of the yeast ERO 1 gene have shown that the 
N-terminal active site cysteines are involved in a dithiol-disulfide reaction with PDI. 
Accepted electrons are then transferred on to the C-terminal active site cysteines that 
then pass on electrons to molecular oxygen via FAD (Figure 4.1; (Frand & Kaiser, 
2000; Tu & Weissman, 2002)). 
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FIGURE 4.1: Schematic representation of dithiol-disulfide exchange of Erol 
Model of the flow of electrons donated from PDI to molecular oxygen via Ero and 
FAD. TheN terminal CXXXC and C-terminal CXXCXXC active site motifs are shown. 
s.s = signal sequence. (Reproduced from (Dias-Gunasekara & Benham, 2005)). 
The yeast C353/C355 pair is part of a conserved CXXCXXC motif found in both Ero1a 
and Ero1P (Figure 3.1 and 4.2). 
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FIGURE 4.2: Alignment of the CXXCXXC motifs 
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Human Ero1a (Ero1a_H.s, Q96HE7; H. sapiens), human Ero1P (Ero1b_H.s, Q86YB8; 
H. sapiens) and yeast Ero1p (Ero1_S.c, Q03103; S.cerevisiae) are aligned. The C-
terminal active site cysteines CXXCXXC are shaded red, and identical residues are 
shaded in black. 
Mutational studies at the CXXCXXC motif in Ero 1 a has shown that this active site is 
important for the folding, structural integrity, as well as the stability of the Ero 1 a -PDI 
complex (Benham et al. , 2000). Mutations at C394 (C394A) and C397 (C397 A) 
inhibited oxidation of two soluble immunoglobulin subunits; glycosylated JcM (Murine 
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J chain) with three intra-chain disulfide bonds and the non-glycosylated K chains 
(Mezghrani et al., 2001). This work showed that the C394/C397 pair was essential in 
Erola mediated oxidative folding of substrate proteins and complemented Erolp work 
by Frand and Kaiser (Frand & Kaiser, 2000). A more recent study by Bertoli and 
colleagues using a panel of cysteine replacement mutants showed that Erola contains 
two essential cysteine triads, C85/C94/C99 and C391/C394/C397 which cooperate in 
electron transfer (Bertoli et al., 2004). In Erol p, the role of the CXXCXXC motif had 
not been previously studied and this chapter investigates these Erolp mutants and the 
requirement for the CXXCXXC motif in Erolp interactions. 
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4.2 Results 
4.2.1 Construction of Erol p CXXCXXC mutants 
To investigate the nature of Erol~ C-terminal active site (CXXCXXC) mutants, wild-
type pcDNAErol~-Myc and pcDNAErol~-HA constructs were used in site-directed 
mutagenesis to create cysteine to alanine mutants, namely Erol ~C390A-Myc, 
Erol~C393A-Myc, Erol~C396A-Myc and Erol~C390A-HA, Erol~C393A-HA, 
Erol~C396A-HA. The primers used have been detailed in Chapter 2, section 2.3.1. 
4.2.2 ER localisation of Erol p CXXCXXC mutants 
ER localisation of wild-type Erola and Erol~ gene products in mammalian cells were 
determined in COS-7 and HeLa cells using immuno-localisation studies (Cabibbo et al., 
2000; Pagani et al., 2000). To determine the intracellular localisation of the three C-
terminal mutants of Erol~, HeLa cells were transfected with wild-type Erol~-Myc 
(Figure 4.3A), Erol~C390A-Myc (Figure 4.38), Erol~C393A-Myc (Figure 4.3C), and 
Erol~C396A-Myc (Figure 4.3D). Transfected cells were fixed in MeOH prior to co-
staining with an anti-serum against the ER resident protein PDI (Figure 4.3A-D, panel 
2) and a Myc monoclonal antibody (Figure 4.3A-D, panel 1). Immunofluorescence 
analysis using confocal microscopy showed that wild-type Erol ~ and the three 
CXXCXXC mutant distribution largely overlapped with that of PDI (Figure 4.3A-D, 
panel 3) demonstrating their localisation in the ER and consistent with the isolation of 
Erol~ by Con A (Figure 3.5B). 
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FIGURE 4.3: Wild-type ErolP and the three active site mutants localise to the ER 
A-D. HeLa cells transfected with pcDNA3.1 wild-type Erol~ and three 
Ero 1 p CXXCXXC mutants were fixed 24 hrs after transfection in ice cold MeOH and 
co-stained with aMyc and aPDI primary antibodies, followed by fluorescein donkey 
anti-mouse Ig (FITC) and TRITC swine anti-rabbit Ig before analysis under confocal 
microscopy. Each panel of three images has the aMyc-FITC, aPDI-TRITC and the 
aMyc/aPDI overlap image from left to right. A. wild-type Erolp, B. Ero1PC390A, C. 
Ero1PC393A and D. Ero1PC396A. 
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4.2.3 Erol fJ CXXCXXC mutants form alkylation independent complexes 
Analysis of Ero1a CXXCXXC mutants has demonstrated that this C-terminal active site 
motif is important for protein folding, function, structural integrity, protein half life and 
the stability of the Ero1a-PDI complex (Benham et al., 2000; Mezghrani et al., 2001). 
Pulse-chase experiments were carried out to examine the oxidative folding of Ero 1 j3 C-
terminal mutants in living cells. Ero1j3C390A-Myc, Ero1j3C393A-Myc and 
Ero1j3C396A-Myc constructs were transfected into HeLa cells, starved for 40 min in 
medium lacking cysteine and methionine, radio-actively pulse-labelled for 10 min, 
chased for the indicated times and lysed in the presence of NEM. Post-nuclear 
supernatants were subjected to immunoprecipitation with aMyc antibody and analysed 
on non-reducing (Figure 4.4A, lanes 5-10; 4.48, lanes 5-10) and reducing SDS-PAGE 
(Figure 4.4A, lanes 1-3 and 12-14; 4.48 lanes 1-3 and 12-14). Wild-type Ero1j3 formed 
the same smear of oxidised bands (OX) as Figure 3.6D under non-reducing SDS-PAGE 
(Figure 4.4A, lanes 5-7). Ero1j3C390A was less compact and mostly reduced (R) after 
the 10 min pulse and remained predominantly the same after the 60 min chase (Figure 
4.4A, lanes 8-10). Ero1j3C393A was the most similar to wild-type but even this mutant 
was more reduced (R) after the longest chase time point (Figure 4.48, lanes 5-7). 
Ero1j3C396A on the other hand, was more compact and remained reduced (R, Figure 
4.48, lanes 8-10). These results indicated that mutations at the CXXCXXC motif 
affected the redox state of Ero1j3. Note the presence of a band around 75 kDa present in 
wild-type and all three CXXCXXC mutants, (not present in mock transfectants) but 
showing far less intensity with Erolj3C396A (Figure 3.6, C and D and 4.4, A and B). 
Attempts to identify this Ero1j3 interacting protein will be discussed in Chapter 5. 
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FIGURE 4.4: Oxidative folding of Eroll3 C.XXC.XXC mutants 
A. HeLa cells transfected with wtEroli3-Myc (lanes 1-7) and Eroli3C390A-Myc (lanes 
8-14) were starved for 40 min, pulse labelled for 1 0 min, chased for the times indicated 
and immunoprecipitated (IP) with aMyc (lanes 1-14) prior to non-reducing (NR, lanes 
5-10) and reducing (R, lanes 1-3 and 12-14) SDS-PAGE. B. Same as for A, but 
transfected with Ero1PC393A-Myc (lanes 1-7) and Ero1PC396A-Myc (lanes 8-14). 
Under non-reducing conditions wtErolp (A, lanes 1-3) and Ero1PC393A (B, lanes 1-3) 
monomers form a smear of oxidation states (OX) compared to Ero1j3C390A (A, lanes 
8-10) and Ero1PC396A (A, lanes 8-10) which are more reduced (R). Note the band 
around 75 kDa seen at varying intensities in wild-type and mutant Ero1p. 
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To investigate the behaviour of the ErolP CXXCXXC mutants at steady state, HeLa 
cells were transfected with the three Myc-tagged mutants, ErolPC390A-Myc, 
ErolPC393A-Myc, ErolPC396A-Myc together with wild-type Erolp-Myc. The 
transfected cells were lysed either in the presence or in the absence of the alkylating 
agent NEM, and the post nuclear supernatants were examined by western blotting using 
a Myc antibody after non-reducing and reducing 8% SDS-PAGE. 
At steady state, wild-type Erol p monomer is party oxidised partly reduced (Figure 
4.5A, lane 1) as seen in Chapter 3. ErolpC390A was in a less compact state (Figure 
4.5A, lane 3) which was comparable to the ErolaC391A mutant (Benham et al., 2000). 
ErolPC393A was found as a mixture of oxidised (OX) and reduced (R) forms (Figure 
4.5A, lane 5), similar to wild-type Erolp, whereas ErolpC396A was found 
predominantly in a reduced state (Figure 4.5A, lane 7). Alkylation was required to trap 
the oxidation states (Figure 4.5A, compare lanes 1 and 2). The mock transfectants were 
negative (Figure 4.5A, lane 9 and 10). Reduction of the samples with DTT prior to 
SDS-PAGE analysis gave a single band (Figure 4.5B). These results are similar to the 
Erola CXXCXXC mutant behaviour, although in Erola the monomer oxidation states 
are more discrete ((Benham et al., 2000) and Figure 3.6C, lane). The behaviour of 
Erolp monomer states was comparable between steady state and pulse chase analysis. 
The same lysates when analysed under non-reducing SDS-PAGE, were used to study 
the ability of the mutants to form higher molecular weight complexes (Figure 4.5C). 
The transferred proteins were probed with aMyc to detect Erol p protein. In the 
presence and in the absence of NEM, wild-type Erolp formed a ladder of complexes 
similar to that seen in Figure 3.7A and B (Figure 4.5C, lane 1-2). All three C-terminal 
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mutants were able to form a number of higher molecular weight complexes, although 
they all gave a slightly different pattern from wild-type (Figure 4.5C, compare Lanes 1-
2 with lanes 3-8). The non-specific nature of the band around 130 kDa (Figure 4.5C, 
lane 9 and 11) was discussed in Chapter 3, section 3.2.2. 
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FIGURE 4.5: ErolJ3 CXXCXXC mutants form redox dependent, NEM 
independent complexes 
A. non-reducing (NR) and B. reducing (R) SDS-PAGE ofMyc tagged wtEro1J3 (lanes 
1-2), Ero 1 J3C390A (lanes 3-4), Ero 1 ~C393A (lanes 5-6), Ero 1 J3C396A (lanes 7-8), and 
mock transfectants (lanes 9-1 0) lysed in the presence (lanes 1, 3, 5, 7 and 9) or absence 
(lanes 2, 4, 6, 8 and 10) ofNEM after western blotting (WB) probed with aMyc. Ero1J3 
oxidised (OX) and reduced (R) monomer forms are indicated. C. same as for A, except 
that lane 10 is loaded with sample buffer only and lane 11 is loaded with mock 
transfected cell lysate in the absence ofNEM. The Ero-PDI complex is indicated. 
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4.2.4 Erol p C390A interacts weakly with PDI 
Having established that Erolp CXXCXXC mutants are able to form higher molecular 
weight complexes, the same lysates as in Figure 4.5 were used to compare their ability 
to interact with PDI. Wild-type and CXXCXXC mutant HeLa cell transfectants, lysed in 
the presence or in the absence of NEM, were either directly analysed by reducing SDS-
PAGE and transfen·ed proteins probed with an anti-serum raised against PDI (Figure 
4.6A) to detect the presence of PDI or first subjected to immunoprecipitation with a 
PDI anti-serum, separated by non-reducing (Figure 4.6B) and reducing (Figure 4.6C) 
SDS-PAGE. Transferred proteins were probed with a Myc antibody which should 
detect any ErolP-PDI interactions. Wild-type Erolp forms disulfide-dependent Ero-
PDI dimers in the presence of NEM (Figure 4.6B, lane 1), also seen in Figure 3.8B. 
ErolPC393A (Figure 4.6B, lanes 5 and 6) and ErolPC396A (Figure 4.6B, lanes 7 and 
8) both interacted with PDI in a NEM dependent manner, although less strongly than 
with wild-type. The ErolpC390A mutant hardly interacted with PDI (Figure 4.6B, lane 
3) although it did form disulfide dependent complexes (Figure 4.5C, lane 3). Again, 
ErolPC390A complexes were preserved in the absence of an alkylating agent, showing 
that ErolPC390A could interact with partner protein(s) other than PDI (Figure 4.5C, 
lane 4). All three Erolp mutants behaved similar to Erola CXXCXXC mutants with 
respect to their disulfide dependent interactions with PDI (Benham et al., 2000). 
Reduction of the immunoprecipitates prior to SDS-PAGE analysis revealed that wild-
type (Figure 4.6C, lane 1) and the C396A mutant (Figure 4.6C, lane 7) were able to co-
immunoprecipitate with the PDI antibody in the presence of NEM. Both C390A and " 
C393A mutants co-immunoprecipitated weakly, if at all, with PDI in the presence of 
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NEM (Figure 4.6C, lanes 3 and 5). Both wild-type Erolp and ErolPC396A mutant 
interacted weakly with PDI in the absence of an alkylating agent (Figure 4.6C, compare 
lanes 1 and 7 with lanes 2-6 and 8). Taken together these results revealed a covalent 
and a relatively small non-covalent pool of Ero-PDI interactions. These very weak non-
covalent interactions are preserved even in the absence of NEM (Figure 4.6C, lanes 2, 
4, 6 and 8). 
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A. HeLa cells transfected with Myc tagged wtErolj3 (lane 1-2), Erolj3C390A (lane 3), 
Erolj3C393A (lane 4) and Erolj3C396A (lane 5) were lysed in the presence (lanes 1, 3-
5) and absence (lane 2) of NEM and analysed under reducing (R) SDS-PAGE and 
probed with aPDI. B. non-reduced (NR) and C. reduced (R) SDS-P AGE of Myc-
tagged wtErolj3 (lane 1-2), Ero l j3C390A (lane 3-4), Erolj3C393A (lane 5-6), 
Erolj3C396A (lane 7-8) and mock transfectants (lanes 9-10) lysed in the presence 
(lanes 1, 3, 5, 7 and 9) or absence (lanes 2, 4, 6, 8 and 10) of NEM, subjected to 
immunoprecipitation with aPDI and probed after western blotting (WB) with aMyc. B. 
PDI formed covalent complexes with wtErolj3, Erolj3C393A and Erolj3C396A in the 
presence ofNEM. Antibody complexes (ab) migrated just above the Ero-PDI dimer. C. 
Prominent Ero-PDI interactions (non-covalent plus the covalent pool) were seen with 
wtErolj3 and Erolj3C396A in the presence ofNEM. ab= antibody. 
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4.2.5 Erol f3 CXXCXXC mutants can dimerise with wild-type Erol p 
In both Erola and Erol~ the CXXAXXC and CXXCXXA mutants were able to form 
disulfide-dependent dimers with PDI ((Benham et al., 2000) and Figure 4.6B, lanes 5 
and 7). However, in Erola the C394A and C397 A mutants were not able to rescue the 
temperature sensitivity of the yeast ero1-1 mutant (Cabibbo eta!., 2000). On the other 
hand, the AXXCXXC mutant in both Erola and Erol~ interacted poorly with POI 
((Benham et al., 2000) and Figure 4.6B, lane 3), but the C391A mutant of Erola was 
able to rescue the ero1-1 yeast phenotype (Cabibbo et al., 2000). Taken together these 
results implied that interactions other than covalent Ero-PDI interactions could be 
required for Ero function. Given that wild-type Erol~ dimerisation could occur (as 
discussed in Chapter 3, section 3.2.3) the effects of the active site on dimerisation were 
investigated. 
To investigate whether mutant Erol~ proteins could associate with wild-type Erol~, 
Erol~C390A-Myc (Figure 4.7, A and B), Erol~C393A-Myc (Figure 4.7, C and D) and 
Erol~C396A-Myc (Figure 4.7, C and D) were co-transfected with wild-type Erol~-HA. 
Reduced blots showed that single and double transfectants expressed the expected 
proteins (Figure 4.7, A and C). Celllysates were then subjected to immunoprecipitation 
with the HA antibody, followed by blotting with the Myc antibody (Figure 4.7, B and 
D). No co-immunoprecipitaion, thus no signal, was detected in the single or the mock 
transfectants (Figure 4.7B, lanes 1-3, 5, 8; 4.7D, lanes 1-3 and 6). Wild-type Erol~­
Myc could be co-immunoprecipitated with wild-type Erol~-HA, verifying this 
interaction (Figure ·4.78, lane 4). Erol'~C390A-Myc (Figure 4.7B, lane 6), 
Erol~C393A-Myc (Figure 4.7D, lane 4) and Erol~C396A-Myc (Figure 4.7D, lane 5) 
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specifically co-immunoprecipitated with wild-type ErolB-HA. Cell lysates used in 
Figure 4.7A and C, when analysed under non-reducing SDS-PAGE followed by 
immunoblotting with aMyc and aHA (Figure 4.7£), showed that an intermediate band 
-120 kDa (arrow) was present only in the double transfectants (Figure 4.7£, lanes 4, 5, 
7 and 8). This intermediate band was more prominent in Erol BC393A plus wild-type 
ErolB (lane 4) and ErolBC396A plus wild-type ErolB (lane 5) compared with the 
Eroli3C390A (lane 8) mutant. Thus mutations of the CXXCXXC motif do not interfere 
with disulfide-linked complex formation with wild-type ErolB. 
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FIGURE 4.7: Ero1J3 CXXCXXC mutants dimerise with wild-type Ero proteins 
A. HeLa cell lysates expressing wtEro1J3-Myc (lane 1), Ero1J3C390A-Myc (lane 2), 
wtEro1P-HA (lane 3), wtEro1P-Myc and wtEro1P-HA (lane 4), Ero1J3C390A-Myc and 
wtEro 1 P-HA (lane 5) and mock transfected (lane 6) were analysed by reducing SDS-
PAGE and immunoblotted for Ero 1 p with both aHA and aMyc. B. same as for A, 
except that lysates were first immunoprecipitated with aHA prior to immunoblotting 
with aMyc. Lanes 1-4 are the same as in A, lane 5 aHA antibody only, lane 6 is 
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Ero1PC390A-Myc and wtEro1P-HA, lane 7 is sham-loaded, and lane 8 contains the 
mock sample. Ab = antibody from the immunoprecipitates. C and D. HeLa cell lysates 
expressing ErolPC393A-Myc (lane 1), Ero1pC396A-Myc (lane 2), wtEro1P-HA (lane 
3), Ero1PC393A-Myc plus wtEro1P-HA (lane 4), Ero1PC396A-Myc plus wtErolP-HA 
(lane 5), and mock (lane 6) were analysed by reducing SDS-PAGE and immunoblotted 
for Ero1P directly (C) or first subjected to immunoprecipitation with aHA and 
immunoblotted with aMyc (D). All CXXCXXC mutants interact with wild-type Erolp. 
ab = antibody from the immunoprecipitate. E. Cell Iysates from A and C analysed 
under non-reducing SDS-PAGE and probed with both aHA and aMyc. Ero1PC393A 
and Ero1PC396A showed a more prominent intermediate band -120 kDa similar to 
wtEro1p, whereas Ero1PC390A was more smeary. 
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4.2.6 C396 is required for Erol P homodimer formation 
Since mixed complexes could be formed between wild-type Erolp and CXXCXXC 
Erolp mutants, the ability of the C-terminal mutants to form mutant-mutant dimers was 
investigated. HA-tagged versions of ErolpC390A, ErolPC393A and ErolPC396A 
were constructed and co-transfected into HeLa cells with the equivalent Myc-tagged 
Erolp mutants. Cell lysates were analysed by reducing SDS-PAGE and transferred 
proteins probed with Erolp serum to confirm the expression of the proteins (Figure 
4.8A), or the cell lysates were first subjected to immunoprecipitation with the Myc 
antibody and immunoblotted with aErolp (Figure 4.88). 
The a-Myc monoclonal antibody did not pull down any HA-tagged Erol p protein in 
the mock and single transfectants (Figure 4.88, lanes 2-5), but did bring down Myc-
tagged protein, as expected (Figure 4.88, lane 1). Wild-type ErolP-HA as well as 
ErolPC390A-HA and ErolpC393A-HA proteins co-immunoprecipitated with their 
Myc tagged counterparts (Figure 4.88, lanes 6-8). However, the Erol pC396A mutant 
did not co-immunoprecipitate (Figure 4.8A, lane 9). These data demonstrated that 
Erolp AXXCXXC and CXXAXXC mutants were able to interact with themselves and 
with wild-type Erolp protein. On the other hand, an Erolp CXXCXXA mutant was able 
to interact with wild-type Erolp but could not dimerise with the mutant counterpart. 
125 
Chapter 4: CX'.XCXXC mutants of Ero1 p 
A 
WB:cxErop, R 
J: J: J: 
I I I 
c::c. c::c. c::c. 
~ <( <( ('I) (0 (J) (J) (J) 
('I) ('I) ('I) 
J: u (.) u 
<( <( <( cb. + + + 
J: J: J: ~ ::E ::E ::E 
0 cb.cb.cb.+cb. I I >- <( c::c. c::c. E J: <( <( <( ::E <( ~ <( 0 ('I) (0 0 (0 ~ 
cb. I (J) (J) (J) cb. (J) (J) (J) 0 c::c. ~ ~ ('t) ('I) ('I) ..... ('t) ('I) ('I) 0 uuu ~u (.) u ::!: 
~~ 
~~-~~ ~·~·~ 
-50 
1 2 3 4 5 6 7 8 9 10 
B 
IP:cxMyc, WB:cxErop, R 
J: J: J: 
I I I 
c::c. c::c. c::c. 
<( ~ <( 0 (0 
(J) (J) (J) 
('I) ('I) ('I) 
J: (.) u (.) 
<( <( <( I + + + 
J: J: J: c::c.::E ::!: ::!: 
0 cb. cb. I ~ I I I <( c::c. + c::c. c::c. c::c. >- <( <( <( ~ <( ~ <( E J: 0 ('I) ~ 10 (0 ~ I I (J) (J) c::c.CJ> (J) (J) 0 c::c. c::c. ('I) ('I) ('I) ..... ('I) ('I) ('I) 0 ~ ~ (.) (.) u 5:: (.) (.) (.) ::E 
-
-· 
~ 
..-. •;.o;,·:r . 
-50 
1 2 3 4 5 6 7 8 9 10 
FIGURE 4.8: Ero1PC396A proteins do not form mutant-mutant dimers 
A. HeLa cell lysates expressing wtEro 1 ~-Myc (lane 1), wtEro 1 ~-HA (lane 2), 
Ero1~C390A-HA (lane 3), Ero1~C393A-HA (lane 4), Ero1~C396A-HA (lane 5), 
wtEro1~-Myc and wtEro1~-HA (lane 6), Ero1~C390A-Myc and Erol~C390A-HA 
(lane 7), Ero1PC393A-Myc and Ero1PC393A-HA (lane 8), Ero1PC396A-Myc and 
Erol~C396A-HA (lane 9) or mock (lane 10) were analysed by reducing SDS-PAGE 
and immunoblotted with aEro~. B. same as for A, except that the lysates were first 
subjected to immunoprecipitation with aMyc antibody prior to immunoblotting with 
aEro~. 
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The ability of Erolp CXXCXXC mutants to interact with their CXXCXXC counterparts 
in Erola was investigated by double transfecting Erolp Myc tagged mutants together 
with non-tagged Erola mutants (Figure 4.9). HeLa cells were either mock transfected 
(Figure 4.9A and B, lane 13), single transfected (Figure 4.9A and B, lane 1-8) or double 
transfected with wild-type Erola and wild-type ErolP-Myc (Figure 4.9A and B, lane 
9), ErolaC391A plus ErolpC390A-Myc (Figure 4.9A and B, lane 10), ErolaC394A 
plus Ero1PC393A-Myc (Figure 4.9A and B, lane 11) and ErolaC397 A plus 
ErolPC396A-Myc (Figure 4.9A and B, lane 12). Cell lysates subjected to 
immunoprecipitation with aMyc pnor to reducing SDS-PAGE and probing the 
transfened proteins with D5 antibody, showed that the AXXCXXC (Figure 4.9A, lane 
10), and CXXAXXC (Figure 4.9A, lane 11) mutants of Erola and Erolp were able to 
interact with each other similar to wild-type Erola and Erolp (Figure 4.9A, lane 9). 
However, Erolp CXXCXXA mutant was unable to interact with the CXXCXXA Erola 
mutant (Figure 4.9A, !Cme 12). The cell lysates were directly analysed by reducing 
SDS-PAGE, probed with D5 antibody (Figure 4.9B) and aMyc (Figure 4.9C) to 
confirm the expression of the transfected proteins. Taken together the results were 
consistent with a symmetrical, redox-dependent Ero dimer in which the C396/C397 
residue was required for dimerisation. 
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FIGURE 4.9: Erola and Eroll3 CXXCXXA mutants do not interact 
A. HeLa cell lysates expressing wtErola (lane 1), wtErolj3-Myc (lane 2), 
ErolaC391A (lane 3), ErolaC394A (lane 4), ErolaC397A (lane 5), Erolj3C390A-
Myc (lane 6), Erolj3C393A-Myc (lane 7), Erolj3C396A-Myc (lane 8), wtErola and 
wtErolj3-Myc (lane 9), ErolaC391A and Erolj3C390A-Myc (lane 10), ErolaC394A 
and Erolj3C393A-Myc (lane 11), ErolaC397A and Erolj3C396A-Myc (lane 12) or 
mock (lane 13) were first subjected to immunoprecipitation (IP) with aMyc antibody 
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pnor to reducing SDS-PAGE analysis and immunoblotting with aErola (05). 
ErolaC397 A mutant does not co-immunoprecipitate with Erol~C396A (lane 12). ab = 
antibody from the immunoprecipitate. B and C. same as for A, except that the lysates 
were directly analysed by reducing SDS-PAGE (Before IP) and immunoblotted with 
(B) aEroa (D5) or with (C) aMyc. 
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4.2. 7 Model for the Erol dimer 
To identify a molecular basis for the dimer of Erol ~' and to understand the role of 
C396A mutant in disrupting it, the recently determined crystal structure of yeast Erolp 
(Gross et al., 2004) was analysed. Although there is only a single monomer in the 
asymmetric unit of the two different crystal forms of the enzyme reported (PDB codes 
1RP4 and lRQl), examination of the crystal contacts revealed a single dimer 
interaction between the monomers (Figure 4.10A). This is consistent with the 
symmetrical dimer suggested by the immunoprecipitation experiments in Figure 4.7 to 
4.9. In the model of this dimer, the N termini are bought into close proximity and could 
thus interact to form part of the dimer interface. This part of theN terminus is absent in 
the construct used to crystallise the two forms of Ero 1 p. The crystal structure was of a 
truncated S. cerevisiae Erolp protein, which shares -25% sequence identity with full 
length human Erol~. The human enzyme has several amino acid inserts, ranging in size 
from 5 to 25 residues. Analysis of the crystal structure confi1med that these inserts are 
all found at the surface in positions where additional structure can be accommodated. 
In addition, none of these inserts would disrupt the presumed dimer interface. 
In the proposed Erolp dimer the monomers are arranged so that the active sites are on 
the same side of the dimer facing each other. The dimer brings together the adenosine 
groups of the two FAD moieties to close proximity; in fact the two hydroxyls of the 
ribose sugars of the adenosine moiety of FAD form hydrogen bonds to each other 
(Figure 4.10A). The FADs contribute to 20% of the dimer inte1face and therefore might 
be essential for dimer formation. Mutagenesis at the CXXCXXC motif revealed that the 
Erol~C396A mutation disrupted dimer formation (section 4.2.6) but this 396 cysteine 
is buried within the active site (Figure 4.10B) and so is highly unlikely to be involved 
130 
Chapter 4: CXXCXXC mutants of ErolfJ 
in an inter-molecular disulfide bond to form the dimer. Rather, due to its contact with 
the FAD cofactor (Figure 4.108), mutation at C396 is more likely to disrupt FAD 
binding leading to the FAD-FAD dimer interface being lost. 
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A 
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FIGURE 4.10: Structural model of an Ero dimer 
A. two Ero 1 p monomers form significant interactions (non-bonded and four hydrogen 
bonds) between the two symmetrically related FAD molecules (space filling). The four 
glycans per monomer are located away from the dimer interface (stick and ball 
representations). B. detail of the dimer interface showing the C90-C349 disulfide bond 
(C81-C391 in Erolp), the C353-C355 active site disulfide (C393-C396 in Erolp), and 
C100-C105, which is not labelled for clarity. C355 (C396) is buried within the 
monomer, and is in Vander Waals contact with the FAD (stick and ball representation), 
but is unlikely to form a dimeric, intermolecular disulfide. Graphics were generated 
using the PyMOL program (DeLano, W. L., The PyMOL Molecular Graphics System 
(2002) DeLano Scientific, Can Carlos, CA) by Adrian Lapthom, University of 
Glasgow, UK. 
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4.3 Discussion 
This chapter focuses on characterising three Ero1P C-tetminal active site mutants. All 
three mutants showed ER localisation similar to wild-type protein and under steady 
state conditions formed higher molecular weight complexes independent of an 
alkylating agent (Figure 4.5). Prior to this study it was known that Ero proteins and PDI 
are required for disulfide bond formation in the ER (Cabibbo et al., 2000; Pagani et al., 
2000; Frand & Kaiser, 2000; Frand & Kaiser, 1999). However, an Ero1a C391A 
mutant can rescue the temperature sensitivity in yeast ero1-1, but had little affinity for 
PDI (Cabibbo et al., 2000; Benham et al., 2000; Bertoli et al., 2004). Results from this 
chapter show that in Ero1p, this C390A mutant can still only interact weakly with PDI 
(Figure 4.6) but is able to homodimerise (Figure 4.8). On the other hand, the inactive 
Ero1P C396A mutant (Pagani et al., 2000) is able to interact with PDI (Figure 4.6) but 
cannot homodimerise (Figure 4.8). Although both Erola and Ero1p allow the growth 
of mutant ero1-1 yeast cells at the restrictive temperature (Cabibbo et al., 2000; Pagani 
et al., 2000), Ero1a (and probably Ero1p) cannot complement ~EROI cells in which 
the endogenous ERO gene has been disrupted (Pagani et al., 2001). A similar result was 
seen when an Ero1p~C mutant (Erolp mutant lacking the C-terminal tail) was 
expressed in ero1-1 and ~EROl cells (Pagani et al., 2001). The authors suggest that in 
the ero1-1 transformants, functional hetero-dimers are being formed between 
endogenous Era 1 p and the expressed proteins. Taken together, the literature and the 
data from this chapter suggest that Ero-Ero dimers are important for the functional 
activity of this family of Ero proteins. 
Experimental data from this chapter shows that dimerisation is partly controlled by the 
CXXCXXC motif, although other covalent and non-covalent interactions are likely to 
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play a role in establishment of the dimers. Both the Ero-PDI and Ero-Ero interactions 
are stable under non-reducing conditions (in the presence of SDS), but the strength of 
these interactions vary, given that the Ero-PDI interaction requires trapping by an 
alkylating agent while Ero-Ero interactions do not. 
Reconstruction of an Ero-Ero dimer from the Erolp crystal structure suggests that the 
glycosylation sites of Erolp, Erola and Erolp are all located away from the dimer 
interface, and thus would not prevent Ero-PDI interactions (Figure 4.10A). Comparison 
of the two Erolp crystal forms revealed a flexible loop containing the Cl00/Cl05 
disulfide bond which adopts an 'in' and 'out' conformation (Figure 4.11). Electrons 
accepted from PDI by the Cl00/Cl05 disulfide bond in the 'out' conformation could 
shuttle the electrons onto the C352/C355 active site disulfide when in the 'in' 
conformation. This likely site for PDI docking is also positioned away from the dimer 
interface, which suggests that Ero-PDI heterodimers and Ero-Ero dimers might not be 
separate entities. The immunodepletion experiments from chapter 3 (Figure 3.8C and 
D) suggest that Ero-PDI complexes are separate from Ero-Ero dimers in a Triton-X-
100 lysate. However it remains possible that tetrameric complexes between Ero-PDI 
and Ero-Ero could still operate under different situations in vivo. 
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FIGURE 4.11: Flexibility ofthe Erolp C100/Cl05 loop 
The two Ero1p crystal forms are superimposed to give the 'in' and 'out' conformations 
to the C 1 00/C 105 loop which can move by about 17 A. Disulfide bonds are shown in 
yellow. Reproduced from (Grosset al., 2004). 
The Ero 1 p dimer model is held together by a hydrogen bonding network at the dimer 
interface (Figure 4.1 0). Two hydrogen bonds link the two FAD molecules and are 
likely to be important for stability of the dimer, given that the Ero 1 PC396A mutation 
disrupts dimer formation. C396 together with C393 probably passes on electrons to 
FAD for donation to oxygen (Tu & Weissman, 2002). Thus the loss ofC396 is likely to 
lead to the loss of dimerisation indirectly by disrupting FAD binding. The proximity of 
theN-termini in the model of the truncated Ero1p dimer, suggests that theN-terminal 
cysteines upstream of the CXXXC redox motif (C42 and C44, Figure 3.1) could be 
close enough to form an intermolecular disulfide bond. This could explain the 
appearance of dimers under non-reducing conditions. The Ero 1 a./Ero 1 P heterodimers 
(Figure 4.9) add another level of complexity to the disulfide bond formation pathway, 
indicating that these heterodimers might play a role in the response to combined UPR 
and hypoxia. 
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In Erolp, the formation of an intra-molecular disulfide bond between C90 and C349 
was first suggested through mutagenesis studies (Frand & Kaiser, 2000). Bertoli and 
colleagues used a panel of Erola deletion and cysteine replacement mutants which 
showed that C85 and C391 (equivalent to C90 and C349 in Erolp respectively) are 
important for Erola function, probably by allowing efficient PDI oxidation (Bertoli et 
al., 2004). The prediction for a C90/C349 inter-molecular disulfide bond was 
confirmed with the published Erol p crystal structure (Gross et al., 2004). The weak 
covalent association of Eroli)C390A (equivalent to C349 in Erolp) mutant with PDI 
(Figure 4.6B), can also be explained using this long-distance intra-molecular disulfide 
bond, which when disrupted, probably causes structural changes which are needed for 
interactions with PDI. 
Having seen the Ero protein cofactor, FAD, playing an important role in stabilising a 
model of the homo/heterodimer, two mutations in Eroll) FAD binding domain were 
investigated and will be discussed in Chapter 5. 
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5.1 Introduction 
The CXXCXXC motif in Ero proteins is in contact with a non-covalently bound FAD 
molecule and in yeast Ero 1 p the FAD cofactor is held between helixes a2 and a3 in a 
bent conformation (Grosset al., 2004). Two mutants ofEro1p, ero1-1 and ero1-2 were 
identified through genetic screens as having a temperature-sensitive and DTT-
hypersensitive phenotype, respectively (Frand & Kaiser, 1998; Pollard et al., 1998). In 
the yeast ero1-1 strain under restrictive temperatures a subset of secretory proteins 
showed defects in maturation and were retained in the ER (Frand & Kaiser, 1998), 
whereas the ero1-2 strain showed extreme DTT sensitivity and had a modestly up 
regulated UPR even under non stress conditions (Pollard et al., 1998), thus implying a 
defect in oxidative protein folding due to both mutations. Each of the mutant strains 
had a single amino acid substitution; G229S (equivalent to G252S in Ero1P) was 
responsible for the ero1-1 phenotype and H231Y (equivalent to H254Y in Ero1P) 
resulted in the ero1-2 phenotype. Sequence alignment of FAD binding regions from 
Ero 1 p, Ero 1 a and Ero 1 p shows the conserved nature of glycine and histidine residues 
(Figure 5.1). 
Erolb H.s 
Erola H.s 
Erol S.c 
* 
FIGURE 5.1: Alignment of the FAD binding regions 
20 
* 
FAD binding regions from Human Ero 1 p (Ero 1 b _ H.s; Q86YB8), human Ero 1 a 
(Ero1a_H.s; Q96HE7) and yeast Ero1p (Ero1_S.c; Q03103) are aligned. Conserved 
residues are shaded in black. The conserved Glycine and Histidine residues mutated in 
the ero1-1 and ero1-2 yeast strain are shaded in green. 
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The flavin fold found in Era proteins is novel among other known FAD-binding protein 
and thiol-oxidoreductases (Fraaije & Mattevi, 2000), but is related to that of Erv2p, an 
alternative oxidoreductase in the yeast ER (Gross et al., 2002). Comparing the crystal 
structures of Erv2p (Grosset al., 2002) and the recently published Erolp (Grosset al., 
2004), shows that the catalytic cores of both these enzymes are formed by four anti-
parallel a-helixes which occur in a different order in the primary sequence, but do 
create the flavin-binding pocket. The G229 and H231 residues of Ero 1 p are both within 
the flavin fold, with H231 in contact with ribose 5'phosphate group of the FAD moiety 
(Grosset al., 2004). In Erolp, residues Rl87, T189, W200, S228, H231 and R260 form 
hydrogen bonds or salt bridges with the FAD cofactor and are conserved in Erola and 
Erolp. 
Molecular oxygen was found to be the preferred terminal electron acceptor for Erolp 
by monitoring the consumption of 0 2 during reoxidation of RNase A catalysed by 
purified Erolp (Tu & Weissman, 2002). At the structural level however, Erolp does 
not have a channel or a clear path for oxygen to gain access to the isoalloxazine ring of 
the FAD (Grosset al., 2004). This is in contrast to Erv2p which has a channel suitable 
in diameter for the passage of an oxygen molecule (Gross et al., 2002). The lack of a 
oxygen channel in Erolp suggests the presence of a possible gating mechanism to 
allow access to the active site (Lario et al., 2003). 
The erol mutants are thus likely to have alterations in their flavin fold due to changes 
in their structure and charge, which could lead to loss of function by preventing the 
normal transfer of electrons to occur. However, the biochemistry of the FAD binding 
site mutants has not been fully examined so far. Since yeast Erolp and human ErolP 
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both share conserved binding site residues (Figure 5.1), this chapter uses the knowledge 
from the charactetised Ero1~ protein from Chapters 3 and 4 to study the effects of the 
erol-1 and erol-2 mutations on ERO gene products. 
5.2 Results 
5.2.1 Construction of Erolp FAD mutants 
To investigate the behaviour of Erol~ FAD domain mutants, the wild-type 
pcDNAErol ~-Myc construct was used in site-directed mutagenesis to create a glycine 
to serine mutation at 252 (Ero1~G252S) and a histidine to tyrosine mutation at 254 
(Ero1~H254Y). The primers used have been detailed in Chapter 2, section 2.3.1. Two 
FAD domain mutants with an HA tag were constructed by cloning the appropriate 
mutation region from the Myc tagged counterpatt into pcDNAEro1~-HA vector. 
Vector and both Erol~G252S-Myc and Ero1~H254Y-Myc constructs were digested 
with Nhel and ligated as described in Chapter 2 section 2.3.1, to fotm Ero1~G252S­
HA and Ero1~H254Y-HA. Each construct was vetified by DNA sequencing. 
5.2.2 Biosynthesis of Erol f3G252S and Erol PH254Y mutants 
To investigate whether these FAD mutant proteins were glycosylated, wild-typeEro1 ~­
Myc (Figure 5.2A, lanes 2-3), Ero1~H254Y-Myc (Figure 5.2A, lanes 4-5) and 
Ero1~G252S-Myc constructs were 35S labelled during in vitro translation in the 
presence of semi-permeabilised (SP) cells (Figure 5.2A, lanes 2-7). Cell pellets were 
lysed in the presence of NEM, digested with endoglycosidase H (Endo H; Figure 5.2A, 
lanes 3, 5 and 7) and analysed under reducing SDS-PAGE. Endo H cleaves between 
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the two N-acetylglucosamine residues in high mannose N-glycan structures, thus a 
protein will be Endo H resistant if its' N-glycans are modified by the Golgi apparatus. 
The presence of only a non-glycosylated form of Ero1P (nG) after Endo H treatment, 
indicated that wild-type (Figure 5.2A, lanes 3) and mutant proteins (Figure 5.2A, lanes 
5 and 7) were Endo H sensitive and confirmed the proteins were glycosylated and 
resident in the ER. 
In Ero1a, mutations at the C-terminal CXXCXXC motif altered the half-life of the 
protein as well as causing folding defects and alteration to Ero-PDI complex formation 
(Benham et al., 2000). Thus it was formally possible that the reason for the temperature 
sensitivity and DTT hypersensitivity phenotypes was the rapid turnover of the protein 
causing disruption of Ero function. To investigate whether protein biosynthesis was 
affected, HeLa cells were transfected with ErolPH254Y-Myc (Figure 5.2B), 
Ero1PG252S-Myc (Figure 5.2C), wild-type Ero1p-Myc (Figure 5.2D), or mock 
transfected (Figure 5.2£) and used in a metabolic labelling experiment. Following a 40 
min starvation in cysteine and methionine-free medium, cells were pulse-labelled for 
10 min and chased up to one hour, prior to lysis in the presence of NEM. Lysates were 
subjected to immunoprecipitation with the Myc antibody and analysed by non-reducing 
(Figure 5.2B, C and D, lanes 1-4; E, lane 1) and reducing (Figure 5.2B, C and D, lanes 
6-9; E, lane 2) SDS-PAGE. Ero1PH254Y-Myc and Ero1PG252S-Myc monomer both 
resolved as a smear of bands under non-reducing conditions (OX, Figure 5.2B and C, 
lanes 1-4) which compact to a single band upon reduction with DTT (R, Figure 5.2B 
and C, lanes 6-9). No folding defect could be detected in the two FAD binding site 
mutants when compared to wild-type Erolp (Figure 5.2D) during the one-hour chase 
period. To detennine the half-life of wild-type Ero1P and the two FAD mutants, an 
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extended pulse-chase experiment was canied out with chase points up to 22 hrs (Figure 
5.2F). Quantitation revealed that wild-type Ero1~ is a relatively stable protein with a 
half life of 24-25 hrs (Figure 5.2 F, lanes 1-4). Ero1~H254Y (Figure 5.2 F, lanes 5-8) 
and Ero1~G252S (Figure 5.2 F, lanes 9-12) had somewhat shorter half-lives when 
compared to wild-type Ero1~, these being 16-19 hrs and 15-17 hrs respectively. These 
results indicate that although the FAD binding domain mutants have slightly reduced 
half-lives when compared to wild-type Ero1~, the mutant proteins do not rapidly 
degrade and the mutations do not affect Ero1~ behaviour as judged by reducing SDS-
PAGE. 
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FIGURE 5.2: Biosynthesis of ErolJ3H254Y and Ero1J3G252S proteins 
A. Wild-type (wt) Erol~-Myc (lanes 2-3), Erol~H254Y-Myc (lanes 4-5) and 
Ero1J3G252S-Myc (lanes 6-7) mRNA was translated at 30°C for 1 hr in the presence of 
-1 X 105 semi-permeabilised (SP) HeLa cells with 35S-cys/meth. The cell pellet was 
lysed in the presence of NEM and mock treated ( -EndoH, lanes 2, 4 and 6) or digested 
with Endo H (+EndoH, lanes 3, 5 and 7) for 1.5 hr at 37°C prior to reducing (R) SDS-
PAGE. HeLa cells transfected with wtEro1~-Myc, pulse-labelled with 35S-cys/meth for 
10 min, lysed in the presence of NEM and immunoprecipitated (IP) with aMyc were 
used as a positive control ( +ve, lane 1). G = glycosylated protein, nG = non-
glycosylated protein. As expected Ero1~ wt and both mutant proteins are glycosylated. 
HeLa cells were transfected with B. Ero1J3H254Y-Myc, C. Ero1~G252S-Myc, D. 
wtEro1J3-Myc or E. mock were pulse-labelled with 35S-cys/met for 10 min and chased 
for 15, 30 and 60 min (B-D) prior to lysis in the presence of NEM. Lysates were 
subjected to immunoprecipitation with aMyc and analysed by non-reducing (NR, B, C 
and D, lanes 1-4; E, lane 1) and reducing (R, B, C and D, lanes 6-9; E, lane 2) SDS-
PAGE. Ero1~ oxidised (OX) and reduced (R) monomer forms are indicated. F. Cells 
pulse-labelled with 35S-cys/met as in B-E and chased for 1, 3, 6 and 22 hr prior to 
immunoprecipitation with aMyc and analysed by reducing SDS-PAGE. 
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5.2.3 Erolpand the FAD mutants interacts with ERp72 
Wild-type Erol p (Figure 5.2D, 3.6, C and D) as well as all mutants investigated during 
this study (Figure 4.4, A and B; Figure 5.2, 8 and C) co-immunoprecipitated with an 
unknown protein around 70 kDa, that was not present in the mock transfectants (Figure 
5.2£). However, the ErolPC396A mutant interacted weakly with the putative 70 kDa 
protein (Figure 4.48, lanes 8-14), Erola transfectants also co-immunoprecipitated with 
a similar protein around 70 kDa (Figure 3.6C; (Benham et al., 2000)). Given that this 
interacting protein does not shift upon in vitro reduction and SDS-PAGE analysis 
(Figure 5.2B, compare lanes 1-4 with 6-9), it was unlikely to be a disulfide-rich 
substrate. Of the possible candidates, BiP and the PDI homologue ERp72 were 
investigated due to the band being around 70 kDa. 
HeLa cells were mock transfected (Figure 5.3A, lanes 4, 8, 12) or transfected with 
wild- type Erolp (Figure 5.3A, lanes 1, 5, 9), ErolPH254Y-Myc (Figure 5.3A, lanes 2, 
6, 10) and Ero1PG252S-Myc (Figure 5.3A, lanes 3, 7, 11), lysed in the presence of 
NEM and either directly analysed by reducing SDS-PAGE (Figure 5.3A, lanes 1-4) or 
subjected to immunoprecipitation with an aERp72 antibody (Figure 5.3A, lanes 5-12). 
Expression of ERp72 in the cell lysates was confirmed by probing the transfened 
proteins with aERp72 antibody (Figure 5.3A, lanes 1-4). lmmunoprecipitation with 
aERp72 retrieved ERp72 itself, as expected (Figure 5.3A, lanes 5-8) and co-
immunoprecipitated Erolp (Figure 5.3A, lanes 9-12). 
To investigate whether a similar interaction could be identified between ERp72 and 
Erola, HeLa cells were mock transfectecl (Figure 5.38, lane 3) or transfected with 
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wild-type Erola (Figure 5.3B, lane 1) or wild-type-Erol~ (Figure 5.3B, lane 2) and 
lysed in the presence of NEM. Lysates were analysed directly by reducing SDS-PAGE 
and transferred proteins probed with aERp72 (Figure 5.3B) which detected endogenous 
ERp72. The lysates were subjected to immunoprecipitation with aERp72 prior to 
reducing SDS-PAGE analysis, and after western blotting, the membranes were probed 
with aERp72 (Figure 5.3C) and aMyc (Figure 5.3D). Immunoprecipitation with 
aERp72 retrieved ERp72 itself as expected (Figure 5.3C) and co-immunoprecipitated 
Erola (Figure 5.3D, lane 1) and Erol~ (Figure 5.3D, lane 2). Thus under steady state 
conditions ERp72 interacts with both human EROs. 
The same cell Iysates as Figure 5.3A were analysed by reducing SDS-PAGE and 
blotted with aBiP to confirm expression of BiP (Figure 5.3£, lanes 1-4), prior to 
subjecting the Iysates to immunoprecipitation with aMyc and analysis by reducing 
SDS-PAGE. Probing the transferred proteins with aBiP showed no co-
immunoprecipitation of BiP with wild-type or mutant Erol~ proteins (Figure 5.3£, 
lanes 5-8). The aBiP antibody failed to immunoprecipitate (Figure 5.3£, lanes 9) and 
so was only used in western blotting. Expression of the transfected proteins was 
confirmed by analysis of the lysates by reducing SDS-PAGE and blotting with aMyc 
(Figure 5.3F, lanes 1-4). Thus under steady-state conditions no interaction could be 
detected between Erol~ and BiP. 
Although ERp72 was recognised as a novel interacting protein of Erol ~ at steady state, 
it is formally possible that this protein might not be identical to the 70 kDa band 
observed during pulse-chase analysis (Figure 5.2). 
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FIGURE 5.3: Eroll3 interacts with ERp72 but not with BiP 
A. Post nuclear lysates from HeLa cells transfected with wtErolp-Myc (lane 1, 5, 9), 
Ero1PH254Y-Myc (lane 2, 6, 10), Erolj3G252S-Myc (lane 3, 7, 11) and mock (lane 4, 
8, 12) were directly analysed (Before IP) by reducing SDS-P AGE and irnmunoblotted 
with aERp72 (R, lanes 1-4) or first subjected to irnmunoprecipitation (IP) with 
aERp72 prior to reducing SDS-PAGE and immunoblotted with aERp72 (lanes 5-8) or 
with aMyc (lanes 9-12). ERp72 and Eroll3 are indicated, ab =antibody. wtErolP and 
the two FAD domain mutants co-immunoprecipitate with aERp72. HeLa cells 
transfected with wild-type Erola-Myc (lane 1), wtErolp-Myc (lane 2) or mock (lane 
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3) were B. directly analysed by reducing SDS-PAGE and probed with aERp72, or C 
and D. subjected to immunoprecipitation with aERp72, and immunoblotted with 
aERp72 (C) and aMyc (D). ERp72 is indicated, ab = antibody. wtErola co-
immunoprecipitates with aERp72. E. Same lysates as in A, directly analysed (Before 
IP, lanes 1-4) or lysates subjected to immunoprecipitation with aMyc (IP, lanes 5-8) or 
with aBiP (lane 9) prior to reducing SDS-PAGE and immunoblotting with aBiP (lanes 
1-9). BiP is indicated with an arrow, ab =antibody. BiP is not co-immunoprecipitating 
with wild-type Erolp or with the two FAD domain mutants. F. Same lysates as A, 
directly analysed (Before IP) by reducing SDS-PAGE and immunoblotted with aMyc. 
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5.2.4 Limited proteolysis of Erol jJG252S and Erol PH254Y 
The FAD binding domain is partly buried within the Ero1P protein (Grosset al., 2004). 
The two FAD binding domain mutations could cause a conformational change that 
might lead to protein misfolding, giving the two phenotypes in yeast erol-1 and erol-2. 
To compare the overall conformation of the two Ero1p mutant proteins with wild-type 
Ero1p, limited proteolysis was carried out on cell transfectants. Partial trypsin digestion 
can occur at exposed lysine residues in native proteins and has been used effectively to 
map conformational changes in a number of ER proteins which include PDI (Freedman 
et al., 1998), CFTR (Zhang et al., 1998; Kleizen et al., 2005) and polyomavirus 
(Magnuson et al., 2005). Post-nuclear supernatants from HeLa cells transfected with 
wild-type Ero1p, Ero1PH254Y-Myc and Ero1PG252S-Myc or mock, lysed in the 
absence of protease inhibitor, were treated with a concentration range of TPCK-trypsin 
for 30 min on ice. Proteolytic reaction was quenched with soybean trypsin inhibitor and 
the lysates analysed by reducing SDS-PAGE prior to probing the western blotted 
membranes with either aMyc or aEro1p antibody. The Myc tag is positioned at the C-
terminus whereas the epitope recognised by the aErolP serum (residues Y329-L343) is 
located upstream of the CXXCXXC motif. Use of both these antibodies provided a tool 
for obtaining positional information about the fragments generated by trypsin digestion. 
In wild-type Ero1p, detection with both antibodies gave rise to a fragment around 55 
kDa with 1.25 ~tg/ml concentration of trypsin (fragment A, Figure 5.4A and B, lane 3), 
which must at least contain the C-terminus Myc tagged region and the CXXCXXC motif, 
and is therefore likely to have lost theN-terminus of the protein. However when Ero1 p 
was digested with 2.5 ~g/ml of trypsin, a fragment around 45 kDa was detected only 
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when probed with aErol p but not with aMyc (fragment B, Figure 5.4A, lane 4 
compare with Figure 5.4B, lane 4). This fragment B lacked the C-terminal Myc tag, but 
retained the CXXCXXC motif based on size and the presence of the Y329-L343 epitope. 
Given the sizes of the fragments generated, the results suggested that Erolp was 
selectively cleaved between the two redox active domains where a clustering of lysine 
residues can be found on an exposed loop. 
The digestion pattern of the Ero1PH254Y mutant (Figure 5.4A and 5.4B, lanes 5-8) and 
the Ero1PG252S mutant (Figure 5.4A and 5.4B, lanes 9-12) and their overall sensitivity 
to trypsin were comparable to wild-type Ero1J3, suggesting that the gross conformation 
of the two mutants is similar to wild-type protein. However, there were some 
differences between the substrates, such as the appearance of a shadow band under the 
full length protein in the mutant digestions when probed with aMyc (Figure 5.4B, lanes 
7, 811 and 12) and the lower abundance of fragment Bin ErolPG252S digestion when 
probed with aEro 1 p (Figure 5.4A, lanes 12). The H254Y mutation and in particular the 
G252S mutation may have subtle or localised effects on the Ero structure and folding. 
However, given the overall similarity of the digestion product sizes, the data suggest 
that gross conformational changes are unlikely to result from the point mutations at the 
FAD binding domain under normal steady state conditions. 
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FIGURE 5.4: Limited proteolysis ofErolf3H254Y and Erolf3G252S mutants 
Post nuclear supernatants from HeLa cells transfected with wtEro1f3-Myc (lane 1-4), 
Ero1f3H254Y-Myc (lane 5-8), Erolf3G252S-Myc (lane 9-12) and mock (lanes 13-14) 
were incubated with 0, 0.25, 1.25 and 2.5 J.!g/ml TPCK treated trypsin for 30 min at 4 
°C, analysed by reducing SDS-PAGE and immunoblotted with aEro1p (A) and aMyc 
(B). Generated fragments are labelled A and B. 
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5.2.5 Differences zn the covalent and non-covalent interactions of 
Erol f3G252S and Erol PH254Y with PDJ 
Having seen no major defect in protein biosynthesis, tum-over rate or gross 
conformational change in Ero1PH254Y -Myc and Ero1PG252S-Myc proteins compared 
to wild-type Erol p, the next step was to investigate whether these two mutations 
disrupted interactions with partner proteins. The ability to form Ero-PDI complexes 
was studied by analysing HeLa cells transfected with mock, Erolf3G252S-Myc or 
Erolf3H254Y -Myc and lysed in the presence of an alkylating agent. Post-nuclear 
supernatants were directly analysed by non-reducing (Figure 5.5A and B, lanes 1-2) and 
reducing (Figure 5.5A lanes 3-4, Figure 5.58 lanes 4-5) SDS-PAGE and transferred 
proteins probed with aMyc. Under non-reducing conditions, the monomer form of 
Erolf3G252S mutant ran as a collection of oxidised forms (OX, Figure 5.5A, lane 1), 
which disappear upon reduction with DTT giving a single reduced state (R, Figure 5.5A, 
lane 3). Erolf3G252S also formed a smear of disulfide dependent complexes(*, Figure 
5.5A, lane 1). 
Immunoprecipitation with aPDI serum specifically co-immunoprecipitated 
ErolJ3G252S under reducing conditions (Figure 5.5A, lane 8) but could not detect any 
disulfide-dependent Ero-PDI complexes (other than the antibody bands also seen in 
mock transfectant, Figure 5.5A, lanes 4 and 7). Similar to Erol J3G252S, the 
ErolPH254Y mutant also ran as an oxidised population of monomers (OX, Figure 5.58, 
lane 1) but the trapped, higher molecular weight complexes were more abundant and 
less diffuse (compare Figure 5.58, lane 1 with Figure 5.5A, lane 1). The Ero1PH254Y 
mutant specifically co-immunoprecipitated PDI (Figure 5.58, lanes 9 and 10), but 
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unlike Erolj3G252S, Erolj3H254Y became trapped in a disulfide-dependent complex 
with PDI under non-reducing conditions (compare Figure 5.5B, lanes 6 and 7 with 
Figure 5.5A, lanes 6 and 7). Note the background band also present in mock 
transfectant (Figure 5.5A, lanes 2 and 4; Figure 5.5B, lanes 2 and 5) which was 
discussed in section 3.2.2. 
The ability of Erolj3G252S-Myc and Erolj3H254Y-Myc mutants to interact with PDI 
was then directly compared alongside Erolj3C390A-Myc (the C-terminal active site 
mutant which has altered PDI binding properties) and with wild-type Eroll3. HeLa cells 
transfected with these constructs were lysed in the presence of NEM and cell lysates 
either directly analysed by non-reducing SDS-PAGE (Figure 5.5C, lanes 1 -4) or first 
subjected to immunoprecipitation with aPDI prior to reducing (Figure 5.5C, lanes 5-8) 
and non-reducing (Figure 5.5C, lanes 10-1 3) SDS-PAGE. Detection of transfeJTed 
proteins with aMyc showed that prior to immunoprecipitation all Eroll3 proteins 
resolved as a collection of monomeric and disulfide-dependent forms (Figure 5.5C, 
lanes 1-4). Erolj3G252S, Erolj3H254Y, Erolj3C390A and wild-type Eroll3 all co-
immunoprecipitated with aPDI (Figure 5.5C, lanes 5-8), however, only Erolj3H254Y 
(Figure 5.5C, lane 11) and wild-type Eroll3 (Figure 5.5C, lane 13) formed prominent, 
discrete disulfide-dependent complexes with PDI. These results indicate that both 
Erolj3G252S and Erolj3H254Y mutants can interact non-covalently with PDI, but that 
in the Erolj3G252S mutant, inter-molecular disulfide-bonded (covalent) interactions 
with POI are compromised. 
153 
Chapter 5: Behaviour of Ero 1 f3 FAD mutants 
FIGURE 5.5: ErolJ3H254Y and ErolJ3G252S interaction with PDI 
Lysates from HeLa cells transfected with ErolJ3G252S-Myc (A) and Ero1J3H254Y-
Myc (B) analysed directly by immunoblotting with aMyc after non-reducing or 
reducing SDS-PAGE (lanes 1-4) or after immunoprecipitation with aPDI (lanes 6-
9/10). C. Lysates from HeLa cells transfected with wtErolJ3-Myc (lanes 4, 8, 13), 
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Erol~G252S-Myc (lanes 1, 5, 10), Erolf3H254Y-Myc (lanes 2, 6, 11), and 
Erol~C390A-Myc (lanes 3, 7, 12) were immunoblotted with aMyc before (lanes 1-4) 
or after (lanes 5-13) immunoprecipitation with aPDI. Lane 5 from (A), lanes 3 and 8 
from (B) and lane 9 from (C) are loaded with sample buffer only. ab = cross-reactive 
antibody. Disulfide dependent complexes are shown as *. Oxidised (OX) and reduced 
(R) Erolf3 monomer forms as well as co-immunoprecipitated Erolf3 (Erol~) are 
indicated. 
155 
Chapter 5: Behaviour ofEro1 f3 FAD mutants 
5.2.6 Both Erolf3G252S and Ero1PH254Y can dimerise 
Wild-type Eroll3 is able to homodimerise (section 3.2.3). The Eroll3 C-terminal mutant 
Erolj3C396A is unable to self-complex and is also non-functional (section 4.2.6, 
(Cabibbo et al., 2000). Having seen the potential importance of the FAD co-factor in a 
model of dimer formation (Figure 4.10), it was possible that FAD was required for Ero-
Ero associations. The two FAD domain mutants ability to complex with wild-type 
Eroll3 was investigated by transfecting HeLa cells with Erolj3G252S-Myc, wild-type 
Erolj3-HA,. Erolj3G252S-Myc plus wild-type Erolj3-HA. Post nuclear lysates were 
analysed by reducing and non-reducing SDS-P AGE and transferred proteins probed 
with aMyc and aHA antibodies. Lysates analysed under reducing conditions allowed 
the detection of the transfected proteins (Figure 5.6A). Under non-reducing conditions 
any mixed disulfide-dependent dimers should appear as an intermediate band in the 
double transfected Iysates (similar to wild-type Erolj3-Myc - Eroli3-HA dimer, Figure 
3.9A). An intermediate band (*) was present only in the double transfected lysate 
(Figure 5.6B, lane 3) representing a wild-type Eroll3- Erolj3G252S dimer. 
Lysates from these transfectants were subjected to immunoprecipitation with aHA 
prior to analysis by reducing SDS-PAGE (Figure 5.6C). Blots probed with aMyc did 
not detect an Eroll3 signal from the single transfectants or mock Iysates (Figure 5.6C, 
lanes 1, 2, 4). Erolj3G252S-Myc clearly co-immunoprecipitated with wild-type Erolj3-
HA (Figure 5.6C, lane 3). Similar results were obtained with the Erolj3H254Y-Myc 
mutant: single and double transfected Iysates all expressed the differently tagged Ero 113 
proteins as expected (Figure 5.6D, lanes 1-4) and the Erolj3H254Y-Myc mutant gave 
an intermediate band m the double transfectant under non-reducing SDS-PAGE (*, 
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Figure 5.6£, lane 3) and co-immunoprecipitated with wild-type Erol~ (Figure 5.6F, 
lane 3). Thus both FAD domain mutants were able to form disulfide-dependent dimers 
with wild-type Erol~. 
Since both FAD domain mutants were able to interact with wild-type Erol ~'the ability 
of the mutants to homodimerise was investigated. This was of interest because 
Erol~C396A is able to interact with wild-type Erol~ but was not able homodimise, as 
discussed in section 4.2.6. HeLa cells were mock transfected or transfected with 
Erol~H254Y-HA, Erol~G252S-HA or double transfected with Erol~H254Y-HA plus 
Erol~H254Y-Myc and Erol~G252S-HA plus Erol~G252S-Myc. The lysates were 
analysed by reducing SDS-PAGE to verify transfection and subjected to 
immunoprecipitation with aMyc prior to immunoblotting with aErol~ antibody. The 
single and double transfectants expressed the expected proteins (Figure 5.6G, lanes 1-
4) while no signal was observed from the mock transfectants (Figure 5.6G, lane 5). In 
both single transfectants as well as mock, no Erol~ signal was detected after 
immunoprecipitation with aMyc (Figure 5.6G, lane 7, 8, 11). However, Erol~H254Y­
HA tagged mutant co-immunoprecipitated with the Erol~H254Y-Myc (Figure 5.6G, 
lane 9) and likewise Erol~G252S-HA co-immunoprecipitated with Erol~G252S-Myc 
(Figure 5.6G, lane 10). These data clearly indicate that both mutations at the FAD 
binding domain do not prevent interactions (heterodimerisation) with wild-type Erol ~ 
or with themselves (homodimerisation) in the ER. 
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FIGURE 5.6: Dimerisation ofErol~ H254Y and Erol~G252S 
A - C. HeLa cells transfected with Ero 1 PG252S-Myc (lane 1), wtEro 1 P-HA (lanes 2), 
Ero1~G252S-Myc plus wtEro1P-HA (lanes 3) and mock (lanes 4) were analysed 
following reducing (A) and non-reducing (B) SDS-PAGE by immunoblotting with 
aMyc and aHA or first subjecting the lysates to immunoprecipitation with aHA (C) 
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prior to immunoblotting with aMyc. D ~F. HeLa cells transfected with Erolf3H254Y-
Myc (lanes 1), wtEroli3-HA (lanes 2), Erolf3H254Y-Myc plus wtEroli3-HA (lanes 3) 
and mock (lane 4) were analysed as for A-C. * indicates the mutant-Myc + wt-HA 
dimer. G. HeLa cells transfected with Erolf3H254Y-HA (lanes 1, 7) Erolf3G252S-HA 
(lanes 2, 8) Erolf3H254Y-HA plus Erolf3H254Y-Myc (lanes 3, 9) Erolf3G252S-HA 
plus Erolf3G252S-Myc (lanes 4, 10) and mock (lanes 5, 11) were analysed directly by 
reducing SDS-PAGE (Before IP) or first subjected to immunoprecipitation with aMyc 
and immunoblotted with aErol3. ab =cross-reactive antibody. 
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5.2.7 Aberrant oxidation of Erolf3G252S and Ero1PH254Y during a 
reducing stress 
The yeast counterparts of Ero1BG252S and Ero1BH254Y are hypersensitive to 
temperature and reductants (Frand & Kaiser, 1998; Pollard et a!., 1998). The effects of 
the reductant DTT on mammalian cells transfected with wild-type Ero1B was studied in 
Chapter 3, section 3.2.6, which showed that a reducing environment is capable of 
abolishing most of wild-type Ero1 B disulfide-linked interactions including homodimers 
under steady state conditions. 
The two FAD binding domain mutants, Ero1BH254Y and Ero1BG252S, were subjected 
to similar in vivo DTT treatments. Treated and untreated HeLa cell lysates from 
EroLBH254Y-Myc, Ero1BG252S-Myc and wild-type Ero1B-Myc were analysed by 
non-reducing (Figure 5.7A) and reducing (Figure 5.78) SDS-PAGE, ptior to 
immunoblotting with aMyc. Wild-type Ero1B lost the majority of its disulfide-
dependent complexes due to DTT treatment similar to Figure 3.12C (Figure 5.7A, lanes 
1 and 2; * and**). The two ErolB mutants behaved differently from wild-type Ero1B. 
Erol BH254Y retained most of its complexes in the face of a DTT challenge (Figure 
5.7A, lanes 3 and 4; *), whereas ErolBG252S not only retained its complexes (Figure 
5.7A, lanes 5 and 6; *) but also formed higher molecular weight complexes and 
aggregates(**). As an internal control, the Ero1B monomer states were mostly reduced 
after DTT treatment (R, Figure 5.7A, lanes 1, 3, 5). In vitro reduction with DTT caused 
all ErolB proteins to collapse to a single reduced monomer form (R, Figure 5.78, lanes 
/-6). Data from these experiments suggest mutations at 0252 and H254 cause the 
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Erolp protein to undergo abnormal oxidation in the face of fairly harsh reducing 
environments. 
To investigate whether misoxidation caused by the two FAD binding domain mutants 
was reversible, HeLa cells transfected with the most severe mutant, Ero1PG252S-Myc, 
were treated with 10 mM DTT for 15 min and allowed to recover for 30 min after 
washing off DTT in the medium and replacing with normal medium. Post-nuclear 
supernatants were analysed under non-reducing conditions and transferred proteins 
probed with a aMyc (polyclonal) antibody (Figure 5.7C). Misoxidation observed after 
DTT treatment (Figure 5.7C, lane 2, **), could be recovered upon removal of DTT 
(Figure 5.7C, lane 3). 
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A and B. HeLa cells transfected with wtEro1~-Myc (lanes 1-2), Ero1~H254Y-Myc 
(lanes 3-4), Ero1~G252S-Myc (lanes 5-6), and mock (lanes 7-8) were treated with 10 
mM DTI for 15 min and post nuclear lysates were analysed under non-reducing (A) 
and reducing (B) SDS-PAGE prior to immunoblotting with a.Myc. Disulfide dependent 
Ero-PDI and Ero-Ero complexes are denoted as *, with higher molecular weight 
complexes and aggregates as * *. Oxidation states of Ero 1 ~ monomer are shown as OX 
(oxidized) and R (reduced). C. HeLa cells transfected with Erol~G252S-Myc (lanes 1-
3) and mock (lanes 4-6) were treated with DTI as for A (lanes 2-3 and 5-6) and 
allowed to recover by washing out DTT for 30 min (lanes 3 and 6). Post-nuclear lysates 
were analyzed by immunoblotting with a polyclonal Myc antibody after non-reducing 
SDS-PAGE. Misoxidation of Ero1~G252S protein can be reversed by the removal of 
DTT. 
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Ero1~H254Y and Ero1PG252S mutant proteins were also introduced to a number of 
different cellular stress conditions to study their behaviour. HeLa cells transfected with 
the above two Myc tagged mutants and wild-type Ero1P-Myc, were subjected to 
overnight buthionine sulphoximine (BSO) treatment or 10 min of hydrogen peroxide 
(H20 2) treatment. BSO depletes the intracellular pool of glutathione (GSH) by 
inhibiting the initial enzyme in GSH synthesis (y-glutamylcysteine synthase, (Griffith 
& Meister, 1979)), thus altering the redox state within the ER. H20 2 is an oxidative 
stress inducer which producers free oxygen radicals. Under non-reducing conditions 
both 25 1-1M BSO and 1.5 M H202 treatments did not cause oxidative misfolding of 
either mutant or of wild-type Ero1P at steady state (Figure 5.8A, compare lanes 9-11 
with lanes 1-3 and lanes 5-7). In vitro reduction of the proteins and analysis by SDS-
p AGE showed no alteration to the level of Ero 1 ~ protein present after each treatment 
when compared to mock treatment (Figure 5.88). The membrane-permeable oxidant, 
diamide, which can drive the formation of disulfide bonds in living cells (Kosower & 
Kosower, 1995), was also tested on BeLa transfectants with wild-type Ero1p-Myc, 
Ero1~H254Y-Myc and Ero1PG252S-Myc (Figure 5.8C). Diamide treatment increased 
the proportion of oxidised monomers in each case and caused some oxidative 
misfolding of wild-type Ero1~ as well as both mutant proteins (Figure 5.8C, lanes 1, 3 
and 5, **). Both mutants showed more aggregates in the stacking gel when compared 
to wild-type Ero1P (***). 
Taken together these results demonstrate that both mutations in the FAD binding site 
cause Ero1 p protein to misoxidise when reducing conditions are encountered but does 
not alter Ero1 p protein behaviour in the presence of the other stress conditions that 
were tested so far. 
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FIGURE 5.8: Glutathione depletion and hydrogen peroxide treatment does not 
cause oxidative misfolding of ErolJ3G252S and ErolJ3H254Y mutants 
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FIGURE 5.8: Glutathione depletion and hydrogen peroxide treatment does not 
cause oxidative misfolding of Erolj3G252S and Erolj3H254Y mutants 
A and B. HeLa cells transfected with wtErolj3-Myc (lanes 1, 5, 9), Ero1j3H254Y-Myc 
(lanes 2, 6, 10), Ero1j3G252S-Myc (lanes 3, 7, 11) and mock (lanes 4, 8, 12) were 
either mock treated (lanes 9-12), treated with 25 f.lM butathione sulfoxamine (BSO) for 
18 hrs (lanes 1-4) or 1.5 M hydrogen peroxide (H202) for 10 min (lanes 5-8). Post-
nuclear lysates were analysed on non-reducing (A) and reducing (B) SDS-PAGE prior 
to immunoblotting with aMyc. Disulfide dependent Ero-PDI and Ero-Ero complexes 
are denoted as *. C. HeLa cells expressing wtErolj3-Myc (lanes 1-2), Erolj3H254Y-
Myc (lanes 3-4), Erolj3G252S-Myc (lanes 5-6), and mock (lanes 7-8) were treated 
with 5 mM diamide for 5 min prior to analysis of post nuclear lysate on non-reducing 
SDS-PAGE and immunoblotting with aMyc. Oxidative misfolding is indicated as **, 
and aggregates in the stacking gel indicated as***. Oxidation states ofEro1j3 monomer 
are shown as OX (oxidized) and R (reduced). 
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5.2.8 Temperature dependent misfolding of Erol PH254Y and Erol fJG252S 
Having seen that DTI is able to cause misoxidation of Erol~ protein with G252S and 
H254Y mutations, these two mutant proteins were tested against a range of 
temperatures to study any behavioural changes. Thus transfected HeLa cells were 
incubated at 24°C, 37°C and 42°C for 1 hr prior to lysis and post-nuclear supernatants 
analysed by non-reducing and reducing SDS-PAGE. Wild-type Erol~ was stable 
across the temperature range and maintained their disulfide-bonded complexes, 
including Ero-PDI and Ero-Ero interactions (Figure 5.9A, lanes 1-3, *).However, both 
Erol~H254Y and Erol~G252S lost most of its disulfide-linked interactions at 24°C 
(Figure 5.9A, lanes 4 and 7, *) and misoxidised at 42°C, with mutant complexes being 
retained in the stacking gel (Figure 5.9A, lanes 6 and 9, **). The temperature 
treatments did not influence the monomer states of either the wild-type or mutant 
Erol~. All Erol~ molecules could be reduced to a single band upon in vitro DTT 
treatment prior to SDS-PAGE analysis, showing that all complexes detected on the 
non-reducing gel were disulfide-dependent (Figure 5.98, lanes 1-9). 
To investigate whether Erol~ mutant interactions were temperature-dependent, the 
same lysates as in Figure 5.9A were analysed by non-reducing (Figure 5.9C) and 
reducing (Figure 5.9D) SDS-PAGE and tested for PDI interactions by western blotting 
with aPDI. Regardless of temperature and transfected Erol ~ protein, under non-
reducing conditions PDI expression remained unchanged and was mostly present in the 
monomer form with a faint smear of bands in the upper pm1 of the gel (Figure 5.9C) 
representing vmious disulfide-bonded partner proteins (compare Figure 5.9C with 
Figure 5.9D). To assess whether Ero-PDI interactions were affected in mutant proteins 
and wild-type Erol~ after temperature treatment, the same lysates were subjected to 
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immunoprecipitation with aPDI serum prior to reducing SDS-PAGE analysis. Probing 
the transferred proteins with aM yc showed no major differences between the Ero 1 ~ 
mutant proteins (Figure 5.9£, lanes 4-6 and 7-9) or wild-type (Figure 5.9£, lanes 1-3) 
after the different temperature incubations, although wild-type Erol~ interacted more 
strongly with PDI than did the mutant proteins (Figure 5.9£, compare lanes 1-3 with 
lanes 4-9). However, in some expe1iments, prolonged exposure to high temperatures 
resulted in an increase of co-immunoprecipitated Erol~ with PDI for both mutants and 
for wild-type (data not shown). 
Data from the above experiments demonstrate that Ero 1 ~ and PDI are stable at steady-
state between 24°C and 42°C. Both mutations at the FAD binding domain cause Ero1~ 
protein to misoxidise and disrupt disulfide-dependent interactions when subjected to a 
temperature stress. 
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FIGURE 5.9: Misfolding of Eroll3 H254Y and Erolj3G252S after temperature 
stress 
A- D. HeLa cells transfected with wtEro1j3-Myc (lanes 1-3), Erolj3H254Y-Myc (lanes 
4-6), Erolj3G252S-Myc (lanes 7-9), and mock (lanes 10-12) were incubated at 24°C, 
37°C and 42°C for 1 hr. Post nuclear lysates were analysed on non-reducing (A and C) 
and reducing (B and D) SDS-P AGE prior to immunoblotting with (A) aMyc, (B) 
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aErop and (C and D) aPDI. E. As for (A-D), except lysates were first subjected to 
immunoprecipitation with aPDI p1ior to reducing SDS-PAGE and immunoblotting 
with aMyc. Disulfide dependent Ero-PDI and Ero-Ero complexes are denoted as * with 
higher molecular weight and aggregates as**. Oxidation states of Erolp monomer are 
shown as OX (oxidized) and R (reduced). 
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5.3 Discussion 
This chapter focuses on the behaviour of two FAD binding domain mutants of Erol~ 
which were first discovered in Saccaromyces cerevisiae. It was recently suggested that 
the glycine to serine substitution at 229 in the yeast ero1-1 strain might cause a folding 
or co-factor binding defect which could account for its phenotype (Gross et al., 2006). 
However, both G252S and H254Y mutant proteins showed no folding defects, any 
major difference in half-life (Figure 5.2) or substantial difference in trypsin sensitivity 
(Figure 5.4) when compared with wild-type Erol~, demonstrating that the human 
versiOns of the FAD fold mutants do not have a protein biosynthesis problem or 
undergo gross conformational changes. The two FAD domain mutant proteins do 
however have an inducible misoxidation defect when subjected to reducing conditions 
or temperature changes. Both G252S and H254Y show misoxidation when introduced 
to a DTT environment, with G252S mutant being more severe. This defect was 
reversible with the removal of the reductant (Figure 5.7), presumably allowing normal 
oxidation conditions to prevail. Indeed, when both mutants encountered a more 
oxidising environment (treatment with diamide) their monomer forms showed the 
ability to increase the ratio of oxidised monomers (Figure 5.8). These findings may 
explain why oxidising agents such as diamide can restore viability to the ero1-1 yeast 
strain (Frand & Kaiser, 1998). Upon DTT treatment, the mutant Ero proteins seemed 
incapable of becoming properly oxidised thus revealing free -SH groups which form 
incorrect intermolecular disulfide bridges. Introducing cells to H20 2 and the glutathione 
synthesis inhibitor BSO, did not markedly affect wild-type or mutant Erol ~redox state 
or complex formation (Figure 5.8). Recent studies using BSO on tPA (tissue-type 
plasminogen activator)-expressing CHO cells showed that lowering the level of 
glutathione increased the rate of non-native disulfide bond f01mation of tPA molecules 
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but did not affect the redox state of PDI (Chakravarthi & Bulleid, 2004). In light of 
these studies BSO not having an effect on Erolp redox state is not surprising. 
Misoxidation of the two Erolp FAD mutants mainly affected the ability of Ero proteins 
to engage in disulfide dependent interactions (Figure 5.7 ancl5.9). PDI was still able to 
form non-covalent interactions with Erolp mutant proteins even after temperature 
stress, but whether this association is clue to PDI clocking onto Ero protein prior to 
misoxidation, or whether PDI was operating as a chaperone trying to refold Erolp is a 
question that needs further investigation. Recently it was shown that a PDI mutant 
lacking its four active site cysteines (PDI-ASAS) was still able to interact with Erola 
non-covalently, which suggests PDI is able to chaperone Ero proteins (Otsu et al., 
2006). 
ERp72 was identified as a novel interacting pmtner of Erolp and Erola (Figure 5.3) 
and could also act as an alternative electron donor for hEROs. Previous studies using 
pulse-labelled cell lysates and aMyc immunoprecipitations had failed to detect an 
interaction between ERp72 and hERO proteins (Mezghrani et al., 2001). However, 
experimental conditions used in this study (at steady state using aErp72 
immunoprecipitaion) were different from the published literature, thus it is possible that 
these interactions arc preserved/detected under specific conditions. Fmther work is 
required to identify functional differences between Ero-PDI and Ero-ERp72 
interactions. immunodepletion (as in Figure 3.8) could be used to monitor the effects of 
ERp72 and Ero-ERp72 interactions. In vivo, it will be interesting to find out if reducing 
the levels of PDI through RNAi wmild effect levels of ERp72 and would compromise 
or compensate Erol mediated oxidative folding. Although ERp72 could be the 70 kDa 
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interacting protein detected under pulse-chase conditions, mass spectrometric analysis 
of this band is needed to verify the identity of this protein. An interaction between 
Erolp and BiP could not be readily detected under the steady-state conditions used in 
this study. 
Chapters 3-4 and recent studies by Seiver and Kaiser (Sevier & Kaiser, 2006b) have 
shown that Ero-Ero dimers contribute to Ero function. It was possible that mutations at 
the FAD binding domain could also prevent dimerisation leading to loss of function in 
the erol-1, erol-2 mutants. However, data from this chapter shows that Ero-Ero 
associations do not depend entirely on the FAD binding domain (Figure 5.6) and so 
inability to self-complex is not likely to explain the yeast mutant phenotypes. It still 
remains possible that intermolecular disulfide bond formation is altered in these two 
mutants, but this would require structural and mass spectrometry studies to be carried 
out on the G252S and H254 Y mutants. 
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6.1 Introduction 
Expression of Ero1a and Ero1~ differ at the transc1iptional level in human tissues, with 
an up regulation of Ero1a in the oesophagus and Ero1~ in the stomach, pancreas, testis, 
liver, appendix, thyroid and pituitary glands (Pagani et al., 2000). Chapter 3 section 
3.2.1 discussed the specific detection of Ero1~ in mammalian stomach and pancreas 
tissues. 
6.1.1 Histology of the pancreas 
The human pancreas is made up of two types of tissues; exocrine and endocrine tissue. 
Exocrine tissue consists of acini which synthesise and secrete several digestive 
enzymes transported via a duct system to the duodenum. The endocrine tissue consists 
of the islets of Langerhans which secrete hormones into the bloodstream. The islets 
house four major cell types, glucagon producing alpha-cells, insulin producing beta-
cells, somatostatin producing delta-cells and pancreatic polypeptide producing F cells 
(Kierszenbaum, 2002; Stevens & Lowe, 1993). Insulin-secreting beta cells occupy the 
central area of the islets and are the most common cell type. Insulin is a 6 kDa 
polypeptide derived from proinsulin which consists of a disulfide linked A and B chain 
connected with a C peptide (Brange & Langkjoer, 1993). Mature insulin is produced in 
secretory vesicles by the cleavage of peptide C. Hyperglycemia is a result of increased 
blood glucose levels for prolonged periods of time leading to diabetes (Kierszenbaum, 
2002). Type I diabetes or insulin-dependent diabetes mellitus (IDDM), is a lack of 
insulin caused by autoimmune, toxic or viral damage to beta cells. Although 90% of the 
cases begin in- childhood (juvenile diabetes), it can occur at any time of life. Type II 
diabetes or non-insulin-dependent diabetes mellitus (NIDDM) is caused by insufficient 
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insulin secretion relative to glucose levels and by resistance of peripheral target tissue 
to insulin. This type of diabetes is more common and observed in adults, and within 
first-degree relatives the risk of developing type II diabetes is -20-40% compared with 
-5-7% in the population at large (Kierszenbaum, 2002; Kumar et al., 1997). 
6.1.2 Histology of the upper Gl tract 
The oesophagus is a muscular tube which transports undigested but fragmented food to 
the stomach for digestion. The oesophageal mucosa is composed of non-keratinised 
stratified squamous epithelium and an underlying lamina propria and muscularis 
mucosa. Cells at the basal membrane have rounded nuclei and are pyramidal or 
polygonal in shape. The more mature epithelial cells not in direct contact with the 
basement membrane take a more flattened squamous morphology with elliptical nuclei. 
Mucosal and submucosal glands are found in the oesophagus which continuously 
produce a thin layer of mucus to lubricate the surface of the epithelium (Kierszenbaum, 
2002). 
The squamous epithelium of the oesophagus is protected from the exposure of gastric 
acid especially at the gastroesophageal junction (OG junction) by the anatomical 
arrangement of the OG junction as well as by the small oesophagogastric muscular 
sphincter, which in most cases prevents the reflux of gastric contents in to the lower 
oesophagus (Stevens & Lowe, 1993). However this system can fail, allowing the reflux 
of gastric acid and digestive enzymes from the stomach into the oesophagus which 
gives rise to Barrett's oesophagus. Barrett's oesophagus is considered a premalignant 
.. .·- . -
condition and is identified by the replacement of the normal distal stratified squamous 
mucosa by columnar type epithelium, which is gastric, intestinal or mixed in 
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composition (Kumar et al., 1997). Prolonged and recurrent gastroesophageal reflux can 
lead to inflammation leading from specialised metaplasia to dysplasia and onto 
adenocarcinoma. Dysplastic cells show considerable variation in size and shape, and 
often posses abnormally large nuclei for the size of the cell. Cancerous cells also have 
extremely hyperchromatic large nuclei with the nuclear-cytoplasm ratio reaching 1:1 
instead of 1:4 or 1:6 in normal cells. Barrett's oesophagus is one of the recognised 
precursors of oesophageal adenocarcinoma (Kumar et al., 1997). 
In healthy tissue, at the gastroesophageal junction the stratified squamous epithelium 
changes to a simple columnar type which marks the beginning of the stomach tissue. 
The surface area of the stomach is increased by the formation of glands which secrete 
acid and digestive enzymes. The two major cell types found in these gastric glands are 
pmietal or oxyntic cells and chief or peptic cells. Parietal cells are large pyramidal cells 
with a central nuclei and pale eosinophilic cytoplasm which secrete hydrochloric acid 
and intrinsic factor. Chief cells on the other hand have large basal nuclei and secrete the 
inactive enzyme precursor, pepsinogen into the gastric lumen where it is converted to 
the proteolytic enzyme pepsin by gastric acid. Other cell types found within these 
glands are mucous cells (surface and neck mucous cells), stem cells and 
enteroendocrine cells (Kierszenbaum, 2002; Stevens & Lowe, 1993). 
Studies have not been published on Ero1P or Ero1a protein expression in the digestive 
system. This chapter uses healthy human stomach and pancreas tissue as well as 
healthy oesophagus, Barrett's oesophagus, oesophageal tumour, OG junction tumour 
and gastric tumour tissue to investigate, using immunohistochemistry, the protein 
expression patterns of hEROs and several chaperone proteins found in the ER. 
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6.2 Results 
6.2.1 Expression of hEROs and chaperone proteins in healthy human 
pancreas 
6.2.1.1 Optimisation of antigen retrieval techniques 
Human pancreatic tissue sections were treated as described in section 2.2.1 prior to 
catTymg out a series of digestion techniques. Digestion techniques and antibody 
dilutions for some of the primary antibodies (aPDI, aBiP, D5) used in this study had 
been previously optimised by an undergraduate project student, but for the rest of the 
primary antibodies (H-86, aERp72, aERp57, aEroJ3, aERp44) different digestion 
techniques and dilutions were performed (all of the antibody dilution data are not 
shown). 
When primary antibody was omitted during pancreas section staining (TBS, Figure 6.1 
left panels), microwave digestion in high pH citrate buffer gave a very faint non-
specific staining (Figure 6.1A) but gave negative staining after microwave digestion in 
citrate buffer (Figure 6.1 C), trypsin digestion (Figure 6.1£) and pressure cooker 
digestion in citrate buffer (Figure 6.1G). Sections exposed to pre-immune rabbit sera 
(PS, Figure 6.1 right panels) instead of primary antibody gave a faint non-specific 
staining after microwave high pH citrate digestion (Figure 6.1B), negative staining after 
microwave digestion in citrate buffer (Figure 6.1D), and trypsinisation (Figure 6.1F) 
and a very faint staining after pressure cooker digestion (Figure 6.1H). Overall the pre-
immune serum gave a faint non-specific staining after all four digestion techniques. 
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FIGURE 6.1: Optimisation of digestion techniques for human pancreatic tissue 
Paraffin embedded human pancreas sections were cleared through xylene, taken 
through a 100 - 70% alcohol senes and endogenous peroxidase activity blocked in 
H20 2 prior to performing four different antigen retrieval techniques; microwave with 
high pH citrate buffer (A and B), nucrowave with citrate buffer (C and D), 
trypsinisation (E and F) and pressure cooker with citrate buffer (G and H). Primary 
antibody was omitted (TBS; A, C, E and G) or sections exposed to pre-immune serum 
(PS; B, D, F and H) prior to detection with DAB; bar= 200 J.lm. Overall TBS and PS 
all showed non-specific staining with all four digestion techniques. 
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The insulin antibody, H-86, was used as a pancreatic islet marker with the same four 
digestion techniques as in Figure 6.1. This antibody specifically stained the pancreatic 
islets (arrows), but with different specificities after each of the antigen retrieval 
techniques (Figure 6.2). Microwave with citrate buffer was the least specific antigen 
retrieval step for the H-86 antibody which showed very faint staining of the islets 
(Figure 6.2, A and B). Trypsinisation allowed more access for the H-86 antibody and 
thus resulted in recognition of islets more effectively (Figure 6.2, C and D). However, 
microwave with high pH citrate buffer (Figure 6.2, E and F) and pressure cooker with 
citrate buffer (Figure 6.2, G and H) proved to be the most effective digestion 
techniques for H-86, showing strong staining of the islets. Pressure cooker with citrate 
buffer (Figure 6.2, G and H) however, did show the highest level of specificity, with 
almost exclusive staining of the islets when compared with the sunounding acinar cells, 
and so was chosen as the optimal digestion technique for H-86 antibody. Results from 
figures 6.1 and 6.2 are summarised in table 6.1. 
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FIGURE 6.2: Optimisation of antigen retrieval technique for insulin antibody 
Paraffin embedded human pancreas sections were cleared through xylene, taken 
through a 100 - 70% alcohol series and endogenous peroxidase activity blocked in 
H20 2 prior to performing four different antigen retrieval techniques; microwave with 
citrate buffer (A and B), trypsinisation (C and D), microwave with high pH citrate 
buffer (E and F) and pressure cooker with citrate buffer (G and H). All sections were 
probed with the H-86 (insulin) primary antibody prior to detection with DAB and 
photographed at 5X (A, C, E and G) and 20X (B, D, F and H) magnification. Bar = 
200 ~m, arrow = islets. The best digestion technique was pressure cooker with citrate 
buffer (G and H). 
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Table 6.1: Summary of results from optimisation of digestion techniques for wax 
embedded human pancreas sections 
Antigen retrieval technique 
Microwave Trypsinisation Microwave Pressure 
Antibody with citrate with high pH cooker with 
buffer buffer citrate buffer 
TBS Negative Negative Very weak non-
specific staining 
Negative 
Pre-immune Weak, non-
Weak, non-
serum (PS) Negative Negative specific 
specific staining 
staining 
Very weak Strong but less 
Strong and 
H-86 Weak staining specific 
staining of the 
of the islets 
specific staining 
staining of the 
islets of the islets 
islets 
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6.2.1.2 Expression of hEROs and chaperone proteins 
Erol~ was expressed in both islets (arrow) and the surrounding enzyme producing 
acinar cells, with a stronger expression in the islets (Figure 6.3, A-C). This expression 
pattern was also seen with different digestion techniques and primary antibody 
dilutions tested in this study (Figure 6.3, A-C). The expression of the second 
mammalian oxidoreductase Erola was studied using the D5 primary antibody. After 
digestion of the tissue, D5 showed no specific staining in the pancreas (Figure 6.3D). 
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A 
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aEro1~ 
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FIGURE 6.3: Erolf3 is expressed strongly in the pancreatic islets 
B 
1-150 
aEro1~ 
D 
Paraffm embedded human pancreas sections were cleared through xylene, taken 
through a 100 - 70% alcohol series and blocked for endogenous peroxidase in H202. 
Prior to incubating with primary antibody, sections were digested in microwave with 
citrate buffer (A, B and D) and pressure cooker with citrate buffer (C). Sections were 
incubated with aEro1P primary antibody at 1-100 (A), 1-150 (B), 1-125 (C) and 
aEro 1 a (D5) primary antibody at 1-1000 (D) dilution prior to detection with DAB and 
photographed at 20X magnification (A-D). Ero1P is expressed in both exocrine and 
endocrine tissue with stronger expression in endocrine tissue. Bar = 200 J..lffi, arrow = 
islets. 
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Next, the expression pattern of ER chaperones involved in protein oxidation and 
folding was investigated. The pancreas-specific PDI homolog, PDip, showed 
expression in the acinar cells with very weak staining of the islets, as previously 
reported (Figure 6.4, A and B, (Desilva et al., 1997)). However in contrast to Erol~, 
PDI expression was lower in the islets (anow) compared with the surrounding acinar 
cells (Figure 6.4C). Having seen a difference in expression patterns between Erol~ and 
PDI, the expression of several other ER chaperones was also tested. 
aERp57 antibody (after tissue digestion in pressure cooker with citrate buffer) gave a 
similar staining to Erol ~ with the islets staining stronger than the acinar cells (Figure 
6.4D), although the overall staining wasn't as strong as with the aEro l ~ serum. The 
aERp57 antibody. gave less distinct staining patterns after trypsinisation and 
microwave digestion with citrate buffer (data not shown). aBiP (Figure 6.4£) and 
aERp72 (Figure 6.4F) showed strong expression throughout the pancreas, including 
the islets which were difficult to identify after aERp72 antibody staining and thus not 
labelled. Two antibodies against full length ERp44 from two different hybridomas 
(ERp44a arid ERp44b) were also tested. Digestion with citrate buffer in microwave 
gave no staining with either antibody (data not shown) whereas digestion in pressure 
cooker did give some signal (Figure 6.4, G and H). However, these expression levels 
were quite similar to pre-immune sera staining (Figure 6.1H), demonstrating that under 
conditions used in this study ERp44 was not detectable in the pancreas. Taken together 
the data suggest that Erol ~ is found in both exocrine and endocrine tissue, with 
stronger expression in endocrine tissue, whereas PDI is more prominently expressed in 
exoci·ine tissues. ERp57, ERp72 and BiP are however ~xpressed in pancreatic 
endocrine tissue, indicating a possible involvement of these proteins with Erol~. An 
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interaction between ERp72 and Erol ~ was already shown under steady state conditions 
(Figure 5.3A), whereas no direct interaction could be detected between BiP and Erol~ 
(Figure 5.3£). 
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aBiP aERp72 
G 
aERp44a 
FIGURE 6.4: ER chaperone expression in human pancreatic tissue 
Paraffm embedded human pancreas sections were cleared through xylene, taken 
through a 100 - 70% alcohol series and blocked for endogenous peroxidase in H202. 
Prior to incubating with primary antibody, sections were digested in microwave with 
citrate buffer (A, C and E), pressure cooker with citrate buffer (B, D, G and H) and 
water bath with citrate buffer (F). Sections were incubated with aPDip at 1-1000 (A 
and B), aPDI at 1-800 (C), aERp57 at 1-200 (D), aBiP at 1-40 (E), aERp72 at 1-1000 
(F), aERp44a at 1-200 (G) and a ERp44b at 1-200 (H) prior to detection with DAB 
and photographed at 20X magnification (A-H). Bar= 200 J..lm, arrow= islets. 
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6.2.2 Erol p interacts with PD/p 
The pancreas specific PDI homolog, PDip is expressed strongly in the exocrine tissue 
(Figure 6.4, A and 8, (Desilva et al., 1997)). Since Ero1~ was also expressed in 
exocrine tissue, the ability of Ero1 ~ to interact with PDip was investigated. Samples of 
mouse pancreas were lysed in the presence of NEM, clarified by centrifugation and 
either directly analysed by reducing SDS-PAGE or subjected to concanavalin A (con 
A) affinity chromatography prior to reducing SDS-PAGE analysis. Immunoblotting 
with aEro 1 ~ showed expression in mouse pancreatic tissue but not in kidney tissue 
lysates as expected (Figure 6.5A, compare lanes 1 and 5 with 2 and 6). Wild-type 
Erol~-Myc transfected HeLa lysate was used as a positive control (Figure 6.5A, lane 3). 
The same tissue lysates were used in an immunoprecipitation with aPDip antibody 
prior to reducing SDS-PAGE. Probing the western blotted membrane with aEro1~ 
gave a signal from the pancreatic lysates (Figure 6.5A, lane 8) but not the kidney 
lysates (Figure 6.5A, lane 9), confirming that PDip interacted with Ero1~ in vivo. The 
same mouse tissue lysates as in figure 6.5A together with Erola-Myc transfected HeLa 
cell lysates were analysed by reducing SDS-PAGE and transfened proteins probed with 
D5 antibody to detect the expression of Erola. Ero1a expression was detected in 
transfected cell lysate (Figure 6.58, lane 3) but was not detected in pancreas or kidney 
tissue Iysates (Figure 6.58, lane 1-2). Immunoprecipitation with aPDip, showed no 
interaction between PDip and Erola (Figure 6.58, lane 4-5). PDip expression in the 
pancreas was confirmed through western blotting before and after con A precipitation 
(Figure 6.58, compare lanes 6 and 9 with 7 and 10). The data suggests that the 
pancreas specific PDI family member PDip binds to one of the hEROs, Erol~, in the 
pancreas. 
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FIGURE 6.5: PDip interacts with Eroll3 in vivo 
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A. Mouse pancreas and kidney tissue samples or wtEro 113-myc transfected HeLa cells 
were lysed in the presence of NEM, and analysed directly (lanes 1-3) or subjected to 
con A affinity chromatography (lanes 5-6) or subjected to immunoprecipitation with 
a.PDip (lanes 8-9) prior to reducing SDS-PAGE. Western blotted membrane was 
probed with a.Eroll3. Lanes 4 and 7 are loaded with sample buffer only. B. wtErola.-
myc cell lysate (lane 3), pancreas and kidney lysates (lanes 1-2, 4-5) were directly 
analysed by reducing SDS-PAGE (lanes 1-2) or first subjected to immunoprecipitation 
with a.PDip (lanes 4-5). Immunoblotting was with D5 (lanes 1-5). C. Pancreas and 
kidney lysates were directly analysed (lanes 4-5) or first subjected to con A affinity 
chromatography (lanes 1-2) prior to immunoblotting with a.PDip after reducing SDS-
PAGE. Lane 3 is loaded with sample buffer only. 
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6.2.3 Expression of hEROs and chaperone proteins in healthy human 
stomach 
6.2.3.1 Optimisation of antigen retrieval techniques 
Human stomach tissue sections were examined using immunohistochemistry to further 
investigate whether high levels of Erolp expression conelated with high expression 
levels of ER chaperone proteins, similar to that observed in the pancreas. Paraffin 
embedded stomach sections were subjected to four different antigen retrieval 
techniques; microwave digestion in high pH buffer, microwave digestion in citrate 
buffer, trypsinisation and pressure cooker digestion. When primary antibody was 
omitted (TBS, Figure 6.6 left hand panel) stomach sections showed faint background 
staining after microwave with high pH buffer (Figure 6.6A), negative staining after 
microwave with citrate buffer, and trypsinisation (Figure 6.6, C, and E respectively) 
and non-specific but relatively high levels of staining after pressure cooker digestions 
(Figure 6.6G). Sections exposed to pre-immune rabbit sera (PS, Figure 6.6 right hand 
panel) showed a patchy staining pattern after microwave with high pH buffer (Figure 
6.6B), non-specific faint staining after microwave with citrate buffer (Figure 6.6D), 
non-specific but relatively high levels of staining after pressure cooker digestions 
(Figure 6.6F), and negative staining after trypsinisation (Figure 6.6H). Due to the 
higher level of staining observed after microwave digestion with high pH buffer and 
pressure cooker digestion with citrate buffer, these two antigen retrieval techniques 
were not used with specific antibodies on human stomach sections. Results from figure 
6.6 are summarised in table 6.2. 
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FIGURE 6.6: Optimisation of digestion techniques for human stomach tissue 
Paraffm embedded human stomach sections were cleared through xylene, taken 
through a 1 00 - 70% alcohol series and endogenous peroxidase activity blocked in 
H20 2 prior to performing four different antigen retrieval techniques; microwave with 
high pH buffer (A and B), microwave with citrate buffer (C and D), trypsinisation (E 
and F) and pressure cooker with citrate buffer (G and H). Primary antibody was 
omitted (TBS; A, C, E and G) or sections exposed to pre-immune serum (PS; B, D, F 
and H) prior to detection with DAB and photography at 20X magnification (A-H); bar 
= 200 J..lm. Microwave with high pH buffer and pressure cooker with citrate buffer gave 
a fairly high level of non-specific staining after TBS and pre-immune serum and so was 
not used as a antigen retrieval technique with subsequent antibodies on stomach tissue 
sections. 
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Table 6.2: Summary of results from optimisation of digestion techniques for wax 
embedded human stomach sections 
Antigen retrieval technique 
Microwave Microwave Pressure 
Antibody with citrate Trypsinisation with high pH cooker with 
buffer buffer citrate buffer 
TBS Negative Negative Very weak non-
Non-specific 
specific staining 
but strong 
staining 
Pre-immune Weak, non- Non-specific 
serum (PS) specific Negative 
Weak, patchy 
but strong 
staining 
staining 
staining 
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6.2.3.2 Erol f3 and ER chaperone proteins are expressed in the chief cells of the 
stomach 
Sections probed with the ErolP antiserum showed very strong, specific staining in the 
basal area of the stomach (Figure 6.7A). At higher magnification, Erolp showed a 
patchwork like distribution representing strong expression in the enzyme producing 
chief cells of the stomach (arrows) and weaker expression in the acid producing parietal 
cells (arrowhead) within the same glands (Figure 6.7, B-D). This staining pattern was 
evident after microwave with citrate buffer with three Erol p antibody concentrations 
(Figure 6.7, B-D). Expression of the second oxidoreductase Erola was also analysed 
after microwave with citrate buffer conditions using two antibody concentrations 
(Figure 6.7, E and F), which gave a similar but a weaker expression pattern to Erolp. 
To look for any conelation between oxidoreductase expression and ER chaperone 
expression within the stomach, a selection of ER chaperone proteins were tested under 
the same optimal digestion conditions as for Erola and Erolp. Unlike pancreatic tissue, 
in the stomach, POI expression was identical to Erolp expression, with staining 
observed in chief cells (arrows) but weaker in parietal cells (aiTowheads, Figure 6.7G). 
BiP (Figure 6.7H), ERp57 (Figure 6.71), ERp72 (Figure 6.71), and ERp44 (Figure 
6.7 K) were all expressed at a high level in the same cell types. The ERp44b (Figure 
6.7 L) antiserum did not show any staining in the stomach. Data from this study suggest 
that ER chaperones as well as oxidoreductases are expressed at high levels in enzyme 
producing cells in the stomach. 
Table 6.3 summarises the hERO and chaperone protein staining results from the human 
pancreas and stomach tissues. 
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FIGURE 6.7: Erol~ and ER chaperones strongly expressed in chief cells of the 
stomach 
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FIGURE 6.7: Eroll3 and ER chaperones strongly expressed in chief cells of the 
stomach 
Paraffin embedded human stomach sections were cleared through xylene, taken 
through a 100 - 70% alcohol seties and endogenous peroxidase activity blocked in 
H202. Prior to incubating with primary antibody sections were digested in a microwave 
with citrate buffer (A-1 and K-L) or digested according to the protocol in section 2.2.2 
(J) and were incubated with aEro113 at 1-100 (A and B), aEro1j3 at 1-125 (C), aEro113 
at 1-150 (D), D5 at 1-800 (E), D5 at 1-1000 (F), aPDI at 1-800 (G), aBiP at 1-40 (H), 
aERp57 at 1-200 (1), aERp72 at 1-1000 (J), aERp44a at 1-200 (K), aERp44b at 1-
200 (L) dilutions prior to detection with DAB and photographed at 5X (A) and 20X 
magnification (B-L); bar= 200 ~J.m. Arrow= chief cells, arrowhead= parietal cells. 
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Table 6.3: hERO and ER chaperone protein expression in human pancreas and 
stomach tissue. Summary of results when using the optimum digestion technique for 
each antibody. 
Expression levels 
Antibody used 
Pancreatic tissue Stomach tissue 
aErolj3 Expressed in acinar cells Strong expression in chief cells 
and stronger in islets and weaker in parietal cells 
a.Erola (DS) Not detected Similar to a.Erolj3, but weaker 
a.PDI Expressed in acinar cells Similar to aEro 1 p 
but weak in islets 
aPDip Expressed in acinar cells Not detected 
but very weak in islets 
a.ERp57 Similar to a.Erolp, but Similar to a.Ero1P 
overall weaker 
a.ERp72 Expressed in acinar cells Similar to a.Ero1p 
and in islets 
a.ERp44a Not detected Similar to a.Ero1P 
a.ERp44b Not detected Not detected 
a.BiP Similar to a.ERp72 Similar to a.Erolp 
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6.2.4 Expression of hEROs and chaperone proteins in human oesophagus 
6.2.4.1 Nomwl oesophagus 
Erola transcripts were found to be up regulated in human oesophagus tissue compared 
to Erolp levels (Pagani et al., 2000), and to investigate whether this pattern is repeated 
at the protein level, immunohistochemistry was used on healthy human oesophagus 
sections (3396-00 B 1). Sections were digested by following protocol 2 (section 2.2.2) 
and incubated with pre-immune serum (PS, Figure 6.8A and B) or primary antibody 
was omitted (TBS, Figure 6.8C and D), both of which did not stain the stratified 
squamous epithelium (double headed arrow). Sections probed with the Erolp antiserum 
showed weak staining throughout the epithelium (Figure 6.8E and F). Erola 
expression however was more prominent and was detected in more mature epithelial 
cells (arrows) compared to cells closer to the basal membrane (Figure 6.9, C-H). This 
expression pattern was also seen with several D5 antibody dilutions, although at the 
highest antibody concentration (1-50) this pattern was less prominent (Figure 6.9, 
compare C-H with A-B). 
To investigate the expression of ER chaperone proteins in healthy oesophagus tissue, 
sections were probed with aPDI (Figure 6.10A and B), aBiP (Figure 6.10C and D), 
aERp72 (Figure 6.10E and F) and aERp57 (Figure 6.10G and H) which all showed 
different expression patterns. BiP showed only very weak expression, PDI was 
expressed throughout the epithelium whereas ERp72 showed the strongest expression. 
ERp57, however, showed no expression throughout the epithelium. 
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FIGURE 6.8: Weak expression ofErol~ in normal oesophagus (3396-00 Bl) 
Paraffin embedded human normal oesophagus sections were cleared through histoclear, 
taken through a 100 - 70% alcohol series and endogenous peroxidase activity blocked 
in H202. Prior to incubating with primary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-F) and were incubated with pre-
immune serum (PS, A and B), TBS (C and D) and aEro 1 ~ at 1-150 (E and F) dilutions 
prior to detection with DAB and photography at 5X (A, C, E) and 20X magnification 
(B, D, F). Double headed arrows indicate the stratified squamous epithelium; bar = 200 
,....m. 
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FIGURE 6.9: Specific expression of Erola in normal oesophagus (3396-00 Bl) 
Paraffm embedded human normal oesophagus sections were cleared through histoclear, 
taken through a 100 - 70% alcohol series and endogenous peroxidase activity blocked 
in H20 2. Prior to incubating with primary antibody, sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-H) and were incubated with 
aEro1a (D5 antibody) at 1-50 (A and B), 1-200 (C and D), 1-500 (E and F) and at 1-
800 (G and H) dilutions prior to detection with DAB and photographed at 5X (A, C, E, 
G) and 20X magnification (B, D, F, H). Double headed arrows indicate the stratified 
squamous epithelium and the single headed arrows indicate the mature epithelium cells 
with higher Ero 1 a expression. bar = 200 J..tm. 
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FIGURE 6.10: Expression ofER chaperones in normal oesophagus (3396-00 Bl) 
Paraffm embedded human normal oesophagus sections were cleared through histoclear, 
taken through a 100 - 70% alcohol series and endogenous peroxidase activity blocked 
in H20 2. Prior to incubating with primary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-H) and were incubated with aPDI 
at 1-400 (A and B), aBiP at 1-40 (C and D), aERp72 at 1-1000 (E and F) and aERp57 
at 1-800 (G and H) dilutions prior to detection with DAB and photography at 5X (A, C, 
E, G) and 20X magnification (B, D, F, H). Double headed arrow = stratified squamous 
epithelium. ERp72 expression is high throughout the epithelium compared to low 
expression of PDI and very weak expression of BiP. aERp57 shows negative staining. 
bar =200 J..Lm. 
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6.2.4.2 Barrett's oesophagus 
To study the expression pattern of hEROs and ER chaperone proteins m Barrett's 
oesophagus, sections were digested by following protocol 2 (section 2.2.2) and first 
tested with two negative controls; incubating with pre-immune serum (PS, Figure 
6.11A and B) and omitting primary antibody (TBS, Figure 6.11C and D), both of which 
did not stain the columnar type epithelium (arrowhead) or the goblet cells (arrows). 
This Barrett's epithelium is non-dysplastic and due to the presence of goblet cells can 
be classified as intestinal type glandular epithelium. The stratified squamous epithelium 
in healthy oesophagus tissue (double headed arrow in Figures 6.8 - 6.10) is replaced by 
the columnar type epithelium in Barrett's. Sections probed with the Ero1p antiserum 
showed very faint staining throughout the epithelium (Figure 6.11£ and F). However, 
Ero1a expression (using D5 antibody) was strong throughout the columnar epithelium 
(arrows, Figure 6.11, G - 1)). This pattem was repeated with the use of two different D5 
antibody dilutions (Figure 6.11, G- 1). 
To identify any changes in expression of ER chaperone proteins, sections were probed 
with aPDI (Figure 6.12A and B), aBiP (Figure 6.12C and D), aERp72 (Figure 6.12£ 
and F) and aERp57 (Figure 6.12G and H). ERp72 showed the strongest expression 
compared with PDI and BiP, and was expressed in the columnar epithelium. aERp57 
gave a similar result as in the healthy oesophagus (Figure 6.10G and H) with no 
staining observed throughout the epithelium. 
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FIGURE 6.11: hERO expression in Barrett's oesophagus (6199-02 A2) 
F 
H 
Paraffin embedded human Barretts oesophagus sections were cleared through histoclear, 
taken through a 100 - 70% alcohol series and endogenous peroxidase activity blocked 
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in H20 2. Prior to incubating with primary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-J) and were incubated with pre-
immune serum (PS, A and B), TBS (C and D) and aEro1P at 1-150 (E and F), 
aEro1a at 1-50 (G and H) and aEro1a at 1-200 (I and J) dilutions prior to detection 
with DAB and photographed at 5X (A, C, E, G, I) and 20X magnification (B, D, F, H, 
J). Goblet cells are indicated with arrows and the columnar epithelium is indicated with 
an arrowhead. Ero1a expression is strong in the columnar epithelium whereas Ero1P is 
not detected; bar = 200 )lm. 
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FIGURE 6.12: ER chaperone protein expression in Barretts oesophagus (6199-02 
A2) 
Paraffin embedded human Barretts oesophagus sections were cleared through histoclear, 
taken through a 100 - 70% alcohol series and endogenous peroxidase activity blocked 
in H20 2. Sections were digested in a water bath with citrate buffer according to section 
2.2.2 (A-H) and were incubated with aPDI at 1-400 (A and B), aBiP at 1-40 (C and D), 
aERp72 at 1-1000 (E and F) and aERp57 at 1-800 (G and H) dilutions prior to 
detection with DAB and photographed at 5X (A, C, E, G) and 20X magnification (B, D, 
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F, H). Goblet cells are indicated with anows and the glandular epithelium is indicated 
with an anowhead. PDI, BiP and ERp72 are expressed in the glandular epithelium at 
varying levels whereas ERp57 is not detected; bar = 200 ~Lm. 
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6.2.4.3 Oesophageal tumour 
Next, the expression pattern of hERO and ER chaperone proteins was investigated in 
oesophageal tumour (1039-03 B2) sections. Figure 6.13 represents an area in this tissue 
block representing dysplasia (at low power magnification, area within the double 
headed arrow, Figure 6.13A), where some of the single layer columnar epithelium 
found in Barrett's oesophagus (Figure 6.11-6.12) is replaced by a multi-cellular 
glandular epithelium (arrows, Figure 6.13, B-.J), with some of the cells having an 
increased nuclear/cytoplasm ratio. Sections were digested by following protocol 2 
(section 2.2.2) and incubated with pre-immune serum (PS, Figure 6.13A and B) or 
omitting primary antibody (TBS, Figure 6.13C), both of which showed negative 
staining throughout the epithelium. Sections probed with aEro1~ (Figure 6.13D) and 
aEro! a (using D5, Figure 6.13£ and F) antisera showed strong staining throughout the 
dysplastic epithelium. The Ero1a expression pattern was repeated with the use of two 
different D5 antibody dilutions (Figure 6.13£ and F). To identify any changes in 
expression of ER chaperone proteins, sections were probed with aPDI (Figure 6.13G), 
aBiP (Figure 6.1311), aERp72 (Figure 6.13/) and aERp57 (Figure 6.13.!). PDI, ERp72 
and ERp57 all showed strong expression compared to BiP, which showed very faint 
staining in the dysplastic tissue. The ERp57 result contrasts with the negative staining 
seen in nmmal (Figure 6.10) and Barrett's oesophagus (Figure 6.12). 
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FIGURE 6.13: Expression in dysplastic tissue from oesophageal tumour (1039-03 
82) 
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FIGURE 6.13: Expression in dysplastic tissue from oesophageal tumour (1039-03 
82) 
Paraffin embedded human oesophageal tumour sections were cleared through histoclear, 
taken through a 100- 70% alcohol series and endogenous peroxidase activity blocked 
in H20 2 Prior to incubating with primary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-J) and were incubated with pre-
immune serum (PS, A and B), TBS (C), with aEroP at 1-150 (D), aEro1a at 1-50 (E), 
aEro1a at 1-200 (F), aPDI at 1-400 (G), aBiP at 1-40 (H), aERp72 at 1-1000 (I) and 
aERp57 at 1-800 (J) dilutions prior to detection with DAB and photographed at 5X (A) 
and 20X magnification (B-J). Goblet cells are indicated with arrowheads and the 
dysplastic epithelium is indicated with a double headed arrow. The arrows show multi-
nuclei cells in the glandular epithelium. Erolp, Ero1a, and the ER chaperone proteins 
are all expressed in the glandular epithelium at varying levels. BiP shows the weakest 
expression; bar= 200 ).lm. 
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The same tissue block (1039-03 B2) was also used to study hERO and chaperone 
protein expression patterns in adenocarcinoma tissue. Sections were digested by 
following protocol 2 (section 2.2.2) and when primary antibody was omitted (TBS, 
Figure 6.14A and B), the dysplastic epithelium (*) and the infiltrating neoplastic ce11s 
(area within double headed arrow at low power magnification, Figure 6.14A) showed 
negative staining. Incubating with pre-immune serum (PS, Figure 6.14C) also showed 
negative staining. Sections probed with aEro113 (Figure 6.14D) and two concentrations 
of aErola antisera (using D5, Figure 6.14£ and F) showed expression in the 
infiltrating cells. To identify any changes in expression of ER chaperone proteins, 
sections were probed with aPDI (Figure 6.14G), aBiP (Figure 6.14H), aERp72 (Figure 
6.14/) and aERp57 (Figure 6.141). PDI, ERp72 and ERp57 are all expressed in the 
infiltrating cells, whereas BiP is expressed at very low levels. 
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FIGURE 6.14: Expression in adenocarcinoma tissue from oesophageal tumour 
(1039-03 B2) 
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FIGURE 6.14: Expression in adenocarcinoma tissue from oesophageal tumour 
(1039-03 B2) 
Paraffin embedded human oesophageal tumour sections were cleared through histoclear, 
taken through a 100- 70% alcohol series and endogenous peroxidase activity blocked 
in H20 2. Prior to incubating with p1imary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-J) and primary antibody was 
omitted (TBS, A and B) or incubated with pre-immune serum (PS, C), aEro~ at 1-150 
(D), aEro1a at 1-50 (E), aEro1a at 1-200 (F), aPDI at 1-400 (G), aBiP at 1-40 (H), 
aERp72 at 1-1000 (I) and aERp57 at 1-800 (J) dilutions prior to detection with DAB 
and photographed at 5X (A) and 20X magnification (B-J). The dysplastic epithelium is 
indicated with a *, the adenocarcinoma with infiltrating cells is indicated with a double 
headed arrow and the infiltrating cells are indicated with arrowheads. Ero1~, Ero1a, 
and the ER chaperone proteins are all expressed in the adenocarcinoma at varying 
levels. BiP shows weak expression; bar= 200 Jlm. 
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6.2.5 Expression of hEROs and chaperone proteins in OG junction tumour 
and gastric tumour 
To study the expression pattem of hEROs and ER chaperone proteins m 
gastroesophageal tumour, sections were digested by following protocol 2 (section 
2.2.2) and first tested with two negative controls; incubating with pre-immune serum 
(PS, Figure 6.15A and B) and omitting primary antibody (TBS, Figure 6.15C), both of 
which did not stain the tumour tissue. At low magnification (Figure 6.15A) the 
carcinoma has several areas differentiated into glands (double headed arrow), where as 
some areas are poorly differentiated and glands are not visible (not shown). Multi-
nuclear cells with decreasing cytoplasm are evident under higher magnification 
(arrows). Sections probed with the aErolP (Figure 6.15D), and aEro1a (using two 
concentrations of D5 antibody, Figure 6.15£ and F) showed strong expression in 
neoplastic cells. PDI (Figure 6.15G), ERp72 (Figure 6.15/) and ERp57 (Figure 6.151) 
were all expressed comparable to Erola and Ero1p, whereas BiP (Figure 6.15H) 
expression was not detected. 
Next the expression pattems were compared with gastric tumour sections after antigen 
retrieval according section 2.2.2. The two negative controls (Figure 6.16, A-C) showed 
no staining throughout the gastric tumour, whereas Ero1P (Figure 6.16D), Ero1a 
(Figure 6.16£ and F), PDI (Figure 6.16G), BiP (Figure 6.16/l), ERp72 (Figure 6.16/), 
and ERp57 (Figure 6.161) were all strongly expressed in the neoplastic cells (arrows). 
The results from Figures 6.8 - 6.16 are summarised in table 6.4. 
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FIGURE 6.15: hERO and chaperone protein expression in OG junction tumour 
(6591-01 C4) 
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FIGURE 6.15: hERO and chaperone protein expression in OG junction tumour 
(6591-01 C4) 
Paraffin embedded human oesophageal tumour sections were cleared through histoclear, 
taken through a 100- 70% alcohol series and endogenous peroxidase activity blocked 
in H 20 2. Prior to incubating with primary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-J) and incubated with pre-
immune serum (PS, A and B), TBS (C), aErop at 1-150 (D), aEro1a at 1-50 (E), 
aEro1a at 1-200 (F), aPDI at 1-400 (G), aBiP at 1-40 (H), aERp72 at 1-1000 (I) and 
aERp57 at 1-800 (J) dilutions prior to detection with DAB and photographed at SX (A) 
and 20X magnification (B-J). Carcinoma tissue is indicated with a double headed 
arrow and neoplastic glands are indicated with an arrow. Ero1p, Ero1a, and the ER 
chaperone proteins are all expressed in the tumour tissue at varying levels, ex,pect for 
BiP, which shows negative staining; bar= 200 11m. 
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FIGURE 6.16: Strong expression of hEROs and chaperone proteins in Gastric 
tumour (6591-01 C4) 
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FIGURE 6.16: Strong expression of hEROs and chaperone proteins in Gastric 
tumour (6591-01 C4) 
Paraffin embedded human oesophageal tumour sections were cleared through histoclear, 
taken through a 100 - 70% alcohol series and endogenous peroxidase activity blocked 
in H 20 2 Prior to incubating with primary antibody sections were digested in a water 
bath with citrate buffer according to section 2.2.2 (A-J) and incubated with pre-
immune serum (PS, A and 8), TBS (C), aEro~ at 1-150 (D), aEro1a at 1-50 (E), 
aEro1a at 1-200 (F), aPDI at 1-400 (G), aBiP at 1-40 (H), aERp72 at 1-1000 (I) and 
aERp57 at 1-800 (J) dilutions prior to detection with DAB and photographed at 5X (A) 
and 20X magnification (B-J). Neoplastic glands are indicated with an atTow. Bar= 200 
~tm. 
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Table 6.4: Expression of hEROs and ER chaperone proteins in patient tissue 
sections 
Healthy Barrett's Oesophageal OG Gastro 
oesophagus oesophagus tumour junction Tumour 
(dysplastic and tumour 
adenocarcinoma) 
Erolj3 very weak Not strong strong strong 
detected 
Erola. strong in strong strong strong strong 
mature 
epithelium 
cells 
PDI stronger strong strong strong strong 
than Erolj3 
BiP very weak weak weak Not strong 
detected 
ERp72 strong strong strong strong strong 
ERp57 Not Not strong strong strong 
detected detected 
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6.3 Discussion 
The expression patterns of Ero1p, Ero1a and several ER chaperone proteins were 
studied in this chapter. Prior to this study it was known that Ero1P can be induced by 
UPR and that at the mRNA level it is highly expressed in secretory tissues (Pagani et 
al., 2000). Nothing was known about the protein expression of Ero1p in these tissues. 
The Ero1 P expression pattern was first studied in pancreatic tissue, which showed that 
it was present in both endocrine and exocrine cells, but with stronger expression in 
endocrine tissue. However, the low level of PDI expression in the islets suggests that 
perhaps PDI might not be the sole electron donor for Ero1P in the pancreas. The 
pancreas specific PDI homologue PDip, can use hydroxyl groups as ligands (Klappa et 
al., 2001) and in theory could replace PDI function in the islets. However, PDip is only 
expressed strongly in acinar cells (Desilva et al., 1997). ERp57 and ERp72 are both 
expressed strongly in the islet cells, and could be alternative electron donors. Specific 
interactions between Ero1P and ERp57 have not so far been detected in transfected 
HeLa cells under pulse-chase conditions but fmther analysis in pancreatic tissue could 
shed light on possible endogenous Ero1p interactions with ERp57. An interaction 
between Ero1p and ERp72 was shown in transfected HeLa cells in Chapter 5 (section 
5.3.2), and therefore ERp72 could be a potential electron donor in the pancreas. Human 
Quiescin-sulphydryl oxidase (QSOXl) has also been reported (using 
immunohistochemistry) to be highly expressed in the islets of Langerhans compared 
with weak expression in acinar cells (Thorpe et al., 2002). Quiescin-sulphydryl 
oxidases (QSOX) are flavin-dependent enzymes that catalyse the formation of disulfide 
bonds in proteins and peptides with the net production of hydrogen peroxide from 
oxygen. More recently using in situ hybridisation (ISH) and immunohistochemistry 
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(IHC), Tury and colleagues have shown that the rat quiescin-sulphydryl oxidase 
(rQSOX) is mostly expressed in a-cells of the islets compared to very weak expression 
in P-cells (Tury et al., 2006). Since the main secreted protein in a-cells is the non-
disulfide containing hormone glucagon, a potential substrate for rQSOX still needs to 
be discovered from these cells (Tury et al., 2006). This contrast in expression of QSOX 
proteins from human and rat pancreatic tissue will no doubt need further investigation. 
Although Erol p antibody shows similar staining to the insulin antibody (H-86) 
indicating expression in P-cells, a true functional relationship between Ero, PDI and 
QSOX proteins has yet to be determined in vivo. Erola and ERp44 expression could 
not be detected in the pancreatic tissue. 
Having seen Erol p and PDip both expressed in pancreatic acmar cells, it was 
interesting to detect an interaction in vivo (Figure 6.5). What this interaction means in 
terms of functionality in the pancreas remains unclear. The finding that a tryptophan or 
tyrosine residue is sufficient to allow PDip recognition of a peptide/protein (Ruddock 
et al., 2000), probably via the hydroxyl group, suggests that different members of the 
POI family might be able to recognise the same unfolded protein but at different 
exposed amino acid residues (Klappa et al., 2001). Thus Erolp might be involved in 
electron transfer with both PDI and PDip. Reconstituting oxidative protein folding in 
vitro (Tu et al., 2000), using purified PDip and Ero to monitor refolding of RNAse A 
could be used to see whether PDip and Eros are involved in a disulfide bond formation 
pathway. Although the data suggests that PDip preferentially binds to Erol~, due the 
very low level of Erola detected from pancreatic tissue (by western blotting and 
immunohistochemistry), it wasn't surprising that an interaction couldn't be detected 
between PDip and Ero I a. For more conclusive evidence of a specific interaction 
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between the hEROs and PDip, one possible strategy would be the use of in vitro 
translation. Co-translating both PDip and Ero1P or to PDip and Ero1a would provide 
direct evidence of an interaction. 
In the stomach, Erolp and the ER chaperone proteins (PDI, ERp57, ERp72 and 
ERp44) showed cell specific expression, with strong expression detected in enzyme 
producing chief cells. Ero1a was also expressed very weakly in the chief cells. 
Although the Erola antibody (D5) concentrations used in pancreas and stomach tissue 
(1:1000) stainings were relatively low when compared to Erolp antibody 
concentrations (1: 150), these concentrations were based on previous work in the lab in 
which Erola protein could be detected in other tissues. In addition, using a series of 
Ero1a antibody (D5) concentrations to study the expression in normal oesophagus 
tissue (Figure 6.9) suggests that concentrations as low as 1:800 are still sufficient to 
detect a specific expression pattern. Ero1p shows tissue-specific (at the mRNA level 
and at the protein level; Figure 3.5) as well as cell-specific expression within stomach 
and pancreas tissue. The implication of having high levels of Ero1P expression will be 
discussed in Chapter 7. 
In normal oesophagus, Erola protein expression was higher than for Ero1p, which 
complements the mRNA data (Pagani et al., 2000). Erola however, was expressed in 
the more mature epithelial cells, an expression pattern that was not detected with other 
chaperone proteins. Ero1a expression remained strong in Banett's epithelium and 
oesophageal tumour, whereas Ero 1 p expression seemed to get switched on in 
dysplastic and adenocarcinoma tissue. Although PDI and ERp72 expression remained 
relatively high throughout these different stages, ERp57 shows dramatic up regulation 
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in the oesophageal tumour tissue. This up regulation in Erol~ and ERp57 protein levels 
could be necessary to cope with the increase in unfolded proteins in rapidly dividing 
neoplastic cells. Further implications of ERp57 up regulation are discussed in Chapter 7. 
Patients with Barrett's oesophagus have a 30 to 40 fold increased risk of developing 
adenocarcinoma (Kumar et al., 1997) but not all patients with Barrett's will develop 
cancer. Finding suitable markers that could be used to discriminate between Barrett's 
and dysplastic epithelium would be very useful to predict cancer onset and to prevent 
unnecessary surgery. 
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The present study focused on characterising the expressiOn and interactions of the 
human endoplasmic reticulum oxidoreductase Erol~. The results presented in this work 
lead to the following main conclusions: 
a) ErolJ3 is able to homodimerise and heterodimerise with Erola. The redox active 396 
cysteine at the C-terminal CXXCXXC motif was identified as important for ErolJ3 
homodimer formation. 
b) When temperature and reducing stress (DTT) conditions were encountered, the FAD 
binding domain mutations (G252S and H254Y) resulted in misoxidation ofErolJ3. 
c) Erol~ was expressed in the endocrine and exocrine tissue of the pancreas as well as 
in the enzyme producing chief cells of the stomach. 
d) In the oesophagus, ERp57 displayed differential expression in healthy, Barrett's and 
oesophageal tumour tissue. 
7.1 Importance of Erol f3 homodimer formation 
Results from this study reveal that the mammalian homologues of Erolp, Erola and 
ErolJ3, are able to form homodimers when expressed in human cell lines (section 3.2.3), 
which suggests the possibility of intermolecular electron transfer. Intramolecular 
electron transfer between an Ero N-terminus and C-terminus active site cysteine pair 
was first suggested by Frand and Kaiser using a panel of yeast Erolp cysteine mutants 
(Frand & Kaiser, 1999). This was later supported by evidence from the Erolp crystal 
222 
Chapter 7: Discussion 
structure which showed that the Cl00/Cl05 was on a flexible loop that could undergo 
conformational change to be positioned within disulfide bond formation distance from 
the C353/C355 (Grosset al., 2004). A recent study with Erolp has provided evidence 
for intermolecular electron transfer (Sevier & Kaiser, 2006b ). Sevier and Kaiser made 
use of two mutant forms of Erol p (one with the amino-terminus of Erol p containing 
the C100/Cl05 pair, second with full length Erolp containing only the C353/C355 
pair) which, when expressed independently, were unable to complement ero1-1 cells at 
37°C. However, when co-expressed these two mutant Ero proteins were able to 
complement ero1-1, restoring viability and partially restoring oxidative folding of 
carboxypeptidase (CPY). Inter-domain disulfide bonds were also detected in vivo when 
expressed in erolll. cells (Sevier & Kaiser, 2006b). Taken together their results show 
that electron transfer can occur between two Ero proteins. 
Mutating cysteine 396 (CXXCXXA, equivalent to C355 in Erolp) prevents homodimer 
formation. The disruption of dimers is probably due to loss of FAD at the dimer 
interface upon loss of the coordinating C396 residue. However, for the formation of a 
functional dimer the C393/C396 pair (which is buried within the Erolp monomer, 
Figure 4.10) must undergo substantial conformational change. The recent mutational 
analysis of Erolp by Sevier and Kaiser did show that the C353/C355 (equivalent to 
C393/C396 pair in Erolp) pair is capable of undergoing structural changes to allow 
direct oxidation of substrates (Sevier & Kaiser, 2006b ), indicating that this cysteine 
pair could be involved in electron transfer even within an Ero dimer. 
Possible dimer complexes were also detected in vivo using gel filtration studies (section 
3.2.4). Complexes other than ErolP-PDI were detected from mouse stomach and 
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pancreas tissue some of which were likely to be dimers when compared with the 
molecular weights of the standards. However, to conclusively prove the existence of 
dimers in vivo, one method would be the use of mass spectrometry following gel 
filtration from mouse tissue. Availability of an immunoprecipitating Erolj) antibody 
could also allow identification of complexes by mass spectrometry. Depletion of PDI 
from mouse tissue lysates (similar to Figure 3.8) could also be used as an alternative 
method to identify non Ero-PDI complexes in vivo. This method would require an 
Erolj) antibody capable of recognising higher molecular weight complexes under non-
reducing SDS-PAGE, conditions under which the Erolj) antibody used in this study 
failed to recognise these complexes (Figure 3.4). 
The general view is for the existence of a linear Ero-PDI-substrate oxidation chain (Tu 
et al., 2000; Tu & Weissman, 2002) which makes the transfer of electrons between two 
Ero molecules seem unlikely at first. However, it has not been shown that the Ero-PDI 
heterodimer can exclusively and directly mediate oxidative protein folding. Although 
experiments by Sevier and Kaiser have not directly proven that Erolp forms dimers 
which are enzymatically active (Sevier & Kaiser, 2006b), work from this study 
(Chapters 3 & 4) taken together with data from Sevier and Kaiser (Sevier & Kaiser, 
2006b) and Pagani and colleagues (discussed in 4.3; (Pagani et al., 2001)), suggest that 
Ero-Ero molecules could exchange electrons and maybe form PDI-Ero-Ero-PDI 
tetramers to facilitate efficient oxidative folding in the ER. An alternative function of 
Ero dimers could be in the storage of oxidizing equivalents in tissues with a high 
demand for secretory proteins, thereby allowing the rapid mobilization of disulfide 
bond donors. However, this function seems unlikely for Erolj)"(although possible for 
Erolp) which is a UPR induced protein (Pagani et al., 2000), and a cell might not 
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switch on expression of a protein only to be stored in an inactive fmm. It will be of 
interest to find out the behavior of Ero dimers under UPR and hypoxic conditions. 
The equilibrium between dimeric and PDI bound forms of Ero could be used to 
regulate oxidoreductase activity through occupation/protection of the active site. In this 
respect, over-expression of the C396A mutant unable to dimerise might be informative 
as it might lead to oxidative stress when compared with the C390A mutant which is 
able to dimerise but unable to bind PDI. 
7.2 FAD binding domain mutants 
The yeast erol-1 (with a G229S mutation m Erolp) and erol-2 (with a H231Y 
mutation in Erolp) mutants caused temperature sensitivity and DTT hyper-sensitivity 
phenotypes respectively. These FAD binding domain mutations were studied in Erol~ 
(G252S and H254Y, Chapter 5) which showed that the corrupted FAD binding domain 
destabilises the Erol~ protein when subjected to reducing and temperature stress 
(section 5.2.7 and 5.2.8). Although an increase in temperature is unlikely to occur 
within mammalian cells under normal physiological conditions, a more reducing 
environment might be mimicked during an UPR response and be more physiologically 
relevant. It would also be interesting to observe whether FAD mutants in Erola 
misoxidise dming hypoxia. 
It is possible that these two mutants no longer bind FAD. In the yeast Erol p crystal 
structure, the H231 (equivalent to H254 in Erol~) residue is in contact (within 
hydrogen bonding distance) with the AMP phosphate of FAD thus the mutation to 
tyrosine could lead to unstable binding of FAD. The G229 (equivalent to G252 in 
225 
Chapter 7: Discussion 
Ero1~) residue is, however, not in contact with FAD, and so the mutation to se1ine 
might lead to local conformational changes leading to Joss of FAD binding. To address 
how the FAD binding domain is able to stabilise this protein under stress conditions 
requires expression of the recombinant proteins and subsequent crystallisation to study 
the structure of these mutant proteins. 
Purified wild type Ero 1 ~ as well as mutant Ero 1 j3 proteins wi II be useful in oxidative 
folding assays to determine the importance of active site cysteines and FAD binding 
domain residues in Erolj3 function and also to identify potential target substrates. 
Attempts to purify wild-type Ero1 ~ from transfected human cells using FAD affinity 
chromatography failed (data not shown), indicating that the co-factor was tightly bound 
and may-not exchange with external FAD (Grosset al., 2004). Wild-type Erol~ could 
be purified from mouse stomach or pancreas tissue, however purification from these 
organs will be difficult due to the presence of high concentrations of proteolytic 
enzymes. Alternatively insect expression systems could be used to express and purify 
glycosylated wild-type and mutant Ero1 ~protein. 
In yeast, both Ero1 p and Erv2p are membrane associated flavoproteins able to directly 
oxidise PDI and catalyse disulfide bond formation. However unlike Erv2p, Ero1p does 
not have a hydrophobic channel that can enable molecular oxygen access to the active 
site FAD (Gross et al., 2004; Gross et al., 2002). Therefore the final steps of electron 
transfer involving Ero proteins are yet to be determined. 
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7.3 Erol f3 and ERp57 in stomach and pancreas 
At the transc1iptional level, Ero1p mRNA is induced during the course of an unfolded 
protein response (Pagani et al., 2000). Thus up-regulation of Erolp protein levels 
would not be expected under normal protein folding conditions in vivo. However, 
healthy stomach and pancreas tissue had very high relative expression levels of Erol p 
in chief cells and islets (section 6.2.1.2 and 6.2.3.2). This indicates that although Erol P 
is physiologically required in cells with a high secretory demand it may-not solely 
function as an UPR responsive gene. 
High constitutive expression of Ero1P in tissues is surprising because this could lead to 
production of high levels of reactive oxygen species (ROS) ultimately leading to 
oxidative stress. Maybe Erolp dimers play a role in keeping reactive cysteines away 
from non-target proteins which would prevent an unregulated increase in ROS. Other 
disulfide oxidoreductases are also highly co-expressed with Ero 1 p. Perhaps, the reason 
for high level of ERp57 expression in the pancreatic islets (Figure 6.4) and in stomach 
chief cells (Figure 6.7) would be to help refold glycoproteins as pa11 of its 
reductive/isomerase pathway (Jessop & Bulleid, 2004) together with the 
calnexin/calreticulin cycle (discussed in section 1.4.1). 
Erolp has not been detected in the pancreatic cell line PANC1, which is surprising if 
Erolp levels are constitutively 'switched on' in the pancreatic tissue. However, this cell 
line is epithelial in nature, thus not actively producing enzymes. It might be that Erolp 
expression in vivo is regulated by many factors including the nutritional status and the 
demand for protein secretion at a given time, which are unlikely to affect cells in 
culture. These cell lines could be treated with UPR-inducing agents (OTT, 
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tunicamycin) to determine whether Erol ~expression would get induced. However, it is 
becoming clear that the physiological UPR is different from UPR induced by chemical 
reagents. It should be noted that immunohistochemistry is not a quantitative technique 
and so to measure the levels of Erol~ more accurately, mouse pancreatic tissue 
samples from islet and acinar cells (isolated by laser-capture microdissection) could be 
used to compare Erol ~ and ER chaperone protein expression levels using western 
blotting and RT-PCR. The pancreatic tissue used in this study was from a healthy 
individual, but the level of Erol ~ expression might also be different between healthy 
and diseased individuals. A larger scale study to establish the relative levels of Erol ~ 
expression in normal and type 2 diabetic individuals would be interesting, given the 
recent link between diabetes and UPR (Ozcan et al., 2004). 
7.4 ERp57 expression in oesophagus 
ERp57 is up-regulated in oesophageal tumour (Figures 6.13 and 6.14), OG junction 
tumour (Figure 6.15) and gastric tumour (Figure 6.16) compared with the healthy 
oesophagus and pre-cancerous stage (Figures 6.10, 6.12). Why would ERp57 show 
dramatic up-regulation in tumour tissue? Tumours require a constant supply of 
nuttients and oxygen to aid in cell division and rapid growth and would also benefit 
from secretion of growth factors. ERp57 might be required for the proper folding and 
secretion of growth factors to keep up with the demands of tumour cell proliferation. 
These initial studies indicate that ERp57 expression gets 'switched on' between the 
Barrett's and dysplastic tissue. To confirm the exact point of ERp57 up-regulation 
would require the use of different stages of dysplastic tissue, from low-grade to high-
grade dysplasia. 
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Although similar results were observed from duplicate patient tissues, these results are 
initial observations and thus need flllther investigation. The different stages from 
normal oesophagus to oesophageal tumour tissue studied in Chapter 6 were obtained 
from different individuals, thus making a direct comparison of the protein expression 
within one individual more difficult. A biopsy taken from a patient with for example 
Barrett's or adenocarcinoma could have areas/patches of different stages of the tumour 
(similar to tissue block 1039-03 B2 which was used to look at dysplastic and 
adenocarcinoma tissue) as well as healthy tissue. These biopsies would provide a better 
platform for studying how protein expression alters (using immunohistochemistry and 
western blotting) in individuals and to study variations between different individuals. 
Studying the expression patterns of a range of oxidoreductase proteins (for example 
ERp57 and ERp72, which is strongly expressed throughout the stages studied) might 
provide a basis for defining a grading system for the progression to cancer; i.e. from 
healthy, Barrett's, low-grade dysplasia and high-grade dysplasia to invasive 
adenocarcinoma. Studying the mRNA expression patterns from biopsy samples of these 
different stages (using RT-PCR) would provide fUJther quantitative evidence to support 
the immunohistochemistry data. 
Expression profiling has been reported for normal oesophageal epithelium, 
premalignant Barrett's metaplasia, and oesophageal adenocarcinoma samples from 
eight patients (http://www.ncbi.nlm.nih.gov/projects/geo/). Here, the general mRNA 
expression pattern for ERp57 is found to be up-regulated in adenocarcinoma tissue. 
However, there is a noticeable variation in expression between the different patients. It 
would be very interesting to relate the gene expression profiles with the protein 
expression patterns to better understand how Erp57 is regulated and at what stage. The 
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possibility of using expression of ER chaperone proteins as a potential marker for 
oesophageal tumour looks promising. 
In conclusion the present thesis has comprehensively detailed the biosynthesis, 
oxidation and expression of Eroll3 and its CXXCXXC and FAD binding domain 
mutants. Several novel interactions namely Ero dimers and complexes with ERp72 and 
PDip have been identified in vivo and in transfectants. The expression pattern of Eroll3 
and several ER chaperone proteins have also been thoroughly characterised in the 
digestive system for the first time. 
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